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Abstract
Alcelaphine herpesvirus-1 (A1HV-1) is gammaherpesvirus that can cause the
devastating, fatal disease malignant catarrhal fever (MCF) in susceptible ruminant
hosts but not in its natural host the blue wildebeest. Despite its scientific and
economic importance little is known about the underlying molecular basis of MCF
pathogenesis. The purpose of this study is to characterise four unique open reading
frames (ORFs) of A1HV-1 and examine their contribution to viral pathogenesis.
These ORFs are located at the left hand end of the genome, a region known to contain
unique transforming and immunomodulatory genes in other gammaherpesviruses, and
are predicted to encode two small gene products with no significant homology to any
known proteins (ORF A1 and ORF A4), a transcription factor (ORF A2) and a
member of the semaphorin family (ORF A3).
A 6.2 Kb fragment from A1F1V-1 containing all four ORFs under their natural
promoters was cloned into the left hand end region of murine gammaherpesvirus-76
(MHV-76). This allowed for the study of the in vivo contribution to pathogenesis of
the gene products in a well characterised small animal model. The recombinant virus
showed no difference in its ability to replicate in vitro. Viral titres and lung pathology
in infected mice were also comparable although the A1HV-1 gene transcripts were
detectable.
The ORF A2 gene product expressed as a recombinant fusion protein in mammalian
cells consistently showed nuclear localisation, supporting the prediction that this
protein functions as a transcription factor. However, attempts to conclusively
demonstrate transcriptional activity of this protein were unsuccessful.
The four left hand end genes were also used to screen a novel bovine cDNA library in
a yeast two-hybrid system. Although no specifically interacting proteins could be
identified and confirmed, analysis of the bait constructs used indicated thai there is a
domain or domains in the C-terminus of the ORF A2 gene product capable of
interacting with DNA or DNA binding proteins, again supporting a role for this
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The family Herpesviridae includes a large number of enveloped, double stranded (ds)
DNA viruses that infect a broad range of host species (reviewed in Roizman & Pellett,
2001). Over 130 herpesviruses have currently been isolated from species as diverse
as humans and oysters. With newer, more sensitive techniques available for the
detection of novel viruses (Ehlers, 2005), the number of known viruses and host range
is likely to increase. Herpesviruses are thought to have co-evolved closely with their
natural host species. This is supported by the presence of cellular gene homologues in
most viruses and the fact that fatal infections in immunocompetent natural hosts are
rare.
The range of clinical outcomes resulting from herpesvirus infections can vary greatly
from inapparent infection to death. Herpesvirus infections, especially in
immunocompromised or heterologous hosts, have been associated with a number of
fatal conditions including encephalitis and tumour formation.
A number of biological properties are shared by all herpesviruses (reviewed in
Roizman & Pellett, 2001). First, all encode proteins involved in DNA synthesis,
nucleotide metabolism and protein processing. Second, viral DNA synthesis and
capsid assembly occurs in the nucleus with capsids initially becoming enveloped as
they pass through the nuclear membrane. Third, the production of infectious virions
is accompanied by the destruction of the infected cell. Finally, all herpesviruses are
capable ofmaintaining a latent infection in their natural host.
In addition to the genes encoding structural proteins and enzymes involved in viral
replication, herpesviruses encode an array of proteins involved in virus-host
interactions. These include proteins responsible for the modulation of the host cell
environment (e.g. interacting with cell cycle machinery) and the subversion of host
resistance at both the cellular (e.g. blocking apoptosis) and organism (e.g. immune
evasion and immunomodulation) levels.
1.1.1 Herpesvirus Structure
Virion architecture is well conserved among the herpesviruses. The structure of a
typical virion is shown in Figure 1.1. The linear dsDNA genome is tightly packed in
















Between the capsid and the envelope is a substance named the tegument. Although
generally amorphous in appearance, cryoelectron tomography and immunoelectron
microscopy have shown the presence of filament structures and polarity across the
tegument indicating that it does possess some order (Grunewald et al., 2003; Stefan et
al., 1997). Surrounding the tegument is a lipid envelope with a typical trilaminar
appearance (Epstein, 1962). The cellular origin of the virion envelope will be
discussed further in Section 1.3.1. Protruding from the envelope are a number of viral
glycoproteins. Cryoelectron tomography has shown that these glycoproteins are
distributed non-randomly in the envelope, suggesting functional clustering
(Grunewald et al., 2003). Due to variation in the tegument thickness, the overall size
of herpesvirus virions can range from 120 to nearly 300 nm.
1.1.2 Herpesvirus Genomes
The genome length of herpesviruses can vary from approximately 120 to 250 kilobase
pairs (kb). Internal and terminal reiterated sequences are commonly found in
herpesvirus genomes. In some cases, the copy number of these repeat sequences can
lead to variation in the genome length of individual viruses of up to 10 kb.
Herpesviruses can be divided into six groups, designated by the letters A to F, based
upon the presence, number and location of these reiterated sequences. Diagrammatic
representations of the sequence arrangements of these six groups adapted from
Roizman et. al. (1992) are shown in Figure 1.2. In group A viruses, a large region
from one terminus of the genome is directly repeated at the other terminus. These
regions are designated the left terminal repeat (LTR) and right terminal repeat (RTR).
The genomes of group B viruses contain a variable number of directly repeated
sequences at both termini. Similar direct repeats are present at the termini of group C
virus genomes although these are generally fewer in number. In addition, the unique
sequences of group C viral genomes are subdivided by other, unrelated, directly
repeated sequences of greater than 100 base pairs (bp). The unique sequences of
group D viral genomes are separated into unique long (or large, Ul) and unique short
(or small, Us) domains by an inverted repeat of the sequence from the other terminus
of the Us domain. The Us domain can invert relative to the Ui. domain. As such,
DNA extracted from virions or infected cells contains two equimolar populations
differing only in the Us orientation. The unique sequences of group E viral genomes
are also divided into Ul and Us domains. Each of these domains is flanked by its own
4
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Figure 1.2. Diagrammatic representations of the sequence arrangements of the six
classes of viral genomes comprising the family Herpesviridae with unique sequences
represented by lines and repeat sequences represented by rectangles. Where
appropriate, the relative orientations of repeat sequences are indicated with arrows. The
genomes of group A viruses (eg. channel catfish herpesvirus) contain a large sequence
from one terminus directly repeated at the other terminus. The genomes of group B
viruses (eg. herpesvirus saimiri) contain a variable number of directly repeated
sequences at both termini. The genomes of group C viruses (eg. Epstein-Barr virus)
contain both terminal repeats and other unrelated repeat sequences that subdivide the
unique sequence. The unique regions of the genomes of group D viruses (eg. varicella-
zoster virus) are divided into two segments separated by an inverted repeat of the
terminal region from the short (Us) segment. The unique regions of the genomes of
group E viruses (eg. herpes simplex virus and human cytomegalovirus) are similarly
divided with inverted repeats flanking both the long (UL) and Us regions. No repeat
regions have been described in the genomes of group F viruses (eg. tupaia herpesvirus).
Adapted from Roizman et. al. 1992. Details in text Section 1.1.3.
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inverted repeat sequence, referred to as the Rl (long or large) and Rs (short or small)
repeat. Like the Us domains of group D viruses, both the Ul and Us domains of
group E viruses can invert relative to each other meaning that four possible isomers





The family Herpesviridae is divided into three subfamilies: Alphaherpesvirinae,
Betaherpesvirinae and Gammaherpesvirinae. Classification of viruses into these
subfamilies was originally performed on the basis of biological properties of the virus
such as host range, reproductive cycle kinetics and the site of establishment of latent
infection (Roizman et al., 1973; Roizman, 1979). Classification is now performed on
the basis of DNA and protein sequence properties including viral DNA polymerase
and glycoprotein B (gB) sequences as well as gene content and genome arrangement
(Roizman et al., 1992). In most cases, this new basis for classification has supported
previous system although it has resulted in the re-classification of March's disease
virus (MDV) as an alphaherpesvirus rather than a gammaherpesvirus. In addition to
the three main subfamilies, the genus Ictalurivirus has been established to contain
channel catfish herpesvirus (Ictalurid herpesvirus 1) and related viruses that do not fit
neatly into any of the other subfamilies.
1.2.1 Alphaherpesviruses
Alphaherpesviruses classically have a wide host range, short reproductive cycle and
rapid spread in culture. Infection of most cell types with alphaherpesviruses leads to
productive lytic infection and the establishment of latency occurs in only a few cell
types, usually neuronal cells. Members of the Alphaherpesvirinae are subdivided into
four genera: Simplexvirus (including herpes simplex virus 1, HSV-1), Varicellovirus
(including varicella-zoster virus, VZV), Mardivirus (including MDV) and Iltovirus
(including infectious laryngotracheitis virus).
HSV-1 and HSV-2
HSV-1 (human herpesvirus 1, HHV-1) and HSV-2 (human herpesvirus 2. HHV-2) are
two closely related, widespread human pathogens. HSV-1 and HSV-2 are generally
associated with oral and genital infections, respectively, although this distinction is far
from absolute. HSV infections have a broad spectrum of disease associations ranging
from mild cutaneous lesions to potentially fatal encephalitis. Primary 11SV infection
is generally asymptomatic and is followed by the establishment of latency in the
ganglia innervating the site of infection. Reactivations are associated with episodes of
7
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disease, the frequency of which can vary depending on virus subtype and site of
infection.
Lesions on the lip (cold sores) are the most common manifestation of HSV-1
reactivation and are estimated to occur in 20-40% of adults (Bader et al., 1978; Embil
et al., 1975). Similarly, genital vesicular lesions are caused by reactivations of HSV-
2 and, based on viral seroprevalence, are estimated to occur in 5-25% of the adult
populations ofWestern countries (Smith & Robinson, 2002).
A number of other conditions are associated with HSV infections. For example,
HSV-1 can cause ocular infections and is a major cause of vision loss (Darougar et
al., 1985). HSV infection can cause potentially serious complications of atopic
eczema (Bork & Brauninger, 1988) and can also trigger the severe cutaneous
conditions erythema multiforme and Stevens-Johnson syndrome (Schotleld et al.,
1993). The most serious manifestation of HSV infection is herpes simplex
encephalitis which can cause neurological impairment and death, particularly in
neonates (Ferrante et al., 2000).
vzv
VZV, or human herpesvirus 3 (HHV-3), is another widespread, highly transmissible
human alphaherpesvirus. Primary infection usually occurs during childhood via the
inhalation of infectious droplets. Virus is disseminated via the blood and viraemia is
normally accompanied by the appearance of widespread skin lesions known as
"chicken pox" or varicella (Asano et al., 1990; Ito et al., 2001; Mainka et al., 1998).
Primary VZV infection can also be associated with pneumonia and other serious
systemic infections (Rawson et al., 2001).
VZV establishes latency in sensory ganglia (Kennedy et al., 1998; Lungu et al.,
1995). In contrast to the frequent reactivations seen with HSV, reactivation of VZV
normally occurs only once. This reactivation results in herpes zoster, the appearance
of a vesicular rash generally restricted to a single dermatome and accompanied by
sharp radicular pain. Following resolution of the zoster rash itself, pain and
sensitivity can persist in the affected dermatome for months or even years in a
condition known as post herpetic neuralgia.
8
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MDV
Marek's disease is a condition of chickens originally associated with polyneuritis and
visceral lymphoma (Marek, 1907; Pappenheimer et ah, 1929a; Pappenheimer et ah,
1929b). The aetiological agent of this disease, MDV (or gallid herpesvirus 2, GaHV-
2), was originally classified as a gammaherpesvirus based on its oncogenic potential
and slow growth in tissue culture but has since been classified as an alphaherpesvirus
(Fukuchi et al., 1984).
The tissue culture isolation of MDV in the 1960s allowed for the production of
vaccine strains of the virus (Churchill et al., 1969). Inoculation with these vaccine
strains initially reduced the incidence of disease by 99%. However, the use of such
vaccines led to the emergence of strains that were both resistant to vaccination and
induced a more severe acute disease referred to as virulent MDV (vMDV). The
production of new vaccine strains to immunise against emerging resistant strains has
influenced the evolution of the virus such that very virulent (vv) and vv+ strains have
since emerged (Witter, 1997). The nature of the disease induced by these emerging
strains has also changed into an acute or peracute condition in which peripheral
neuritis and lymphoma can be absent and neurological signs including paralysis and
massive brain lesions dominate (Gimeno et al., 1999; Gimeno et al., 2001; Witter et
ah, 1999).
1.2.2 Betaherpesviruses
The host range for the members of the subfamily Betaherpesvirinae is more limited
than that of alphaherpesviruses. Betaherpesviruses have a long reproductive cycle
and grow slowly in vitro. Like alphaherpesviruses, infection of most cell types with
betaherpesviruses leads to productive lytic infection although latent infection can be
established, predominantly in cells of the monocyte/macrophage lineage. This
subfamily is subdivided into three genera: Cytomegalovirus (including human
cytomegalovirus, HCMV), Muromegalovirus (including murine cytomegalovirus,




HCMV is a ubiquitous human pathogen infecting between 50 and 90% of the adult
population, depending on geographic location and other socio-economic factors
(Gandhi & Khanna, 2004). Primary infection is generally asymptomatic but can lead
to the development of an infectious mononucleosis similar to that caused by EBV
(Stern, 1968). Latent infection is established in mononuclear cells and reactivations
are associated with shedding of the virus from mucosal sites (Mocarski, 2004).
Although normally asymptomatic, the presence of HCMV has been linked to a
number of chronic inflammatory conditions.
Complications with HCMV infection are a major problem for neonates and
immunosuppressed individuals. Congenital HCMV infection is the leading infectious
cause of mental retardation and a number of other birth defects including deafness
(Boppana et al., 1999; Pass et al., 2006). HCMV is also the most important viral
pathogen related to opportunistic infections following both solid organ and stem cell
transplantation with potentially fatal pneumonitis being the most serious
manifestation of disease (Gandhi et al., 2003). The severity and incidence of these
infections has led to the categorisation of HCMV as a Level 1 vaccine candidate by
the Institute of Medicine (Arvin et al., 2004) and several vaccine studies arc currently
underway.
1.2.3 Gammaherpesviruses
The subfamily Gammaherpesvirinae contains a number of viruses of importance to
human and veterinary health. Gammaherpesviruses are classically perceived to have
a narrow host range although this is not altogether accurate as the natural host range
of some members can extend across an entire animal order. Unlike alpha- and
betherpesviruses, the lytic replication of gammaherpesviruses is generally supported
only by a subset of cell types and they tend to favour latent infection, particularly in
their natural hosts and usually in lymphocytes. As such, many gammaherpesviruses
encode proteins involved in the maintenance of latent genomes in dividing cells. In
addition, the genomes of gammaherpesviruses contain more homologues of cellular
genes than do those of the alpha- and betaherpesviruses. These genes tend to be
located at the terminal regions of the genome and a number of specific examples are
discussed in Section 1.5. The Herpesvirus Study Group of the International
10
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Committee on Taxonomy of Viruses currently has the subfamily
Gammaherpesvirinae subdivided into two genera: Lymphocryptovinis or gamma-1,
(including Epstein Barr virus, EBV) and Rhadinovirus or gamma-2 (including
herpesvirus saimiri, HVS).
EBV
EBV, or human herpesvirus 4 (HHV-4), is the prototypic lymphocryptovirus and one
of the best studied of the gammaherpesviruses. EBV is highly prevalent and infects
the vast majority of adults worldwide. Primary infection usually occurs during
childhood and is asymptomatic. However, primary infection during adolescence can
lead to the development of an acute infectious mononucleosis (IM) (McCollum, 1970)
characterised by fever, lymphadenopathy, tonsillitis, pharyngolaryngitis and skin
eruptions.
Latent EBV infection in B lymphocytes is associated with the formation of a number
of neoplastic conditions including Burkitt's lymphoma, Hodgkin lymphoma, and
nasopharyngeal carcinoma (Henle & Henle, 1970). These and other neoplasms often
present in patients with immunodeficiencies arising from age, human
immunodeficiency virus (HIV) infection or immunosuppressive drug treatment
(Ambinder & Mann, 1994; Hanto et al., 1981; Shibata et al., 1991b; Shibata et al.,
1991a). In certain geographic areas, however, EBV-associated cancers can occur in
the absence of immunodeficiency (Harabuchi et al., 1990; Kawa-Ha et al., 1989;
Magana et al., 1998; Su et al., 1995) indicating a role for host genetic background or
environmental co-factors in their development.
HVS
HVS is the prototypic rhadinovirus. The natural host of HVS is the squirrel monkey
(,Saimiri sciureus) which becomes infected early in life and maintains a lifelong
persistent infection. No apparent disease is caused in the natural host during either
acute infection or persistence (Melendez et al., 1968). In contrast, infection of other
New World and Old World monkeys has been shown to cause lymphomas and can
induce T cell leukaemia.
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HVS strains have been classified based on their left hand end sequence similarities
and their pathogenicity in different hosts (Medveczky et al., 1989; Medveczky et al.,
1984). Subgroup B viruses have the lowest oncogenic potential and subgroup C
viruses have the highest. In vitro, representative strains from all three subgroups have
been shown to immortalise peripheral blood mononuclear cells (PBMC) from
common marmosets (Szomolanyi et al., 1987), although those immortalized by the
subgroup B virus (SMH1) still required supplemental interleukin-2 (1L-2) for growth.
Although all three subgroups sub-clinically infect the HVS natural host, they differ in
their abilities to cause disease in other species. Cottontop tamarins (Saguinus
oedipus) are highly susceptible to HVS and infection by any of the subgroups can
induce disease (Falk et al., 1972; Hunt et al., 1970a; Knappe et al., 1998). Disease
caused by all three subgroups has also been reported in another new world species the
common marmoset (Callithrix jacchus) (Duboise et al., 1998; Laufs & Fleckenstein,
1973; Wright et al., 1977), although there have been reports that this species is not
susceptible to infection with subgroup B viruses (Laufs & Melendez, 1973). Disease
in Old World primate species, such as rhesus monkeys (Macaca mullata) and
cynomolgus macaques (Macaca fascicularis), has only been reported for subgroup C
viruses (Alexander et al., 1997; Knappe et al., 2000) as has the in vitro transformation
of human T cells (Biesinger et al., 1992).
KSHV
Kaposi's sarcoma-associated herpesvirus (KSHV) or human herpesvirus 8 is the most
recently discovered human herpesvirus and, to date, the only human rhadinovirus.
Kaposi's sarcoma (KS) is a connective tissue cancer forming highly vascular, dark
lesions containing abnormal, elongated tumour cells known as spindle cells.
Historically, KS was known to occur rarely in elderly Mediterranean men (classic KS)
and in patients receiving immunosuppressive therapy. In the 1980s, a drastic increase
in the incidence of KS was seen in HIV patients (epidemic KS). KSHV was
discovered in 1994 in the search for an infectious agent related to this outbreak
(Chang et al., 1994) and epidemiological evidence has since demonstrated that KSHV
is the causative agent of all forms of KS (Birley & Schultz, 1997; Sarid et al., 1999).
In addition to KS, KSHV has been associated with a number of other tumours
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including primary effusion lymphoma (PEL) (Cesarman et al., 1995) and some forms
ofmulticentric Castleman's disease (Soulier et al., 1995).
MHV-68
Murine gammaherpesvirus 68 (MHV-68), or murid herpesvirus 4 (MilV-4), has
proven to be a useful model for the in vivo study of gammaherpesvirus infections. As
mutagenesis of the virus is relatively straightforward and it is capable of infecting
laboratory mouse strains, the influence of both virus and host genetics on viral
pathogenesis can be studied.
Transmission of MHV-68 is thought to occur via the intranasal route. Experimental
infection of laboratory mouse strains using this route initially leads to a productive
lytic infection in the lungs, predominantly in the alveolar epithelial cells but also in
mononuclear cells (Sunil-Chandra et al., 1992a). From the lung, the virus is
transported to the draining lymph node (the mediastinal lymph node, MEN) where
infection of B cells takes place. Latently infected B cells traffic from the MLN to the
spleen and undergo a rapid expansion (Sunil-Chandra et al., 1992b). This expansion
and resulting increase in spleen size is accompanied by an increase in the number of
latently infected cells. This peak of latently infected cells recedes over the course of a
few weeks and a latent infection in the spleen is maintained at a fairly constant level
for the life of the animal (Flano et al., 2002; Sunil-Chandra et al., 1992a; IJsherwood
et al., 1996). Although the spleen is the major reservoir of latent virus, latently
infected cells can also be found in other tissues including the lungs (Flano et al.,
2000; Flano et al., 2003).
Although the vast majority of studies are based upon the infection of laboratory
mouse strains, it must be remembered that this does not represent a "natural host".
The virus was first isolated from bank voles (Clethrionmys glareolus) in Slovakia in
1980 (Blaskovic et al., 1980) and has been shown to be endemic in wood mice
(Apodemus flavicollis) in the UK (Blasdell et al., 2003). Recent studies have shown
that viral pathogenesis is markedly different in experimentally infected wood mice as
compared to laboratory strains (Hughes et al., 2005).
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MCF Viruses
A number of related gammaherpesviruses have been shown to cause the devastating
lymphoproliferative disease known as malignant catarrhal fever (MCF) in several
susceptible ruminant species. This disease and its viral agents will be discussed in
greater detail in Section 1.4.
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1.3 Herpesvirus Life Cycle
To successfully persist within individuals and populations as a whole, herpesviruses
have adopted a strategy in which infection at a cellular level can lead to two different
outcomes: lytic viral replication or viral latency. Lytic replication produces infectious
virus to disseminate infection within the host or infect another individual. During
viral latency, however, virus persists within an infected cell as circular episomal DNA
and no infectious virus is produced. Latent virus is able to reactivate to produce a
lytic infection and it is this ability that differentiates latency from abortive infection.
1.3.1 Lytic Replication
This section describes the processes involved in lytic viral replication. A
diagrammatic overview of these processes is also shown in Figure 1.3. The lytic
cycle described here is based primarily on that of HSV-1 (reviewed in Roizman &
Knipe, 2001) as its replication is well studied and thought to be broadly analogous to
that of other herpesviruses.
Attachment and Entry
The attachment of HSV-1 virions to the surface of cells and their subsequent
internalisation can effectively be split into three stages. This begins with relatively
low-affinity attachment to the cell surface followed by more specific receptor
interactions and, finally, fusion of the viral envelope with the cell membrane.
The first stage of attachment involves the interaction of glycoprotein C (gC) and, to a
lesser extent, gB on the viral envelope with glycosaminoglycan (GAG) moieties on
the cell membrane. The predominant, GAG containing, glycoprotein involved in this
process is heparan sulphate (Shieh et al., 1992; WuDunn & Spear, 1989) although
binding can occur in its absence utilising other glycoproteins such as chondriotin
sulphate. The attachment of gC and gB to these GAG moieties is not essential for
infection although, in its absence, the efficiency of infection is reduced (Banfield et
al., 1995).
The second stage of attachment is mediated by interactions between viral gl) and one
of a number of possible cell surface molecules. These coreceptors can be split into
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molecules, immunoglobulin (Ig) superfamily members called nectins and a third class
consisting solely of 3-O-sulphated heparan sulphate. The TNFR family includes
HveA (Montgomery et al., 1996; Warner et al., 1998), a molecule that is present
predominantly on lymphocytes and is therefore unlikely to be the major mediator of
HSV-1 entry in vivo. Nectins, including HveB (Warner et al., 1998) and HveC
(Geraghty et al., 1998), have a wide tissue distribution and can mediate entry of all
HSV-1 strains tested. The 3-O-sulphated heparan sulphates also have a wide tissue
distribution and can mediate efficient HSV-1 entry (Shukla et al., 1999).
Studies on the process of fusion between the viral envelope and the cell membrane
have demonstrated the involvement of gD, gB and the gL-gH heterodimer as virions
lacking any of these proteins show no infectivity (Cai et al., 1988; Forrester et al.,
1992; Ligas & Johnson, 1988; Sarmiento et al., 1979). In addition, cultured cells
expressing this set of glycoproteins are able to fuse with untransfected neighbouring
cells (Muggeridge, 2000; Turner et al., 1998). The precise role of these proteins in
this process, however, remains unclear. Recent studies have suggested that unbound
gD exists in a closed conformation (Cocchi et al., 2004) and assumes different
conformations when bound to one of its receptors (Fusco et al., 2005). It is
hypothesised that these changes permit the recruitment of gB, gL and gfl leading to
the formation of a functional fusogen complex.
The three stage process of viral attachment and entry appears to be similar for all
herpesviruses although the molecules involved differ. Like HSV, initial tethering of
HCMV is mediated by interactions with cell surface GAG containing glycoproteins
(Boyle & Compton, 1998). Both gB and the gM-gN heterodimer are thought to
participate in this interaction. The initial attachment of EBV is mediated by
interactions of the abundant glycoprotein gp350/220 and cell surface complement
receptor 2 (CR2 or CD21) (Carel et al., 1990). Initial attachment interactions are also
thought to be carried out by the gp350/220 homologues identified in other
gammaherpesviruses including gpl50 of MHV-68 (Stewart et al., 2004) and K.8.1 of
K.SHV (Sun et al., 1999) although surface receptors for these molecules have not been
identified. No direct counterpart to gD has been found in the beta- and
gammaherpesviruses and these viruses employ different molecules to mediate specific
attachment. Interactions between cell surface epidermal growth factor receptor
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(EGFR) with viral gB have been shown to be involved in the stable attachment of
HCMV to cells (Wang et al., 2003). However, the absence of EGFR from
haematopoietic cells including monocytes and macrophages indicates that another
HCMV receptor exists. In EBV, this interaction involves viral gp42 and cellular class
II major histocompatibility complex (MHC) molecules (Borza & Hutt-Fletcher, 2002;
Wang et al., 1998; Wang & Hutt-Fletcher, 1998). Homologues of gp42 have also
been described in other gammaherpesviruses including K7 of KSHV (Russo et al.,
1996). The details of beta- and gammaherpesvirus virion entry is not yet known in
detail although, like HSV-1, complexes of gB, gH and gL are thought to be involved
in the final fusion event.
Gene Expression and DNA Replication
Following membrane fusion, viral capsids are transported along the microtubule
network to the nuclear membrane (Lycke et al., 1984; Lycke et al., 1988; Penfold et
al., 1994). During this process, some tegument proteins remain in the cytoplasm
while others are transported along with the nucleocapsid. When nucleocapsids reach
the nuclear membrane, they associate with the nuclear pore complex (Batterson et al.,
1983; Sodeik et al., 1997) through which they release their DNA into the nucleus.
The majority of viral DNA circularises upon nuclear entry without prior viral protein
synthesis (Garber et al., 1993; Poffenberger et al., 1983).
The expression of viral genes occurs as a highly regulated cascade (lioness &
Roizman, 1975). The first viral genes expressed are the a (immediate early or IE)
genes. By definition, the transcription of these genes in all herpesviruses occurs
initially in the absence of prior viral protein synthesis. However, the precise
mechanism by which transcription takes place varies between different viruses.
During HSV infection, the tegument protein VP16 plays an important role in the
induction of a gene transcription (Campbell et al., 1984). VP 16 is released from the
tegument following viral entry into the cell forms a complex first with the cellular
protein host cell factor-1 (HCF-l) (Xiao & Capone, 1990) and subsequently with the
octamer binding protein Oct-1 (Kristie & Roizman, 1987; Gerster & Roeder, 1988;
Kristie et al., 1989). Oct-1 binds 'TAATGARAT' regulatory elements present in the
promoter regions of the five HSV a genes ICP0, ICP4, ICP22, ICP27 and 1CP47. The
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recruitment of the VP16/HCF-1 complex to this protein leads to the transcription of
these genes and the initiation of the viral gene cascade.
In gammaherpesviruses, a number of transactiator proteins are involved in the
initiation of a gene expression. Of these, the R-transactivator or Rta protein encoded
by the BRLF1 gene of EBV (Hardwick et al., 1988) and its homologues encoded by
the ORF50 genes of gamma-2-herpesviruses (Whitehouse et al., 1997; Sun et al.,
1998; Wu et al., 2000) have been shown to have particular importance. Expression of
Rta has been shown to be sufficient for the induction of lytic replication in latently
EBV infected cell lines (Ragoczy et al., 1998). Similarly, the ORF50 gene products
ofMHV-68, HVS and KSHV were also capable of driving lytic replication in latently
infected cells (Gradoville et al., 2000; Goodwin et al., 2001; Wu et al., 2000). EBV
Rta has been shown to activate the transcription of a number of viral a genes
including other transactivators such as Zta and Mta as well as autoregulating its own
transcription (Zalani et al., 1992). Mta and its homologues encoded by ORF57 in the
gamma-2-herpesviruses are important multifunctional proteins whose functions
include the post-transcriptional activation and repression of a number of viral genes
and the shuttling of intronless viral mRNAs (Whitehouse et al., 1998; Goodwin et al.,
2000; Chen et al., 2001; Williams et al., 2005).
The majority of the a gene products are involved in the transcription of [1 (early or E)
genes. The gene products of the P genes have a wide range of functions including
nucleotide metabolism and viral DNA replication. The p gene products involved in
DNA synthesis localise to the nucleus where replication of the circular viral DNA
molecule begins. A number of these proteins cluster at origins of replication of the
viral genome. DNA synthesis initiates in a theta replication mechanism but switches
to a rolling circle mechanism in which long "head-to-tail" concatamers of viral
genomic DNA are produced. As replication proceeds, accumulation of progeny DNA
molecules and replication complexes is seen in globular nuclear structures called
replication compartments (Quinlan et al., 1984).
Following the initiation of DNA replication, the transcription of the y (late or L) genes
occurs. The y genes can be loosely split into the yi (leaky-late or early-late) genes
that are expressed relatively early and whose transcription is increased by DNA
replication and the y2 (true-late) genes that are expressed later. The transcription of
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the 72 genes is intimately linked to DNA replication and can be effectively blocked in
the presence of DNA synthesis inhibitors. The y genes encode, among other things,
the structural proteins necessary for the assembly of progeny virions. The cascade
system of gene expression leads to an increased relative abundance of transcripts of
these later temporal classes (Zhang et al., 1987) and this is likely to represent the
increased need for these structural proteins.
Assembly and Egress
Progeny virus capsids are formed in the nucleus (Gibson & Roizman, 1972) although
the assembly of some capsid proteins begins in the cytoplasm (Nicholson el al., 1994;
Rixon et al., 1996). Before the insertion of DNA, capsids are supported by an inner
protein scaffold. The insertion and packaging of viral genomes into these procapsids
is tightly coupled to their cleavage from the long "head-to-tail" concatamers into unit-
length molecules (Newcomb et al., 1996; Newcomb et al., 1999; Newcomb et al.,
2000).
The majority of current evidence supports a model in which progeny virions mature
through a process in which a primary envelope is acquired and subsequently lost by
budding through the nuclear membrane and a final secondary envelope is acquired by
budding into the trans-Golgi network (reviewed in Mettenleiter, 2002; Mettenleiter,
2004; Mettenleiter, 2006). Following a partial dissolution of the nuclear lamina
(Muranyi et al., 2002), nucleocapsids are directed to the inner leaflet of the nuclear
membrane through which they bud and acquire a primary envelope (Vlazny et al.,
1982). Membrane fusion occurs between the enveloped particle and the outer leaflet
of the nuclear membrane, releasing the nucleocapsid into the cytoplasm. In contrast
to the membrane fusion mediating viral entry into the cell, this process occurs in the
absence of viral glycoproteins but does require the viral protein US3 (Klupp et al.,
2001; Reynolds et al., 2002). Tegumentation of the capsid in the cytoplasm occurs
through a complex series of interactions involving at least fifteen viral tegument
proteins (reviewed in Mettenleiter, 2006). The acquisition of a secondary envelope
takes place as the viral particle buds into the trans-Golgi network (Gershon et al.,
1994; Granzow et al., 2001; Jones & Grose, 1988; McMillan & Johnson, 2001; Severi
et al., 1988; Whealy et al., 1991; Whiteley et al., 1999; Zhu et al., 1995) in a process
requiring the presence of the viral membrane glycoproteins gE and gM (Brack et al..
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1999). Mature progeny virions reach the cell surface by vesicular movement through
the Golgi apparatus. In addition to viral spread from the release of progeny virions
into the extracellular space, HSV has been shown to be capable of direct cell to cell
spread in a process requiring a complex of gE and gl (Dingwell et al., 1994; Dingwell
& Johnson, 1998) that most likely occurs at cell junctions.
1.3.2 Herpesvirus Latency
The ability to establish latent infection is an important feature common to all
herpesviruses. The mechanisms adopted for the establishment, maintenance and
reactivation from latency by different viruses in different cell types show a great deal
of variation. Described below are the strategies employed by HSV-1 and EBV.
HSV-1
At some point during the primary lytic infection of epithelial cells with HSV-1, virus
enters the nerve endings of neurons innervating the mucosal epithelium. Viral entry is
followed by retrograde transport of the capsid to the cell body in the sensory ganglion.
Like all herpesviruses, latent HSV-1 is maintained in the cell as circular episomal
DNA.
The only viral transcripts regularly detected in latently infected neurons are the
latency associated transcripts (LATs) (Stevens et al., 1987). The LATs arc a family
of one large (8.3 kb) transcript that maps to the inverted repeats flanking the Ul
domain of the HSV-1 genome and two smaller (2.0 and 1.5 kb), relatively more
abundant, introns derived from the larger transcript (Devi-Rao et al., 1991; Krause et
al., 1988; Wagner et al., 1988a; Wagner et al., 1988b). Despite being the focus of a
great deal of investigation, the function of the LATs remains unclear. One thought is
that the LATs may play a role in the down-regulation of lytic gene expression,
possibly through the expression of a protein product, structural effects on the viral
genome or antisense down-regulation of transcripts of a genes involved in lytic
replication such as ICPO and 1CP4 (Chen et al., 1997; Garber et al., 1997).
LATs have also been shown to protect infected neurons from apoptosis (Perng et al.,
2000). This function of the LATs has been mapped to a region within the lirst exon
(Ahmed et al., 2002; inman et al., 2001). Recently, it has been shown that this region
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encodes a microRNA (miRNA) and it is this rniRNA that confers resistance to
apoptosis (Gupta et al., 2006). miRNAs are a class of small 21-23 nucleotide non-
coding RNAs that can direct cleavage or regulate transcription of mRNAs containing
complementary sequences. A number of miRNA sequences have been found in other
herpesviruses including the human herpesviruses EBV, KSHV and CMV. The anti-
apoptotic properties of the LAT encoded miRNA was shown to be mediated by the
downregulation of transforming growth factor-(3 1 (TGF-pi) and SMAD3 expression
(Gupta et al., 2006).
A number of physical and chemical stimuli are known to be associated with the
reactivation of HSV-1 from latency including injury, hypothermia, UV irradiation,
hormonal imbalance and stress. The biochemical basis for reactivation is less clear.
Attempts to identify viral genes involved in this process have been hampered by the
fact that many of these same genes are likely also involved in lytic replication and
mutant viruses will therefore be defective other areas.
EBV
Rather than the relatively stable environment of non-dividing neurons, latent EBV
infection occurs in dividing B cells and there are therefore a different set of
requirements placed upon the virus for its continued survival. In order to persist
within this cellular population, the virus must maintain its genome and promote the
survival and proliferation of the host cell by affecting signalling pathways,
manipulating the immune response and preventing apoptosis. Up to eleven viral
genes can be expressed during latency in order to carry out some or all of these
functions. Three states of EBV latency can be seen in infected cells: Latency I, II and
III (Rowe et al., 1992). These distinct forms are defined by the set of viral transcripts
present. Recently, a fourth state of latency in which all latent transcripts are down
regulated has been described in resting peripheral memory B cells (Hochberg et al.,
2004). It has been proposed that signals from the viral genes expressed in the other
states of latency function to drive the differentiation of infected B cells into this long-
lived memory cell type (Thorley-Lawson, 2001; Thorley-Lawson & Gross, 2004).
Latency I can be seen in EBV infected cells derived from patients with Burkitt's
lymphoma. The only viral transcripts from these cells are the nuclear antigen EBNA-
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1 and three untranslated transcripts, one from the BamW\ A region (BAR I s) and the
two EBV-encoded small nuclear RNAs (ERER-1 and EBER-2). EBNA-1 plays a
crucial role in the faithful partitioning of the EBV genome into daughter cells during
mitosis via its interaction with the OriP element of the viral genome (Yates et al.,
1984; Yates et al., 1985). The EBERs are the most abundant RNA population in
latently infected cells (Howe & Shu, 1989) but, like the HSV-1 LATs, their functions
are not well understood although a recent study has demonstrated their involvement in
the transformation of B cells (Yajima et al., 2005). Additional possible functions of
these transcripts may include inactivation of the interferon-induced protein kinase
PKR and RNA splicing. Like the HSV LATs, the BARTs have been shown to encode
two miRNAs with predicted cellular targets involved in cell proliferation and
apoptosis, B cell cytokines and chemokines, transcriptional regulators and
components of signal transduction pathways (Pfeffer et al., 2004). Cells infected with
EBV in the Latency I stage are protected from immune detection as there is no
mechanism for the efficient detection of foreign nucleic acids and there does not
appear to be a cell mediated response directed at EBNA-1.
EBV infected cells expressing EBNA-1, the untranslated RNAs and the three latent
membrane proteins (LMP-1, LMP-2A and LMP-2B) are classed as Latency II.
Neoplastic cells with this expression pattern can be derived from patients with
nasopharyngeal carcinoma, Hodgkin's lymphoma and T cell lymphomas. LMP-l has
been shown to have transforming effects (Kaye et al., 1993) and can prevent
apoptosis by the induction of bcl-2 (Kingma et al., 1996). LMP-2A and LMP-2B are
involved in preventing the induction of lytic replication by inhibiting B cell activation
(Longnecker, 2000).
Latency III can be seen in cultured human B cells infected with EBV as well as cells
derived from B cell lymphomas in immunocompromised patients whose CTL
responses have been exhausted. In addition to the seven genes seen in Latency II,
these cells express another five nuclear antigens: EBNA-2, EBNA-3A. EBNA-3B,
EBNA-3C and EBNA-LP. These five proteins have a variety of roles in the up-
regulation and down-regulation of viral and cellular gene expression as well as
transformation of B cells.
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EBV periodically reactivates to lytic replication. These reactivations appear to occur
in memory B cell populations recirculating through the lymphoid tissue associated
with the oropharyngeal mucosa (Faulkner et al., 2000) upon the terminal
differentiation of these cells into plasma cells (Laichalk & Thorley-Lawson, 2005).
The precise stimuli leading to reactivation are not clearly understood although the
process does involve the viral proteins BZLF1 and BRLF1. BZLF1 alone is capable
of transactivating a number of other EBV a and p genes and thereby initiating the
cascade of lytic gene transcription (Hammerschmidt & Sugden, 1988). Reactivation
leads to the production of infectious virions that can be detected in oral secretions
through which the virus can be transmitted.
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1.4 Malignant Catarrhal Fever
Malignant catarrhal fever (MCF) is a devastating lymphoproliferative and necrotic
disease of cattle and other susceptible ruminant species. The disease can follow an
extremely short time course following the initial presentation of symptoms. MCF was
originally thought to be invariably fatal although a few cases of recovery have since
been reported (Milne & Reid, 1990; O'Toole et al., 1997). MCF was originally
reported in 1923 as a disease of African cattle that was associated with contact with
periparturient wildebeest herds (Mettam, 1923) and this form is often referred to as
wildebeest associated (WA-) or 'African' MCF. The identification of the disease in
European cattle was reported in 1930 (Goetze, 1930) and was associated with sheep
contact (sheep associated or SA-MCF). MCF in cattle is an economically significant
problem, particularly in sub-Saharan African and Indonesia.
The problem ofWA-MCF in sub-Saharan Africa is of particular importance to Maasai
pastoralist communities, to whom livestock play a central economic and social role.
A recent study was undertaken to evaluate the impact of MCF on these communities
(Cleaveland et al., 2001). In high-risk villages, MCF was considered to be the second
most important cattle disease and considered to be the fourth most important cattle
disease in low-risk villages. In high-risk areas, 86% of cattle herds were affected by
MCF with losses of between 5.6 and 6.2% in 2000. The Maasai are forced to
abandon grazing ground during wildebeest calving season to avoid MCF and this
confinement has caused an indirect increase in the burden of vector-borne and
directly-transmitted diseases. The increase in wildebeest numbers in the Serengeti
over recent years has only served to exacerbate the problem.
The preferred livestock in Indonesia, Balinese cattle (Bos javanicus) and the water
buffalo (Bubalus bubalis), are particularly susceptible to MCF (Wiyono et al., 1994b).
These animals are a major source of draught power and economic wealth to small¬
holder farmers. The disease in these animals was thought to be sheep associated, a
finding that was confirmed by detection of the causative agent of SA-MCF, ovine
herpesvirus 2 (OvHV-2) in the peripheral blood of diseased animals (Wiyono et al.,
1994a).
Precise figures for the impact of MCF are difficult to obtain as suspected MCF cases
are usually terminated prior to confirming the diagnosis. A recent report from the
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Veterinary Laboratories Agency has suggested that there is an increasing incidence of
MCF in the UK (Veterinary Laboratories Agency, 2006) although this may be due to
more efficient detection of disease.
Several ruminant species other than cattle are susceptible to MCF and disease in these
animals is also of great economic and scientific importance. Deer species are
particularly susceptible to MCF. Several reports on MCF outbreaks in farmed deer
populations have been published (Denholm & Westbury, 1982; Reid et al., 1979;
Reid et al., 1987; Westbury & Denholm, 1982a) including one in which losses of over
50% of a Pere David's deer (Elaphurus davidianus) herd were reported (Orr &
Mackintosh, 1988). Similarly, three farmed bison herds have been reported as
sustaining losses between 33% and 95% from SA-MCF where very rapid clinical
disease occurred (Li et al., 2006; Schultheiss et al., 2000). Losses due to disease
outbreaks in zoological and wildlife parks has interfered with conservation and
breeding programs (Bridgen et al., 1989; Hanichen et al., 1998) but has also led to the
identification of novel MCF viruses (Flach et al., 2002; Klieforth et al., 2002). The
recent discovery of MCF in pigs (Loken et al., 1998) has expanded the range of
susceptible hosts ofMCF viruses to include non-ruminant species.
1.4.1 MCF Viruses
A number of different but closely related gammaherpesviruses have been shown to
cause MCF.
AIHV-1
Alcelaphine herpesvirus 1 (AIHV-1) was shown to be the causative agent of WA-
MCF (Plowright et al., 1960). This virus inapparently infects its natural host the blue
wildebeest (Conochaetes taurinus taurinus) and all wildebeest calves over the age of
seven months are positive for virus (Plowright, 1967).
Studies on AIHV-1 have predominantly focused on two viral isolates. WC11 and
C500. WC11 was isolated in 1965 from a blue wildebeest (Plowright el al., 1965)
and has cell-free infectivity. The more virulent C500 was isolated from an ox with
MCF in 1975 (Plowright et al., 1975) and the infectivity of this virus is cell-
associated. Following serial passage in cultured cells, the WC11 isolate became
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attenuated and could no longer induce symptoms of MCF in cattle (Plowright et al.,
1975). Similarly, after around 30 rounds of serial passage in cultured cells the
infectivity of cell-associated virulent C500 becomes cell-free (Russell, 1980). This
adaptation in culture was also accompanied by a loss of pathogenicity in cattle. It has
since been shown that the conversion from cell-associated virulent (CAV) to cell-free
attenuated (CFA) forms of the virus is associated with genome re-arrangements
(Handley et al., 1995; Wright et al., 2003). Although the precise nature of these re¬
arrangements is not consistent between different clones, they did all involve the
translocation of a region from around the centre of the genome (containing ORF 50
and ORF A6) to areas at the right or left hand ends of the genome (Wright et al.,
2003). In some cases, the translocation event can cause truncations of ORF 50 and
ORF A6 and nearby genes including ORF 48 and ORF A7 could also be affected.
Preliminary characterisation of the A1HV-1 genomes (Bridgen et al., 1989) showed
that the unique region of low G + C content (L-DNA) of WC11 was approximately
130 kb in length. The high G + C content (H-DNA) region was approximately 30 kb
in length and consisted of a major repeat sequence of 950 bp interspersed with related
sequences of varying length. Analysis of the C500 genome demonstrated that it
contained a similar L-DNA region but the H-DNA was composed of a single repeated
sequence of around 1050 bp. Full sequence analysis of the C500 (CAV) genome
(Ensser et al., 1997) confirmed the presence of a 130,608 bp L-DNA unique region
with 46.17% G + C content flanked by 20-25 H-DNA repeats of 1,113 to 1,118 bp.
As shown in Figure 1.4, the L-DNA sequence encodes homologues of 60 conserved
herpesvirus ORFs, arranged in four blocks collinear to HVS, interspersed with ten
ORFs unique to A1HV-1.
OvHV-2
The isolation of the causative agent of SA-MCF proved more challenging than that of
A1HV-1. Until recently, most evidence for a virus closely related to AIIIV-1 being
responsible for SA-MCF relied on the cross reaction of sera from adult sheep
(Rossiter, 1981), cattle with MCF (Rossiter, 1983) and experimentally infected
animals (Reid et al., 1989b). Lymphoblastoid cell lines grown from established cases
of MCF were found to contain DNA sequences that hybridised to AlFIV-l DNA and
the infecting virus was tentatively classified as caprine herpesvirus-3 (Bridgen &
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Reid, 1991b) but was later re-named ovine herpesvirus-2 (OvHV-2). A fragment of
OvHV-2 DNA was isolated from OvHV-2 infected LCLs and used to develop a PCR
test specific for OvHV-2 (Baxter et al., 1993) that has subsequently been employed to
demonstrate the presence of this virus in several cases of suspected SA-MCF in a
wide range of species (Baxter et al., 1993; Ellis & Masters, 1997; Li et al., 1995;
Loken et al., 1998; Mirangi & Kang'ee, 1997; Muller-Doblies et al., 1998; Wiyono et
al., 1994a).
The genome of OvHV-2 has recently been cosmid cloned and sequenced (GenBank,
Accession # NC_007646). Analysis of an approximately 125 kb region of the L-DNA
has identified at least 70 predicted ORFs (Figure 1.4), 60 of which are conserved
between all herpesviruses and ten of which are unique to OvHV-2 or have
homologues only in A1HV-1 (Rosbottom, 2003). The nature of terminal repeat
sequences is not well characterised although the H-DNA is approximately 25-30 kb in
length.
Other MCF Viruses
In addition to A1HV-1 and OvHV-2, two other closely related gammaherpesvirus are
generally regarded as causative agents of MCF. One virus is known to cause classic
MCF disease in white-tailed dear (Odocoileus virginianus) and is currently termed
MCFV-WTD (MCF virus of white tailed deer) (Kleiboeker et al., 2002; Li et al.,
2000). The carrier species of this virus has yet to be identified. The other virus,
caprine herpesvirus 2 (CpFlV-2) is endemic in domestic goats (Capra hirctts) (Li et
al., 2001b) and has been shown to cause disease in at least two species of deer
(Crawford et al., 2002; Keel et al., 2003; Li et al., 2003b).
Other closely related viruses have been identified in ruminant species. Sequences
from alcelaphine herpesvirus 2 (A1F1V-2) in hartebeest (Alcelaphus buselapltus cokei)
and topi (Damaliscus korrigum) (Mushi et al., 1981), hippotragine herpesvirus 1 in
roan antelope (Hippotragus equinus) (Reid & Bridgen, 1991), MCFV-Muskox in
muskox (Ovibos moschatus), MCFV-Oryx in gemsbok (South African oryx, Oryx
gazelle) and MCFV-Ibex in Nubian ibex (Capra ttubiana) (Li et al., 2003a) have all
been identified using a combination of PCR with degenerate primers and serological
analysis. Although there is no conclusive evidence for these viruses causing disease
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in either their natural hosts or other ruminant species, a virus closely related to A1HV-
2 has been identified in a case of MCF-like disease in a group of Barbary red deer
(■Cervus elaphus barbarus) housed with clinically normal Jackson's hartebeest
(Alcelaphus buselaphus jacksoni) at a wild animal park in California (Klieforth et al.,
2002), suggesting that they may cause disease under certain circumstances.
1.4.2 Clinical Forms of MCF
MCF cases can be broadly classified into four clinical forms of the disease: peracute
MCF, intestinal MCF, head and eye form and mild MCF. The clinical symptoms are
essentially identical whether the disease is sheep (Selman et al., 1974) or wildebeest
associated (Piercy, 1952; Plowright, 1968). Although classification of the clinical
manifestations of MCF is helpful in the understanding of the disease, there is
significant overlap between the forms and they are of little practical value.
Peracute MCF is the most severe form of the disease. Symptoms include fever and
depression and occasionally inflammation of the oral and nasal mucosas. Affected
animals can succumb to disease within a few hours of initially displaying symptoms,
often due to severe hemorrhagic gastroenteritis.
The intestinal form of MCF is similar to the peracute form only with symptoms
becoming more pronounced as disease progresses and lymphadenopathy becoming
detectable. Animals usually die of intestinal MCF within four to nine days.
The head and eye form of MCF is the typical form seen in most instances of disease.
As the name suggests, symptoms are predominantly seen, but not restricted to, the
head and neck regions of the animal. Generalised lesions are frequently seen in the
oral mucosa accompanied by hyperaemia and slight to marked drooling. The muzzle
of the infected animal invariably has a dry, cracked and encrusted appearance. Nasal
discharge progressing from serous to mucopurulent and purulent is also invariably
seen. Mucopurulent discharge from the ocular mucosa is common and the eyelids are
often swollen. The eyes themselves show progressive corneal opacity and animals are
photophobic.
In addition to the symptoms seen in the head mucosa, several other clinical signs are
commonly seen in the head and eye form. Lymph nodes, especially those of the head
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and neck can be severely enlarged. Diseased animals can have a high fever, with
rectal temperatures of 41 to 42°C, but often become hypothermic prior to death. In
some cases, nervous disorders are apparent including head shaking, incoordination
and muscle tremors. The course of this form of MCF is usually seven to eighteen
days.
Mild MCF is classically associated with the disease induced by experimental infection
of susceptible species with attenuated viruses and is usually non-fatal. Reports of
cattle found to be seropositive for MCF viruses suggests that undiagnosed mild MCF
may occur naturally (O'Toole et al., 1997).
1.4.3 Gross Pathology
The severity of gross lesions found following post-mortem examination of MCF cases
can vary depending on the course of disease. Animals that die of peracute MCF can
show few lesions other than hemorrhagic enterocolitis. On the other hand, animals
afflicted with the more protracted head and eye form can show involvement of several
organs and tissues including: kidneys, lymph nodes, joints, liver, brain and
alimentary, urinary and respiratory tracts.
Typical findings (Liggitt et al., 1978; Piercy, 1952; Plowright, 1968; Selman et al.,
1974) include erosions at all levels of the oropharynx. This can include the
oesophagus, tongue and occasionally the forestomachs although it is common to find
no major macroscopic changes in the intestine. Lesions in the upper respiratory tract,
predominantly in the nasal passages and turbinates occasionally extending to the
frontal sinuses are also commonly found. Erosions and ulceration of the pharyngeal
and laryngeal mucosas is seen and ulceration can also be found in the
tracheobronchial mucosa. The enlarged lymph nodes are usually congested and
oedematous. Haemorrhagic infarcts are commonly seen in the kidney as well as
grey/white foci of up to 5 mm in diameter in the cortical regions. Signs of arthritis
such as accumulation of synovial fluid and synovial membrane reddening and
swelling with accompanying fibrin deposition are seen in the joints. The liver is often




The microscopic pathology of MCF can be summarised as cellular infiltrates and
tissue necrosis (Liggitt et al., 1978; Selman et al., 1974). The predominant
histopathological finding is a lymphocytic infiltrate into a large number of affected
tissues. Such infiltrates are seen in the oral and nasal mucosa, ducts of endocrine
organs, gallbladder, urinary bladder, skin, joints and lungs. The infiltrates generally
consist of small to large lymphocytes and macrophages. Plasma cells can be found
but are uncommon. Infiltrates are localised around blood vessels and vasculitis is
consistently observed. Marked infiltrates are frequently associated with epithelial
necrosis and sloughing, the second major histopathological change found in MCF
affected tissues.
Lymphocytic infiltrates are also commonly found in the alimentary tract. Portions of
the ileum, cecum and colon can show very marked lymphoid hyperplasia. In severe
cases, this can result in an almost total loss of crypt architecture.
Lymphocyte hyperplasia can be seen in the paracortical region of enlarged lymph
nodes. There is also marked activity of the mononuclear phagocytic system with
sinuses packed with macrophages. In severely affected nodes, foci of necrosis are
detectable.
In the kidney, foci of mononuclear cells are found corresponding to the grey/white
foci seen macroscopically as well as lymphocytic vasculitis.
Microscopic examination of the eyes revealed a cellular infiltration consisting of
neutrophils, macrophages and lymphocytes. Occasionally, the corneal epithelium can
appear flattened and show signs of superficial ulceration.
1.4.5 Transmission of A1HV-1 and OvHV-2 Infection
Despite epizoological evidence for the acquisition of AlFiV-1 by cattle from
inapparently infected wildebeest being recognised for over 80 years (Mettam, 1923;
Plowright et al., 1960), many details concerning the transmission of this virus remain
unclear. Most evidence suggests that the wildebeest calves are the source of natural
infection. Firstly, there is a seasonal occurrence of MCF outbreaks at the time of
annual calving or in the succeeding three to four months that has long been recognised
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by the Maasai herdsmen. Secondly, the presence of infectious virus has been reported
in the blood (Plowright, 1965a; Plowright, 1965b) and, importantly, in nasal and
ocular secretions (Barnard et al., 1989a; Mushi et al., 1980) of wildebeest calves.
Viraemia can be detected in calves less than one week old and persist for up to 36
weeks (Plowright, 1965b). Under normal circumstances, viraemia cannot be detected
in adult wildebeest although the reactivation of virus has been reported. In these
cases, the reactivation appeared to be associated with stress, either brought on by
confinement and betamethasone treatment (Rweyemamu et al., 1974) or by the
endocrine and metabolic demands associated with late-stage pregnancy (Plowright,
1965a). Indeed, the presence of virus in pregnant wildebeest as well as in foetal
spleens and young calves suggests that vertical transmission of the virus occurs in
wildebeest populations, possibly via in utero infection (Plowright, 1965a; Plowright,
1965b).
Although wildebeest calves are generally accepted as the source of virus, the physical
route of transmission is unknown. Transmission to cattle housed with viraemic calves
can occur (Plowright, 1965b), probably by virus shed through nasal and ocular
secretions. In the wild, however, transmission appears to occur over fairly large
distances (Barnard et al., 1989b) without any direct contact between wildebeest and
cattle herds. The Maasai herdsmen believe that contamination of grazing grounds
with wildebeest calf hair coats or the afterbirth of wildebeest cows to be the source of
infection although failure to detect virus from these sources suggests that this is not
the case. In addition, contamination of grazing grounds by saliva and urine has
generally been ruled out as a source of transmission as attempts to detect infectious
virus from these fluids have been unsuccessful (Mushi et al., 1980), although
detection of viral DNA in the urine of one calf has been reported (Michel, 1993). It
has been proposed that transmission of virus from blood or ocular secretions may be
carried out via an arthropod vector (Barnard et al., 1989b; Goetze, 1930). I lowever, a
number of considerations including the small amount of material transferred, the lack
of cattle-to-cattle transmission and the lack of any precedent for arthropod
transmission of a herpesvirus make this possibility unlikely. Additionally, an
experimental set up to test the possibility of transmission by the African face fly
(Musea xanthomelas) showed that infectious virus was detectable for only 30 minutes
following feeding on infective tears or cell culture medium and the Hies were
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reluctant to take another meal during this time window and, therefore, no transmission
could be achieved (Barnard et al., 1990).
Natural transmission of MCF between cattle is generally not thought to occur
(Goetze, 1930). It is thought that this may be related to the lack of detectable cell-free
virus in the secretions of MCF affected cattle (Plowright, 1965b). Although
horizontal transmission is unlikely, a report of an outbreak in a cattle herd in north¬
western Transvaal indicated that vertical transmission may occur between cattle and
their calves (Barnard et al., 1989b; Barnard, 1990).
The natural transmission of OvHV-2 parallels that of A1HV-1 in many ways. Firstly,
transmission of the virus appears to occur between sheep and cattle or deer but not
amongst these susceptible species (Blood et al., 1961; Goetze, 1930). Secondly, high
levels of virus can be detected in nasal secretions (Baxter et al., 1997; Li et al., 2001a)
and this virus is infectious (Taus et al., 2005; Taus et al., 2006). Finally, although
SA-MCF can occur in all seasons, there does appear to be some seasonal association
of disease outbreaks with lambing. However, there is some disagreement as to
whether perinatal lambs are the source of infectious virus and whether they account
for the seasonal rises in the occurrence of MCF. Virus can indeed be found in the
nasal secretions of perinatal lambs (Baxter et al., 1997) but also in adult sheep (Li et
al., 2001a). It has been suggested that other factors could contribute to the apparent
seasonality of SA-MCF including climatic factors influencing the survival of virus in
the environment, variation in stocking densities and the presence of potential vectors
(Li et al., 2001a).
Experimental transmission of WA-MCF can be achieved via the transfer of intact
blood cells or crude cell suspensions derived from the spleen, lymph node, liver or
brain tissue of infected animals (Mettam, 1923; Plowright et al., 1960; Plowright,
1965a; Plowright, 1965b). Infection can also be established in calves via intranasal
inoculation of cultured cell-free virus or suspensions of lymph node cells (Plowright,
1964). Transmission of SA-MCF from affected to healthy cattle can also be achieved
via transfer of blood or lymph node cell suspensions (Piercy, 1954; Reid et al., 1986;
Selman et al., 1978), although irregularly. The transmission of SA-MCF from
affected to healthy deer however is far more efficient (Buxton & Reid, 1980; Oliver et
al., 1983; Westbury & Denholm, 1982b). It has recently been shown that SA-MCF
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can be transmitted to bovine calves via intranasal inoculation with OvllV-2 positive
nasal secretions (Taus et al., 2006).
Transmission of both WA-MCF and SA-MCF to rabbits has been a useful tool in the
study of the disease and passage of the disease in rabbits was instrumental in the
original isolation of A1HV-I (Plowright et al., 1960). The pathogenesis of MCF in
rabbits is very similar to that seen in other susceptible species (Buxton et al., 1984)
and has allowed for further investigation into the basis of disease (see Sections 1.4.7
and 1.4.8).
Attempts to transmit MCF to small laboratory rodent species have been described
(Buxton et al., 1988; Jacoby et al., 1988a; Jacoby et al., 1988b). Outbred albino
mice, Syrian golden hamsters, Wistar rats and outbred Hartley albino guinea-pigs
were inoculated with lymph node cells from rabbits infected with either the C500
strain of A1HV-1 or an SA-MCF isolate derived from a red deer. No transmission to
mice was seen in any experiments. Disease was transmitted from A1HV-I infected
rabbits to rats, hamsters and guinea-pigs when inoculation was performed on
neonates, but only to guinea-pigs when inoculation was performed on weanlings. Of
the species tested, only hamsters were susceptible to rabbit adapted SA-MCF. In all
cases, attempts to transmit disease back to healthy rabbits were unsuccessful
suggesting that virus expression in the rodent system is defective or incomplete. The
pathology ofWA-MCF seen in rats, hamsters and guinea-pigs was similar to that seen
in infected cattle and rabbits with pronounced lymphoproliferation, multisystemic
mononuclear cell infiltrates, vasculitis and necrosis in all species (Jacoby et al.,
1988a). The pathological changes seen in hamsters with SA-MCF were essentially
identical to those seen in hamsters with WA-MCF (Buxton et al., 1988).
1.4.6 Immunisation
Treatment of MCF with a range of antiviral and immunosuppressive drugs can be
effective (Milne & Reid, 1990) but the expense and duration of treatment mean that
this is not a viable option for the control of disease, even in developed countries. It
has therefore been attempted to produce a protective vaccine against the disease. It
has been reported that the small percentage of animals that naturally survive MCF are
protected from parenteral challenge with virulent material (Plowright, 1964) implying
that vaccination should be possible. Attempts have been made to reproduce the
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protection seen in recovered animals by inoculation with either inactivated viral
material or live attenuated viruses and have had mixed success.
Plowright et al. used formalinised WC11 strain of A1HV-1 in incomplete Freund's
adjuvant to inoculate groups of nai've cattle (Plowright et al., 1975). This treatment
resulted in the induction of a good neutralising antibody response in the-experimental
animals, particularly following booster inoculation. Despite the strong humoral
response, ail laboratory cattle succumbed to MCF following challenge with virulent
cell-free or cell-associated A1HV-1. The disease in the animals progressed with the
same kinetics of incubation and death times as in untreated animals. The same two-
dose treatment was given to 1471 cattle in Kenya Maasailand. The incidence of MCF
in treated herds was the same as that of placebo control groups although, again,
neutralising antibody could be detected in the inoculated animals.
Slightly different results were found using an inactivated virus in rabbits (Fdington &
Plowright, 1980). Rabbits inoculated with inactivated cell-free C500 strain of A1HV-
1 in complete Freund's adjuvant were protected against challenge with virulent cell-
free but not cell-associated virus. The difference in protection between these and the
previous experiments in cattle may be due to the virus strain used, the presence of
killed Mycobacterium tuberculosis in the adjuvant or the susceptibility of the host
animals used.
Vaccination attempts have also been made using live viruses isolated from hartebeest
(Reid & Rowe, 1973) and from sick cattle in America (Mirangi, 1991). The
hartebeest virus (K30) was attenuated by tissue culture passage and had become cell-
free. Inoculation with this virus did not induce disease but induced an antibody
response that neutralised A1HV-1 WC11. Two out of three inoculated cattle were
protected from challenge with a virulent cell-associated form of the hartebeest virus
and from subsequent re-challenge with a virulent wildebeest isolate. No protection
against the virulent wildebeest isolate was seen in cattle that received the initial cell-
free inoculation but were not re-challenged with the cell-associated hartebeest virus.
Similar results were found using the A1HV-1 related virus isolated from sick
American cattle (agent 707K). Two consecutive weekly inoculations with agent
707K were sufficient to protect cattle from challenge with the virulent C500 isolate of
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A1HV-1. One inoculation did not protect against such challenge and repeated
inoculations carried a risk of inducing disease themselves.
These studies suggest that a neutralising antibody response is not suflicient for
protection, with the possible exception of cell-free viral challenge in rabbits, and that
the immunity seen in recovered cattle (Plowright, 1964) is most likely due to a cell-
mediated immune response. The production of an attenuated A1HV-1 strain that
remains cell-associated for use as a candidate vaccine has been hampered by the
genomic instability of the virus in culture. It is hoped that the recent cloning of the
A1HV-1 genome into a bacterial artificial chromosome (BAC) (Dewals et til., 2006)
will now allow for the generation of specifically attenuated mutant viruses capable of
inducing strong cell-mediated immunity but not disease.
1.4.7 Large Granular Lymphocyte Cell Lines
One feature of MCF is the ability to establish lymphoblastoid cell lines from infected
animals. The first of these cell lines was derived from a rabbit infected with the 57th
serial passage of an SA-MCF isolate (Reid et al., 1983). Mesenteric lymph node cells
were cultured and although fusion with foetal ovine kidney cells was attempted, the
cells retained the rabbit cell karyotype as well as a lymphocyte surface antigen
phenotype. The cells contained electron dense granules within their cytoplasm and
were classified as large granular lymphocytes (LGL). The LGLs exhibited non¬
specific cytotoxicity in a 5lCr release assay reminiscent of natural killer cells.
Importantly, as few as 102 LGL could transfer disease to nat've rabbits.
LGL cell lines have also been propagated from naturally infected cattle and deer
(Cook & Splitter, 1988; Reid et al., 1989a; Schock et al., 1998). Cook and Splitter
(1988) were able to culture lymphocyte cell lines from the lymph node cells of both
an MCF-affected and a healthy cow and these were maintained by the addition of
interleukin-2 (IL-2). Cell lines from both animals showed non-specific killer activity
and a T cell surface phenotype but only the lines derived from the MCF-affected cow
could be maintained past five months. Reid et al. (1989a) were also able to establish
LGL cell lines from 20 out of 21 SA-MCF affected cattle as well as red and Pere
David's deer. Cell lines were derived not only from lymphoid tissue including spleen,
lymph nodes and thymus but also from cerebrospinal fluid and corneal tissue. The
cell lines initially required the addition of exogenous IL-2 or feeder cell lines for
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maintenance although the requirement on these factors for growth was lost by some of
the cattle but not deer derived lines. Consistent with previous findings, these LGL
cell lines exhibited non-specific cytotoxicity in vitro. The deer derived lines were
able to transfer disease to rabbits and to other deer. The cattle derived lines, however,
were unable to transfer disease to rabbits, deer or other cattle.
LGL cell lines derived from naturally and experimentally infected animals have since
been further characterised. Bridgen and Reid were able to demonstrate the presence
of viral DNA that hybridised to an A1HV-1 probe not only in LGL cell lines derived
from rats and rabbits experimentally infected with A1HV-1 but also from rabbits,
cattle and deer naturally or experimentally infected with SA-MCF (Bridgen & Reid,
1991a). The surface phenotype of previously studied (Reid et al., 1989a) cattle and
deer derived LGLs was investigated using cross-reactive monoclonal antibodies
against leukocyte surface antigens (Burrells & Reid, 1991). Three out of four cattle
derived lines had the CD4"CD8 phenotype of cytotoxic T cells and one had the
CD4 CD8" phenotype of helper T cells. Both deer derived lines also tested were
CD4"CD8" but stained positive for the T19 antigen also found on bovine CD4 CD8" T
cells. The phenotype of another group of LGL lines derived from SA-MCF affected
cattle was studied by Schock et al. (1998). Three of the five lines studied were
CD4+CD8". one was CD4CD8 and one was a mixture of CD4+CD8~ and CD4CD8
cells. In addition, these cells were shown to contain transcripts for the cytokines
interferon-y (IFN-y), tumour necrosis factor-a (TNF-a) and interleukin-10 (IL-10). It
was not determined whether the IL-10 transcripts seen were of viral or bovine origin.
The cell lines still required exogenous IL-2 for growth and no IL-2 transcription was
seen.
The constitutive activation of the src family kinases Lck and Fyn has been
demonstrated in a cell line derived from an SA-MCF affected cow as well as in two
lines derived from A1HV-1 infected rabbits (Swa et al., 2001). These kinases
normally link cell surface receptors to downstream signalling pathway genes
controlling T cell activation, proliferation and differentiation and their constitutive




1.4.8 Proposed Model for MCF Pathogenesis
Histological examination of MCF lesions indicates that direct viral cytotoxicity is not
involved in the disease pathogenesis. Several alternative hypotheses have been
proposed to account for the pathogenesis of MCF including a mechanism similar to
graft rejection (Liggitt & DeMartini, 1980), transformation of lymphoid cells
(Denholm & Westbury, 1982; Edington et al., 1979; Hunt & Billups, 1979) and cell-
mediated responses to infected vascular endothelium (Liggitt & DeMarlini, 1980;
Selman et al., 1974). It is now generally accepted that viral infection leading to a
generalised cell-mediated immune dysfunction is the basis for disease, although many
of the details remain unclear.
Although it has been possible to establish LGL cell lines from MCF lesions and
demonstrate the presence of virus within these cells following growth in culture, the
presence of viral antigens in the lesions themselves has not been detected. The
presence of viral DNA in these lesions has been demonstrated by in situ hybridisation
and, more recently, by in situ PCR. Using in situ hybridisation, Bridgen et al.
(Bridgen et al., 1992) were able to demonstrate the presence of viral DNA positive
cells in the lesions of A1HV-1 infected rabbits but only in the lung and submandibular
lymph node and only at the extremely low frequency of approximately one in 104
cells. The more sensitive in situ PCR technique has recently been employed (Simon
et al., 2003) to show the presence of OvHV-2 DNA in the infiltrating CD8
lymphocytes in the vascular brain lesions of a bison and a cow with SA-MCF. Taken
together, the difficulty of identifying viral DNA and the absence of viral antigen in
MCF lesions, but not following culture of cells from these lesions implies a host
mediated suppression of viral replication and gene expression.
The nature of the lymphoproliferation in MCF and its role in disease pathogenesis has
also been the subject of much investigation. Lymphoproliferative disorders are
associated with a number of other herpesvirus infections including EBV (Epstein et
al., 1964), MDV (Churchill & Biggs, 1968) and HVS (Hunt et al., 1970b). As in
MCF, the proliferating lymphocytes found in these disorders do not commonly
contain virions but recovery of virus following ex vivo growth of these cells is seen.
In contrast to these other conditions, the lymphoproliferation seen in MCF is thought
to be hyperplastic rather than neoplastic in nature as the proliferating cells do not
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appear to give rise to discrete tumours and the affected lymphoid organs generally
maintain their architecture with necrosis only occurring at late stages of disease
(Buxton et al., 1984). Several studies (Ellis et al., 1992; Nakajima el al., 1992;
Schock & Reid, 1996) have implicated CD8+ T cells as the main cell type involved in
hyperplasia although other cell types can be involved. The finding of Burrells and
Reid (1991) that the LGL cell lines derived from different tissues of the same animal
were similar was taken to imply that cells of one phenotype capable of
immortalisation were widely distributed throughout affected animals. It was also
hypothesised, based on this finding, that the predominant infection of one cell type in
different cases may determine the clinical response to natural infection. It has also
been suggested that only a minority of cells accumulating in MCF lesions may be
infiltrating and that the majority of cells arise from the multiplication of resident T
cell populations within the tissues (Schock & Reid, 1996). Although extensive
lymphoproliferation is one of the hallmarks of MCF, doubt remains as to its
importance in disease pathogenesis. Treatment of SA-MCF infected rabbits with the
potent T cell suppressing agent cyclosporin A (Cs-A) had no effect on the incubation
period or outcome of disease despite the effective suppression of the
lymphoproliferative response (Buxton et al., 1984). This finding implies that the
terminal necrosis and tissue destruction is caused by cells other than those involved in
proliferation, most likely the natural killer (NK) cells.
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1.5 Left Hand End Genes of Gammaherpesviruses
Gammaherpesviruses usually encode between around 70 to 85 genes or open reading
frames (ORFs). ORFs conserved between all or most herpesviruses are arranged in
five blocks and are interspersed with ORFs unique to each virus or conserved only
between closely related viruses. It is these unique ORFs that are of particular interest
to study as they are related to the specific biological characteristics of the virus. Many
of the gammaherpesviruses encode a cluster of unique genes at the left hand end
(LHE) of their L-DNA, between the terminal repeat regions and the first block of
conserved herpesvirus genes (ORFs 6-9). Diagrammatic representations of the LHE
of select gamma-2-herpesviruses are shown in Figure 1.5, adapted from their
published viral genome sequences (Albrecht et al., 1992; Ensser et al., 1997;
Rosbottom, 2003; Russo et al., 1996; Telford et al., 1995; Virgin et al., 1997). In
addition to the virus specific genes, the left hand ends of these often contain
homologues of the purine biosynthetic enzyme formylglycineamide ribotide
amidotransferase (FGARAT, ORF 3) and/or complement control protein homologue
(ORF 4) of HVS.
1.5.1 HVS
The LHE regions of HVS show a great deal of variation and are used as the basis for
subgroup classification (Biesinger et al., 1990; Medveczky et al., 1989; Medveczky et
al., 1984). Albrecht et al. (1992) published the genome sequence of HVS strain 11 of
subgroup A. The LHE of this virus was shown to contain four ORFs including ORF
Ol encoding the saimiri transforming protein (STP-A) and the seven previously
described herpesvirus saimiri untranslated RNAs (HSURs). ORF 2 of this virus
encodes a dihydrofolate reductase protein (DHFR) with 83% amino acid identity to
human DHFR. Subgroup C viruses have also been shown to contain DHFR and
HSUR genes but contain two oncogenic genes positionally equivalent to STP-A, STP-
C and a tyrosine kinase interacting protein Tip (Biesinger et al., 1990).
The STP Genes and Tip
STP genes are encoded by all three subgroups of HVS and are named based on their
strain as STP-A, STP-B and STP-C. These genes show weak sequence homology to
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Figure 1.5. Diagrammatic representations (not to scale) of the ORFs contained within
the regions right of the terminal repeat regions and left of the first block of conserved
genes (ORF 6 - ORF 9) in selected gammaherpesviruses. ORFs unique to each virus
are shown in yellow and those shared between HVS and other members of the
Rhadinovirus genus are shown in orange. Black arrows represent the uRNAs of HVS
and tRNA like molecules ofMHV-68.
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proteins with tumour necrosis factor receptor associated factor (TRAF) binding sites
(Choi et al., 2000; Lee et al., 1999). The Tip ORF also encodes a transmembrane
protein with intracellular signalling domains (Biesinger et al., 1995).
As previously mentioned in Section 1.2.3, subgroup A viruses are highly oncogenic in
New World monkey species. STP-A has been shown to be required for the
transformation of murine embryo 3T3 cells in vitro (Chung et al., 2004) and the
induction of lymphomas in owl monkeys in vivo (Desrosiers et al., 1985). Similarly,
studies have shown that both STP-C and Tip are required for the transformation of
common marmoset primary T cells in vitro and the induction of lymphomas in
common marmosets in vivo by subgroup C viruses (Duboise et al., 1998). In addition,
the transgenic expression of STP-C in mice induced the formation of tumours in the
salivary gland, pancreas, thymus and liver within the first few weeks of life (Murphy
et al., 1994). The absence from STP-B of the signal transduction modules found in
other STP proteins is likely to be the cause of the poor oncogenicity of subgroup B
viruses. The N termini of STP-A and STP-C contain nine and eighteen collagen
repeats, respectively, that are thought to be important in transformation as none are
found in STP-B. Indeed, insertion of eighteen collagen repeats into STP-B allowed
the protein to oligomerise, activate NF-kB and transform rodent fibroblasts (Choi et
al., 2000).
HSURs
Two groups of HSURs are found at the LHE of HVS strain All, one between STP-A
and ORF 2 containing HSURs 1-3 and one between ORF 2 and ORF 3 containing
HSURs 4-7 (Albrecht et al., 1992). These U RNAs are the most abundant viral
transcripts in HVS-transformed, latently infected T cells but do not appear to be
required for transformation or viral replication (Cook et al., 2005). The I ISURs have
been shown to be expressed and assemble into small nuclear ribonucleoproteins
(snRNPs) with Sm proteins (Lee et al., 1988; Lee & Steitz, 1990; Myer et al., 1992).
HSURs 1 and 2 expressed in latently HVS-infected marmoset T cells have recently
been shown to upregulate a small set of host cell genes, including a number of genes
linked to T cell and NK cell activation, indicating that these small RNA molecules are





The LHE of KSHV contains two ORFs, an HVS ORF 4 homologue and the unique
ORF K1 (Russo et al., 1996). The K1 ORF encodes a transmembrane protein
encoding an immunoreceptor tyrosine-based activation motif (ITAM) analogous to
those found in the signalling components of the T- and B-cell receptor complexes
(Lee et al., 1998). Unlike other ITAM-based signal transduction events, K1
signalling occurs constitutively in the absence of any crosslinking ligands (Lagunoff
et al., 1999). ORF K1 is co-linear with STP of HVS and, although the two proteins
share no amino acid similarity, ORF K1 can substitute for the activities of STP to
transform primary T cells and induce lymphomas in common marmosets in the
context of a recombinant virus (Lee et al., 1998). ORF K1 was also found to induce
tumours independently when expressed as a transgene in mice (Prakash et al., 2002).
The role of the ORF K1 gene product in normal KSHV biology remains unclear,
although it is thought that through its signal transducing abilities it can provide
conditions favourable to viral replication.
1.5.3 MHV-68
The left hand end of the MHV-68 genome contains four unique ORFs, ORF Ml, ORF
M2, ORF M3 and ORF M4, as well as eight viral tRNA like molecules (vlRNAs) and
a homologue of the HVS complement control protein ORF 4 (Virgin et a/., 1997). A
second strain of MHV, MHV-76, was found to be genetically identical to MHV-68
with the exception that the left hand end region encoding the vtRNAs, ORF Ml, ORF
M2, ORF M3 and approximately half ORF M4 was absent and there was a single
nucleotide substitution in the coding region of ORF 6 (Macrae el al., 2001).
Comparison of this virus with MHV-68 highlighted the role for these left hand end
genes in viral pathogenesis (Macrae et al., 2001). The in vitro replication and cell to
cell spread of these viruses was found to be identical but major differences were seen
following infection of mice, showing that these genes are dispensable for the
completion of lytic replication but may be involved in immune evasion and/or the
establishment of latency. Mice infected intranasally with MHV-76 replicated to
significantly lower titres and induced more severe pathology in the lung early after
infection compared to those infected with MHV-68. At later time points, virus
induced splenomegaly was significantly reduced. The transient peak of latently
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infected splenocytes, usually seen between about 10 and 30 days post infection with
MHV-68, was also drastically reduced following infection with MHV-76 although the
virus was able to establish long term persistence.
Clambey et al. (Clambey et al., 2002) also investigated the role of the MHV-68 LHE
genes during infection using a spontaneous mutant virus with a 9,473 bp deletion
almost identical to that of MHV-76, yHV-68A9473. Similar to the MHV-76 findings,
this study also demonstrated a role for the LHE genes during acute lytic replication
following both intranasal and intraperitoneal infection with significantly reduced viral
titres seen in the lungs and spleens, respectively, of infected mice. The frequencies of
viral genome positive (vgp) splenocytes and peritoneal exudate cells (PLCs) were
reduced by 24- and 4-fold, respectively, compared to MHV-68 following intranasal
infection. Interestingly, the levels of reactivatable latent virus were reduced by only
13-fold from splenocytes and increased two-fold from PECs. following
intraperitioneal infection, no change was seen in the frequency of vgp splenocytes, the
level of reactivation from splenocytes or the frequency of vgp PECs, however, the
level of reactivatable virus from PECs was again increased. These findings suggest a
role for one or more of the LHE genes in the reactivation of virus from latency.
The relative ease of inserting and deleting genes from the LHE of MHV-68 has
allowed for the specific roles of these genes to be investigated in greater detail.
ORF Ml
ORF Ml encodes a 420 amino acid protein with homology to a poxvirus serine
inhibitor SPI-1 and some similarities to ORF M3 (Virgin et al., 1997). The disruption
of the Ml ORF from MHV-68 by the insertion of a LacZ gene cassette (Ml.LacZ)
resulted in an increase in the frequency of reactivation from both splenocytes and
PECs (Clambey et al., 2000). Following analysis of the viral genome frequency in
the PECs, it was determined that virus reactivated ex vivo from approximately one in
three of the M1 .LacZ vgp PECs compared to one in fifteen of the MHV-68 vgp PECs.
Although it does not ascribe a specific function to the ORF Ml gene product, this
finding does demonstrate the contribution of this protein to the phenotype seen with




The M2 ORF encodes a 193 amino acid protein with expression restricted to latently
infected B cells (Bougeret et al., 1992; Husain et al., 1999) and localises to the
cytoplasm and plasma membrane (Macrae et al., 2003). This gene product contains a
classic H-2Kd epitope and the recognition of this epitope by specific CD8+ T cells has
been shown to be important in the control of initial latent viral load (llusain et al.,
1999; Usherwood et al., 2000). Independent studies using recombinant viruses with
disruptions in the M2 ORF have shown the importance of this gene in producing the
initial peak of latent infection following intranasal infection (Jacoby el al., 2002;
Macrae et al., 2003). The ORF M2 gene product has been shown to bind to Vav
signalling proteins in infected B cells (Madureira et al., 2005). These interactions
were found to promote B cell proliferation and survival which may play a role in the
dissemination of the latent virus and maintenance of latency.
ORF M3
ORF M3 encodes a 44 kilodalton (kD), secreted, broad-spectrum chemokine binding
protein. Chemokines are a family of small, structurally related proteins involved in
directing the homing of leukocytes to specific areas and have been shown to play
important roles in processes such as inflammation, tumour formation, angiogenesis
and hematopoiesis. Chemokines are classified into four subgroups (XC, CC, CXC
and CX3C) based on their conserved cysteine motif. These proteins are secreted, with
the exception of fractalkine (the only member of the CX3C subgroup), and form
gradients via electrostatic interactions with glycosaminoglycans.
The ORF M3 gene product was found in the supernatants of MHV-68 infected cell
cultures and could bind radioiodinated human IL-8, RANTES, MIP-la and
fractalkine (Parry et al., 2000; van Berkel et al., 2000). The binding to labelled IL-8
and RANTES could be inhibited in the presence of a wide variety of chemokines from
the CC (human MlP-la, murine MlP-la, human RANTES, murine RANTES, viral
(v)MIP-2 from KSHV, human MCP-1, human MCP-4 and murine SEC), CXC
(human IL-8, human GRO-a, human IP-10 and murine BCA-1), XC (human
lympotactin) and CX3C (fractalkine) families. No inhibition or weak inhibition was
seen in the presence of human B cell-specific (BCA-1 and SDF-I) or murine
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neutrophil-specific (KC, MIP-2 and LIX) CXC chemokines. Consistent with these
findings, the presence of M3 protein in cell culture supernatants was able to inhibit
the mobilization of calcium in murine neutrophils in response to MIP-lu but not KC
and also inhibit the mobilization of calcium in murine macrophages in response to
MCP-1 but not SDF-1 (van Berkel et al., 2000). The M3 protein was also able to
inhibit the migration of cells expressing the chemokine receptor CCR7 in response to
M1P-3P and SLC (Jensen et al., 2003). These studies demonstrate a functional role
for chemokine binding by this protein.
The role of the M3 protein in vivo was assessed using a recombinant MHV-68 virus in
which the M3 ORF had been disrupted by the insertion of a LacZ gene cassette
(M3LacZ) and therefore lacks secreted chemokine binding activity (Bridgeman et al.,
2001). The disruption of the M3 ORF had no effect on the acute lytic replication of
this virus in vitro or in the lungs of infected mice. However, mice infected with
M3LacZ showed greatly reduced levels of latent virus in their spleens as measured by
infectious centre assay and vtRNA in situ hybridisation. This reduction reflects a
change in immune evasion rather than disruption of the ORF interfering with normal
establishment of latency as mice infected with either M3LacZ or wild type virus that
subsequently had their CD8+ cells depleted showed equal levels of latent virus.
ORF M4
The M4 ORF encodes a secreted glycoprotein (Evans et al., 2006) and is expressed
immediate early/early during lytic replication (Ebrahimi et al., 2003; Townsley et al.,
2004). Townsley et al. found that a recombinant virus expressing ORF M4 in MHV-
76 (MHV-76inM4) replicated to higher titres in the lung than either MI1V-76 or
MHV-68 at very early time points (day 1) post intranasal infection, suggesting that the
ORF M4 gene product targets an innate immune mechanism. The absence of this
phenotype in MHV-68 implies that this effect is somehow masked in the presence of
the other LHE genes. At later time points, increased latent virus as measured by
infectious centre assay and viral DNA load was found in the spleens ofMHV-76inM4
mice compared to those from mice infected with MHV-76 which was unexpected as
ORF M4 transcripts were not detected during latency (Virgin et al., 1999).
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Two independent studies using recombinant viruses in which the ORF M4 gene from
MHV-68 had been disrupted by the insertion of a stop codon cassette found
conflicting results (Evans et al., 2006; Geere et al., 2006). Both studies demonstrated
a role for the ORF M4 gene product in the establishment of acute phase latency,
finding lower levels of reactivatable virus and viral genome copies in infected
spleens. However, in the study conducted by Evans and colleagues, the recombinant
virus was found to replicate to marginally higher titres in the lungs of infected mice at
day 9 post infection and induced significantly less splenomegaly at later time points
but these findings were not reproduced in the later study. The reason for the
discrepancy between these studies is not clear although the use of different mouse
strains may be partially responsible.
Viral tRNA Like Molecules
Eight sequences with the characteristics of tRNAs are encoded at the L11E of the
MHV-68 genome (Bowden et al., 1997). Five of these sequences are located between
the terminal repeats and ORF Ml (vtRNAs 1-5), one between ORF Ml and ORF M2
(vtRNA 6) and two between ORF M2 and ORF M3 (vtRNAs 7 and 8). The vtRNA
sequences have a high level of identity (up to 75%) to some published tRNAs, are
capable of forming cloverleaf-like secondary structures and contain RNA polymerase
III (pol III) promoter elements. Unlike cellular tRNAs, however, the vtRNAs of
MHV-68 are not amino-acylated.
The vtRNAs are encapsulated within progeny MHV-68 virons (Cliffe, 2006) and
abundantly expressed during both lytic infection and latency (Bowden el al., 1997).
Indeed, the detection of vtRNAs by in situ hybridisation has been used as a tool for
the detection of latent infection. The role of vtRNAs during infection, however,
remains unclear. Recently, studies using recombinant MHV-76 viruses in which
vtRNAs 1-5 had been replaced showed that these sequences had no effect on
infectious viral titres in the lung or levels of latent virus in the spleen of infected mice
following intranasal infection compared to wild-type MHV-76 (Cliffe, 2006).
A recent study has shown that up to fourteen miRNA sequences are embedded within
the MHV-68 vtRNA transcripts (Pfeffer et al., 2005). Unlike typical miRNAs, the
MHV-68 miRNAs appear to be driven by the vtRNA pol III promoters rather than by
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pol II. Nine of the fourteen predicted miRNAs were identified by cloning but their
cellular targets and biological significance remain unclear.
1.5.4 EHV-2
In contrast to the other gammaherpesviruses sequenced, analysis of the HI IV-2 strain
86/67 genome revealed that the unique region is flanked by two copies of a relatively
large direct repeat of approximately 18 kb rather than multiple copies of a smaller
repeat (Browning & Studdert, 1989). Contained within this direct repeat region is a
unique ORF, ORF El, meaning that two copies of this gene are encoded by the virus.
Between the direct repeat and the first block of conserved genes, in the left hand end
proper, EHV-2 encodes three further unique ORFs (ORF E2, ORF E3 and ORF E4)
and a homologue of HSV ORF 3 (Telford et al., 1995). ORF E2 and ORF E3 are
predicted to encode proteins of 307 and 174 amino acids, respectively, that have not
currently been assigned functions.
ORF El
The El ORF of encodes a 383 amino acid protein with seven transmembrane domains
which has significant homology to human CC chemokine receptors including CCR3
(47% identity), CCR1 (44%), CCR5 (40%) and CCR8 (35%) and to the 11CMV US28
protein, which has also been shown to bind CC chemokines (Telford et al., 1993).
Cells expressing the ORF El gene product were found to increase intracellular
calcium concentrations and migrate in response to the CC chemokine eotaxin but not
in response to a number of other CC and CXC chemokines including RANTES, MIP-
la, MIP-ip, MCP-3, 1-309, BCA-1, IP-10 and Mig (Camarda et al., 1999).
ORF E4
ORF E4 encodes a homologue of the anti-apoptotic cellular protein Bcl-2 (Marshall et
al., 1999a). Bcl-2 homologues have been found in all sequenced
gammaherpesviruses. HVS, KSHV, RRV and AtHV-3 each have one Bcl-2
homologue encoded by the conserved ORF 16 (Albrecht et al., 1992; Albrecht, 2000;
Russo et al., 1996; Searles et al., 1999). A1HV-1 and MHV-68 also contain one Bcl-2
homologue encoded by the unique ORFs A9 and Mil, respectively (Ensser et al.,
1997; Virgin et al., 1997). OvHV-2 encodes two Bcl-2 homologues (ORF 04.5 and
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ORF 09) (Rosbottom, 2003) as does EBV (BALF-1 and BHRF-1) (Cleary et al.,
1986; Marshall et al., 1999b).
Apoptosis, programmed cell death, can occur in response to a number of stimuli
including death receptor signalling, DNA damage and virus infection. Cell death in
response to virus infection is an innate mechanism to prevent the completion of the
viral replication cycle and therefore the spread of infectious virus to neighbouring
cells. Apoptosis is controlled by levels of pro-apoptotic (Bax and Bak) and anti-
apoptotic (Bcl-2 and Bc1-Xl) members of the Bcl-2 family of proteins. It was
originally proposed that apoptosis is induced by homodimerisation of pro-apoptotic
Bcl-2 family members and that the anti-apototic family members functioned by
forming heterodimers with these proteins, therefore preventing their
homodimerisation (Korsmeyer et al., 1993). Recent studies showing the non-
overlapping localisation of Bax and Bcl-2 (Hsu & Youle, 1997) and the importance of
post-translational modification on Bcl-2 family member function (Cheng et al., 1997;
Clem et al., 1998; Fannjiang et al., 2003; Kerr et al., 2002; Lewis et al., 1999)
highlight the oversimplification of this model.
Bcl-2 homologues encoded by gammaherpesviruses were predicted to function during
acute replication by preventing premature cell death in infected cells in a manner
analogous to the viral Bcl-2 homologue encoded by adenovirus, E1B 19K (Pilder et
al., 1984; Subramanian & Chinnadurai, 1986; White et al., 1986; White et al., 1991).
However, the Mil ORF of MHV-68 was found to be dispensable during lytic
replication but involved in the reactivation of the virus from latency (Gangappa et al.,
2002). It has also been suggested that viral Bcl-2 homologues, in particular those of
EBV and KSHV, play a role in tumour formation.
1.5.5 A1HV-1 and OvHV-2
Analysis of the complete genome sequence of A1HV-1 revealed four unique ORFs
(ORF Al, ORF A2, ORF A3 and ORF A4) between the terminal repeat regions and
the HVS ORF 3 homologue (Ensser et al., 1997). Later analysis of the left hand end
of OvHV-2 (Rosbottom, 2003) found homologues of two of these OR Is (ORF 02
and ORF 03). No homologues of ORF Al and ORF A4 were found in OvHV-2
although the region was found to contain an HVS ORF 3 homologue and three further
50
Chapter I Introduction
unique ORFs, ORF 02.5, ORF 03.5 and the Bcl-2 homologue ORF 04.5 mentioned
in Section 1.5.4.
ORF A1
ORF A1 is a very small ORF encoding only 97 amino acids and shows no significant
sequence or structural homology to any known proteins (Ensser et al., 1997) and has
no homologue in OvFlV-2. Although this ORF has a TATA box downstream and a
polyadenylation site upstream, Northern blot analysis indicates that it may in fact be
an exon of a larger gene (Dr. David Haig, Personal Communication).
ORF A2 and ORF Q2
ORF A2 is predicted to encode a protein with some local similarities to the
transcription factor ATF3 (Ensser et al., 1997). The 199 amino acid gene product is
encoded by a spliced transcript and contains a predicted nuclear localisation sequence
and a basic leucine zipper motif (Ensser et al., 1997). ORF 02 of OvFIV-2 encodes a
slightly smaller gene product of 186 amino acids, also from a spliced transcript, and
shows 71% sequence homology and 56% sequence identity to ORF A2 (Rosbottom,
2003). It is therefore likely that this protein is also a transcription factor of similar
function to the ORF A2 gene product.
ORF Q2.5
ORF 02.5 encodes a 182 amino acid homologue of the cytokine IE-10 over five
distinct exons (Rosbottom, 2003). IE-10 is generally regarded as an
immunosuppressive or regulatory cytokine involved in the control of immune
responses and the resolution of inflammation. Viral 1L-10 homologues are also found
in EBV (BCRF-l) (Flsu et al., 1990; Moore et al., 1990), CMV (UL11 la) (Kotenko et
a/., 2000) and EHV-2 (ORF E7) (Rode et al., 1993).
ORF A3 and ORF Q3
ORF A3 shows homology to genes encoding members of the semaphorin family of
proteins (Ensser & Fleckenstein, 1995). The semaphorin family includes secreted and
surface bound proteins that all contain a conserved cysteine-rich 'sema' domain.
ORF 03 of OvFIV-2 also encodes a semaphorin with 50% amino acid identity and
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63% similarity to ORF A3 although is shorter by 200 amino acids at the C-terminus
(Rosbottom, 2003). Semaphorin proteins were originally found to play a role in
neural development (Kolodkin et al., 1993) but recently several immunological
semaphorins have been found, such as CD 100 (SEMA4D) which has been shown to
play a role in the activation ofT and B lymphocytes (Bougeret et al., 1992; 1 lall et al.,
1996; Herold et al., 1996). Virally encoded semaphorins have also been found in
members of the pox virus family including mousepox virus Ectromelia (ORF A39R)
(Comeau et al., 1998), vaccinia virus (ORF A39R) (Amegadzie et al., 1992;Johnson
et al., 1993; Kolodkin et al., 1993), fowlpox virus (ORF FPV047) (Afonso et al.,
2000) and variola virus (a composite ORF of ORFs A41L, A42R, A43R and A44R)
(Amegadzie et ah, 1992; Kolodkin et al., 1993; Shchelkunov et al., 1993). These pox
virus genes are more closely related to A1HV-1 ORF A3 than to genes encoding other
semaphorins.
A novel cellular receptor for the mousepox virus Ectromelia A39R protein was found
and called virus-encoded semaphorin receptor (VESPR) (Comeau et al., 1998). This
transmembrane glycoprotein has a wide tissue distribution and expression was found
in heart, brain, lung, spleen and at high levels in the placenta of primary human
tissues. Importantly, A39R binding was seen on T and B lymphocytes, monocytes
and dendritic cells. The binding of A39R to monocytes was found to increase the
surface expression of CD54 (intracellular adhesion molecule-1, ICAM-1) and
production of interleukin-6 (IL-6) and interleukin-8 (IL-8) (Comeau et al., 1998).
Binding of the ORF A3 gene product to human VESPR was also seen, albeit at a
much lower affinity, even though ORF A3 and A39R share only 29% amino acid
identity (Comeau et al., 1998).
A functional study on the role of vaccinia virus A39R protein in vivo was performed
using an intradermal murine infection model (Gardner et al., 2001). This study used
the Western Reserve (vWR) strain of vaccinia virus which contains a 13 bp deletion
inducing a premature stop in the coding region of the A39R gene. The truncated
A39R protein encoded by this virus is not secreted from infected cells. The
pathogenesis of the wild-type WR virus following infection of the ear pinnae ofmice
was compared to that of recombinant virus (vWR COPA39R) expressing the full-
length secreted form of the A39R protein encoded by the Copenhagen strain of
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vaccinia virus. The vWR COPA39R virus induced larger lesions that took longer to
resolve than those induced by wild-type or revertant viruses. The finding that similar
titres of infectious virus were found in the infected ears suggests that the increased
lesion severity associated with the expression of full-length secreted A39R protein is
an effect of increased immunopathoiogy rather than direct viral cytopathology.
ORFQ3.5
ORF 03.5 encodes a protein of 163 amino acids with a predicted signal peptide
sequence (Rosbottom, 2003). This ORF shows no homology to any known genes and
no potential function has been assigned to the gene product.
ORF A4
ORF A4 encodes a small protein of 121 amino acids with predicted signal peptide
(Ensser et al., 1997). Although this ORF is positionally homologous to ORF 03.5 of
OvHV-2 and also encodes a predicted secreted protein, no homology between the two
ORFs can be found. This ORF shows no homology to any known genes and no
potential function has been assigned to the gene product.
1.5.6 Project Aims
The aim of this project is to characterise the four left hand end ORFs of All IV-1. To
study the contribution of these genes to pathogenesis in a small animal model, a 6.2kb
region from the left hand end of the A1HV-1 genome was cloned and inserted into the
MHV-68 deletion mutant, MHV-76. In addition to the in vivo pathogenesis studies
using the recombinant virus, supernatants from cell cultures infected with this virus
were used to assess the effects of secreted proteins on lymphocytes. Several in vitro
studies were performed using the individual ORFs. All four ORFs were cloned for
their expression as fusion proteins in mammalian cells and ORF A2 was also cloned
for bacterial expression. Finally, a yeast two-hybrid system was used to screen a
novel bovine cDNA library for proteins interacting with the gene products of ORF
A2, ORF A3 and ORF A4.
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2.1 Molecular Techniques
2.1.1 Polymerase Chain Reaction
Polymerase chain reactions (PCR) were carried out using the reaction mixtures and
thermal cycler conditions listed in Appendix 1. Expand Long Template PCR System
(Roche) was used for high fidelity amplification of DNA fragments for cloning. Taq
DNA Polymerase (Roche) was used for routine screening and RT-PCRs. Taq DNA
Polymerase (Invitrogen) was used for screening yeast colonies. Reactions were set up
using buffers supplied with the enzyme or enzyme mixture. All samples were made
up to a final volume of 50pil in 0.2ml thin-walled PCR tubes and reactions were
carried out in a PCR Sprint thermal cycler (Hybaid). Primers were supplied by MWG
Biotech and were made up to a working concentration of O.lpg/pl. lOmM dNTPs
were obtained from Sigma.
2.1.2 Cloning of PCR Products
PCR products were cloned using the pGEM-T Easy Vector System (Promega)
according to manufacturer's instructions following confirmation of amplilication of
an appropriately sized product. A 3pl sample of the PCR product was mixed with lpl
of vector, 1 pi of T4 DNA ligase and 5pl of 2x ligation buffer and incubated overnight
at 4°C.
2.1.3 Agarose Gel Electrophoresis
DNA was analysed by electrophoresis in 0.7-1.5% agarose gels containing 0.5pg/ml
ethidium bromide in TAE buffer. Samples up to 20pl were mixed with 6.x loading
buffer. Electrophoresis was carried out in horizontal gel tanks containing TAE at 70-
80V for 30ml (8 cm x 6 cm) gels and at 100-120V for 100ml (15 cm x 12 cm) gels.
Samples were compared with DNA ladders (1 Kb DNA ladder, Promega: lOObp DNA
ladder, Promega: 1Kb DNA ladder, New England Biolabs: PCR marker, New
England Biolabs: lOObp DNA ladder, Invitrogen: 1Kb plus DNA ladder. Invitrogen:
DIG-labelled DNA molecular-weight marker VII, Roche: DIG-labelled DNA
molecular-weight marker VIII, Roche) for size estimation. Gels were visualised on a
UV transilluminator.
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2.1.4 Purification of DNA by Phenol:Chloroform Extraction
Protein was removed from DNA samples by phenol extraction. The sample was made
up to at least lOOpl before extraction and 1 volume of phenol:chloroform:isoamyl
alcohol (25:24:1 v/v) was added and mixed by vortexing. The sample was separated
by centrifugation at 17,900 x g in a bench top microcentrifuge for 1 minute and the
upper phase was removed to a fresh tube taking care not to disturb the interface.
Residual phenol was removed by the addition of 1 volume of chloroform:isoamyl
alcohol (49:1 v/v). The sample was vortexed and separated by centrifugalion. The
upper aqueous phase containing the DNA was carefully removed and transferred to a
fresh microcentrifuge tube.
2.1.5 Concentration of DNA by Ethanol Precipitation
DNA was concentrated by adding 0.1 volumes of ammonium acetate (3M, pH 5.2)
and 2.5 volumes of 100% ethanol. The sample was mixed by vortexing and incubated
at -20°C overnight or on dry ice for 30 minutes. The DNA precipitate was pelleted by
centrifugation at 17,900 x g in a bench top microcentrifuge for 15 minutes. The pellet
was gently rinsed with ice cold 70% ethanol and allowed to air dry. DNA was
resuspended in an appropriate volume of UFO or Tris buffer (lOmM Tris, pi I 8.5).
2.1.6 Restriction Digestion of DNA
DNA was digested with restriction endonucleases (Aa/II, Bam\\\, BglII, EcoRl,
Hindlll, Nhe\, Notl, Pst I, Sac I, Sail, Xbal and Xhol, New England Biolabs) according
to manufacturer's instructions using the supplied buffers at the recommended
temperatures. Digests were usually carried out in a total volume of 20-50pl and never
using more than lpl of enzyme per lOpl total volume to reduce the chances of STAR
activity being seen. Digests were incubated from 1-16 hours depending on the
enzyme activity. When performing restriction digests for cloning purposes, lpl of
Shrimp Alkaline Phosphatase (Roche) was added to the vector digestion reaction to
prevent self ligation.
2.1.7 DNA Ligation
For plasmid cloning, a restriction digested insert was combined with restriction
digested and phosphatased vector at a molar ratio of approximately 1:1 and FLO
added to a final volume of 8pl. T4 DNA Ligase (Ipl, Promega) was added to the
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reaction along with lp.1 of supplied 10 x Ligase Buffer. Ligation reactions were
incubated overnight at 12°C.
2.1.8 Quantitation of Nucleic Acid by Spectrophotometry
DNA and RNA were quantitated on a Cecil CE 2041 spectrophotometer. 2pl of
sample was diluted in 98pl of milli-Q filtered FLO. The absorbance of the diluted
sample was read at 260 and 280nm. DNA concentration was calculated using the
following equation: A260 x Dilution (50) x 50ng/pl. RNA concentration was
calculated using the following equation: A260 x Dilution (50) x 40ng/fd. Nucleic acid
purity was estimated using the A260/A280 ratio.
2.1.9 Ethidium Bromide Plate Assay
Petri dishes were prepared containing 0.8% agarose gels with 0.5pg/ml ethidium
bromide in TAE buffer. 1 pi samples of DNA standards (200, 150, 100, 75, 50, 25
and 10 ng/pl) or test DNA were carefully applied to the surface of the gel. The spots
were allowed to absorb into the gel for 10 min at room temperature and the plates
were visualised on a UV transilluminator and the test spots were compared with the
standards for estimation ofDNA concentration.
2.1.10 DNA Extraction from Agarose Gels
DNA fragments were extracted from agarose gels using the QIAquick Gel Extraction
Kit (Qiagen). Following separation in agarose gels, the area containing the DNA
fragment of interest was excised from the gel and trimmed using a clean, sharp scalpel
blade. The gel slice was weighed and solubilised by the addition of 3 volumes of
supplied Buffer QG (1 pi per lmg). The sample was incubated at 50°C until the gel
slice was completely dissolved. 1 gel volume of isopropanol (lpl per I mg) was
added to each sample and mixed by pipetting. The sample was then applied to a
supplied spin column by pipetting. The column was centrifuged at 17,900 x g for 1
minute to bind DNA to the silica-gel membrane and the flow through was discarded.
The sample was washed by applying 500pl of Buffer QG to the column and
centrifuging at 17,900 x g for 1 min. The flow-through was discarded. A second
wash was performed by applying 750pl of Buffer PE to the column and cenlrifuging
as above. The flow through was discarded. The column was centrifuged as above to
completely remove residual wash buffer. The column was placed in fresh 1.5 ml
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microcentrifuge tube. 30pl of Buffer EB (lOmM Tris, pH 8.5) was applied to the
column and allowed to stand for 1 minute. The DNA was eluted by centrifugation as
above.
2.1.11 Purification of PCR Products
PCR products were purified using the QIAquick PCR Purification Kit. 5 volumes of
supplied Buffer PB was added to 1 volume of PCR sample and mixed by pipetting.
The Sample was applied to a supplied spin column. The column was centrifuged at
17,900 x g for 1 minute to bind DNA to the silica-gel membrane and the How through
was discarded. The sample was washed by applying 750pl of supplied Buffer PE to
the column and centrifuging as above. After discarding the flow through, the column
was centrifuged as above to completely remove residual wash buffer. The column
was placed in fresh 1.5 ml microcentrifuge tube. 30pl of Buffer EB (lOmM Tris, pH
8.5) was applied to the column and allowed to stand for 1 minute. The DNA was
eluted by centrifugation as above.
2.1.12 Sequencing of Plasmid DNA
Plasmid DNA sequencing reactions were performed using IRD-800 modilied primers
on a Li-cor automated DNA sequencer. Sequencing reactions were performed by lan
Bennett (Division of Veterinary Biomedical Sciences, University of Edinburgh).
2.1.13 Direct Sequencing of PCR Products
PCR products were purified by gel extraction or PCR purification (Sections 2.1.10
and 2.1.11). 10-50ng of purified product was made up to a volume of 6.75pl with
Milli-Q TEO in a 0.2ml thin-walled PCR tube, lpl of sequencing primer (diluted to
3.2pmol/pl), 1.75(0.1 of 5 x BigDye Buffer and 0.5pl of BigDye was added to the
sample. Sequencing reactions were carried out in a thermal cycler using the following
program:
96°C 10 sec
50°C 5 sec x 30
60°C 2 min
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The sample was transferred to a 0.5ml microcentrifuge tube made up to 25pl with
Milli-Q H2O. 2.5pl of ammonium acetate (3M, pH 5.2) and 50pl of 100% ethanol
was added and the sample was mixed by vortexing. The sample was incubated at
room temperature for 30 minutes and the precipitate was pelleted by centrifugation at
17,900 x g in a bench top microcentrifuge for 15 minutes. The pellet was gently
rinsed with ice cold 70% ethanol and allowed to air dry. Dried samples were sent to
Ms. Lynne Richardson (Department of Zoology, University of Oxford) for
sequencing.
2.1.14 Sequence Analysis
DNA sequences were analysed using NCB1 nucleotide-nucleotide BLAST
(http://www.ncbi.nlm.nih.gov/BLAST) and T1GR Cattle Gene Index BLAST
software (http://tigrblast.tigr.org/tgi). Jemboss software (UK MRC Human Genome
Mapping Project) was used for primer design and restriction digest mapping.
2.1.15 Isolation of RNA (Small Scale)
RNA was isolated from cultured cells or infected tissue using the RNeasy Mini Kit
(Qiagen). Approximately 5x106 tissue culture cells or 30mg of infected tissue was
used as the starting material. Infected tissue was homogenised using a fresh RNase-
free plastic pestle in a 1.5ml microcentrifuge tube prior to extraction. The cultured
cell or tissue homogenate sample was resuspended and 600pl of supplied Buffer RLT
added. The lysate was mixed by pipetting and passed through a QIAshredder spin
column by centrifugation at 17,900 x g for 2 minutes in a bench top microcentrifuge.
600pl of 70% ethanol was added to the homogenised lysate and mixed by pipetting.
The sample was transferred to an RNeasy mini column, centrifuged as above and the
flow-through was discarded. 700pl of supplied Buffer RW1 was applied to the
column. The sample was centrifuged and flow-through discarded as above. The
column was washed twice by adding 500pl of supplied buffer RPE and centrifuging
as above. The column was placed in a fresh 1.5 ml microcentrifuge tube. The RNA
was eluted by adding 30pl of RNase-free HjO and centrifuging as above.
2.1.16 Isolation of RNA (Large Scale)
Cultured Bovine Turbinate cells or freshly isolated PBMC were counted and collected
by centrifugation as described in Section 2.6.18. The supernatant was poured off and
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pellets were resuspended in the remaining liquid. 1ml of RNAwiz (Ambion) was
added per 107 cells (starting volume) in a polypropylene tube and the sample was
mixed by inversion. The sample was incubated at room temperature for 5 minutes
before adding 0.2 starting volumes of chloroform. The sample was mixed by
vigorous shaking and incubated for a further 20 minutes at room temperature in a
bench top centrifuge. The lysate was separated by centrifugation at 12,000 x g for 15
minutes at 4°C. The colourless upper phase containing the RNA was carefully
transferred to a fresh tube and mixed with 0.5 starting volumes of RNase-free HiO.
One starting volume of isopropanol was added and the sample was incubated at room
temperature for 10 minutes. Precipitated RNA was pelleted by centrifugation at
12,000 x g for 15 minutes at 4°C. The RNA pellet was gently rinsed with one starting
volume of ice cold 75% ethanol. The pellet was air dried and redissolved in an
appropriate volume of RNase-free HbO.
2.1.17 DNase Treatment of RNA
RNA was treated with RQ1 DNase (Promega) prior to reverse transcription, lpg of
RNA was resuspended in a volume of 8jul with RNase-free PRO in a 0.2ml microtube.
lpl of RQ1 DNase and lpl of supplied lOx DNase buffer were added and the sample
was incubated at 37°C for 30 minutes. The DNase was inactivated by adding lpl of
supplied Stop solution and incubating at 65°C for lOminutes.
2.1.18 Reverse Transcription of RNA
Reverse transcription was performed using AMV reverse transcriptase (Promega).
2pg of DNase-treated RNA was mixed with lpg of oligo dT(|g) primer (Ambion) and
RNase-free fTO to a final volume of 12.5pl. The sample was heated to 75°C for 5
minutes and rapidly chilled on ice. 5pl of supplied AMV RT reaction buffer, 2.5pl of
dNTP mix (lOmM), lpl (40U) of RNasin ribonuclease inhibitor (Promega), lpl of
lOOmM sodium pyrophosphate and 3pl (30U) of AMV RT was added and the sample
was incubated at 42°C for 1 hour. An RT-minus sample was set up in parallel with
each RT sample and processed identically except 3pl of RNase-free PbO was added in
place of enzyme.
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2.1.19 Isolation of mRNA from Total RNA
Isolation of mRNA was performed using the Poly(A) Purist mRNA purification kit
(Ambion) according to manufacturer's instructions. 500pg of total RNA was made
up to a volume of 500pl in nuclease-free PCO. The dissolved RNA was mixed with
500pl of supplied 2X Binding Solution and mixed thoroughly by pipetting. The RNA
sample was added to a supplied tube of Oligo(dT) Cellulose and mixed by inversion.
The sample was heated to 75°C for 5 minutes to denature secondary structure.
Following heating, the sample was incubated at room temperature for 60 minutes with
constant rocking in a Blood Tube Rotator (Stuart Scientific). The Oligo(dT)
Cellulose with bound mRNA was collected by centrifugation at 4,000 x g in a bench
top microcentrifuge for 3 minutes at room temperature and the supernatant was
carefully removed with a pipette.
The Oligo(dT) Cellulose pellet was resuspended in 500pl of Wash Solution 1 and
applied to a supplied spin column in a 2ml microcentrifuge tube. The Wash Solution
was passed through the sample by centrifugation at 4,000 x g in a bench top
microcentrifuge for 3 minutes at room temperature and discarded. A further 500pl of
Wash Solution 1 was added to the spin column and the sample was vortexed briefly to
resuspend the Oligo(dT) Cellulose. The Wash Solution was passed through the
sample and discarded as above. The sample was washed a further three times as
described above, using 500pl of supplied Wash Solution 2.
After the final wash, the spin column was placed in a fresh RNase-free
microcentrifuge tube. 200pl of supplied THE RNA Storage Solution (pre-warmed to
80°C) was added to the spin column to strip mRNA from the Oligo(dT) Cellulose.
The sample was voretexed briefly and mRNA was collected by centrifugation at
5,000 x g for 2 minutes in a bench top microcentrifuge. This procedure was repeated
with a second 200pl of THE RNA Storage Solution to elute any remaining mRNA.
RNA was precipitated by adding 40pl of 5M Ammonium Acetate (NH.tAc), lpl of
Glycogen and 1.1ml of 100% Ethanol. The solution was mixed by briefly vortexing
and incubated on dry ice for 30 minutes. The RNA was recovered by centrifugation
at 12,000 x g for 30 minutes at 4°C. The supernatant was carefully removed and the
RNA pellet was air dried. RNA was resuspended in 30pl of THFi RNA Storage
Solution and stored at -70°C.
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2.1.20 Library cDNA Synthesis
Library cDNA synthesis was performed using the cDNA Synthesis Kit (Slratagene).
5pg of mRNA was made up to a volume of 37.5pl with nuclease-free ICO in an
RNase free microcentrifuge tube. 5pl of lOx first-strand buffer, 3pl of lirst-strand
methyl nucleotide mixture (lOmM dATP, dTTP and dGTP plus 5mM 5-methyl
dCTP), 2pl of linker-primer and lpl of RNase Block Ribonuclease Inhibitor (all
supplied with kit) were added to the sample and mixed by gentle pipetting. The
sample was incubated at room temperature for 10 minutes to allow for annealing of
primer. 1.5pl (75U) of supplied StrataScript Reverse Transcriptase was added and the
reaction was incubated at 42°C for 60 minutes.
The reaction was placed on ice prior to addition of second-strand synthesis
components to ensure that the temperature did not exceed 16°C. 20pl of lOx second-
strand buffer, 8pl of second-strand dNTP mixture (lOmM), 114pl of sterile distilled
FLO, 2pl (3U) of RNase H and 1 lpl (99U) of DNA polymerase I were added to the
tube. The sample was incubated at 16°C for 2.5 hours and then returned to the ice.
To blunt the cDNA termini, 23pl of blunting dNTP mix (2.5mM) and 2pl (5U) of
cloned Pfu DNA polymerase were added to the tube and the sample was incubated at
72°C for exactly 30 minutes. Protein was removed from the sample by
phenokchloroform extraction (as described in Section 2.1.4). The cDNA was
precipitated and recovered by ethanol precipitation (as described in Section 2.1.5).
The cDNA pellet was resuspended in 9pl of supplied EcoR\ adapters and incubated
for 30 minutes at 4°C. lpl of lOx ligase buffer, lpl of lOmM rAMP and I pi (4U) of
T4 DNA ligase (all supplied with kit) were added to the tube and the sample was
incubated at 4°C for 2 days.
Following the two day incubation, the ligase was heat-inactivated by placing the
reaction tube in a 70°C water bath for 30 minutes. The reaction contents were
collected by brief centrifugation and cooled to room temperature, lpl of I Ox ligase
buffer, 2p! of lOmM rATP, 5pl of sterile FLO and 2pl (10U) of T4 polynucleotide
kinase was added to the tube and the reaction was incubated at 37°C for 30 minutes to
phosphorylate the EcoR\ ends. The kinase was heat-inactivated by placing the
reaction tube in a 70°C water bath for 30 minutes. The reaction contents were
collected by brief centrifugation and cooled to room temperature. The cDNA ends
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were digested by adding 28pl of Xho\ buffer supplement and 3 pi (1201J) of Xho\
(both supplied with kit) and incubating at 37°C for 90 minutes.
The cDNA was precipitated by adding 5pl of supplied 10X STE buffer and 125pl of
100% ethanol to the sample. Following overnight incubation at -20°C, the sample
was centrifuged at 17,900 x g for 60 minutes at 4°C in a bench top microcentrifuge.
The supernatant was discarded and the cDNA pellet was resuspended in I4pl of lx
STE buffer and 3.5pl of supplied column loading dye.
Prior to size fractionation, a drip column was assembled from a sterile 1ml plastic
pipette (Sterilin) and a sterile 10ml syringe (BD Biosciences) as follows. A cotton
plug of the pipette'was cut to approximately 4mm. The syringe was attached to the
large end of the pipette using a small piece of supplied connection tubing. The cotton
plug was forced down to the small end of the pipette by rapidly pushing the plunger
into the syringe. The plunger was removed from the syringe and the column
assembly was secured to a ring stand by a three-fingered clamp. Supplied Sepharose
CL-2B was mixed until the resin was completely resuspended and transferred to the
lml pipette until the settled bed was just below the lip of the pipette taking care to
avoid the inclusion of any air bubbles. The sepharose was washed by adding 10ml of
lx STE to the syringe and allowing it to drip through the column.
The cDNA sample was applied to the column when there was approximately 50pl of
wash buffer remaining above the sepharose. After the sample had entered the resin,
3ml of lx STE buffer was added to the syringe and allowed to drip through the resin.
Sample fractions of 4 drops each were collected from the time that the dye front
reached the 0.4ml graduation on the pipette until the trailing edge of the dye reached
the 0.3ml graduation. A total of 10 fractions were collected and analysed by ethidium
bromide plate assay (as described in Section 2.1.9). Fractions containing the first
wave of eluted DNA (but not the second wave of free linkers and unincorporated
nucleotides) were pooled. The cDNA from the pooled fractions was cleaned by
phenokchloroform extraction (as described in Section 2.1.4) and concentrated by
ethanol precipitation (as described in Section 2.1.5). Library cDNA was ligated into
pGAD-T7 vector (Clontech) which had been digested with EcoR\ and Xhol and
treated with Shrimp Alkaline Phosphatase (see Sections 2.1.6 and 2.1.7). The library
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ligation mixture was incubated overnight at 12°C and transformed into XLIO-Gold
Ultracompetent cells (Stratagene, see Section 2.2.3).
2.1.21 Annealing of Oligonucleotides for Cloning
Long (71 bp) oligonucleotides for cloning were synthesised by MWG.
Oligonucleotides were resuspended in H2O to a concentration of lpg/pl. 5pl of each
oligonucleotide were combined in a microcentrifuge tube along with 5pl of 10 x
Buffer 2 (supplied with New England Biolabs Restriction Endonucleases) and 35pl of
MilliQ HbO. The sample was heated to 95°C for 4 minutes and transferred to a
beaker containing 500ml of HiO at 70°C. The sample was allowed to cool in the
beaker for several hours until it had reached room temperature. Annealed
oligonucleotides were ligated into plasmids cut with appropriate restriction
endonucleases and transformed into One-Shot competent cells (see Sections 2.1.6,
2.1.7 and 2.2.2).
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2.2 Bacterial Techniques
2.2.1 Bacterial Culture
Various laboratory strains of Escherichia coli (E. coli) were grown in Luria-Bertani
(LB) medium or on LB plates with 1.5% agar. Media was sterilised and agar melted
by autoclaving. Media was supplemented with appropriate antibiotics (lOOpg/ml
ampicillin or 50pg/ml kanamycin) prior to use. LB/Agar was supplemented with
appropriate antibiotic when the gel had cooled to approximately 50°C and mixed by
swirling. LB/Agar was poured into 10cm diameter Petri dishes. Bacteria were plated
on the surface of LB/Agar by spreading with a glass spreader or streaking with an
wire loop and plates were incubated, inverted, at 37°C overnight. Single colonies
from agar plates were used to inoculate liquid medium. Liquid cultures were
incubated overnight with shaking at 225 rpm in an orbital shaker at 37"C. Plate
pouring and all bacterial procedures were carried out using aseptic bacteriological
technique.
2.2.2 Transformation of One-Shot Chemically Competent E. coli
Three different strains of One-Shot chemically competent E. coli were purchased
from Invitrogen. The INVaF' strain was used for routine cloning. The 1NV1 10 strain
was used for cloning plasmids that required digestion with methylation sensitive
restriction enzymes. The Topi OF' strain was used for cloning, and the inducible
expression, of protein from the pTrcHis vector. Cells were transformed according to
manufacturer's instructions using aseptic bacteriological technique.
Single aliquots of competent cells were thawed on ice. A 5pl sample of ligation
mixture or <lpl of plasmid was added and the cells were incubated, on ice, for a
further 30 minutes. The cells were then incubated at 42°C for exactly 30 seconds and
returned to the ice. 250pl of SOC medium was added and the samples were shaken in
an orbital shaker at 225 rpm for 1 hour at 37°C. Following this incubation, samples
were plated on 10cm diameter Luria-Bertani (LB)/Agar plates supplemented with
appropriate antibiotic (lOOpg/ml ampicillin or 50pg/ml kanamycin). If blue/white
screening of colonies was required, LB/Agar plates were supplemented with 40pg/ml
X-gal (5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside made up to 20mg/ml in
dimethylformamide). Plates were incubated, inverted, at 37°C overnight.
65
Chapter 2 Materials and Methods
2.2.3 Transformation of XLIO-Gold Ultracompetent Cells
XLIO-Gold Ultracompetent cells (Stratagene) were thawed on ice and lOOpI aliquots
were gently added to pre-chilled 14ml Falcon tubes (BD). 4pl of (3-Mercaptoethanol
was added and the cells were incubated on ice for 10 minutes with occasional
swirling. 5pl of ligation mixture was added and the cells were incubated on ice for 30
minutes. Following incubation, the tube was heat-pulsed for exactly 30 seconds in a
42°C water bath. Tubes were immediately transferred to ice for 2 minutes. 900pl of
pre-warmed SOC medium (Invitrogen) was added to the tube and the sample was
shaken in an orbital shaker at 225 rpm for 1 hour at 37°C. Following this incubation,
200pl aliquots were plated on 10cm diameter Luria-Bertani (LB)/Agar plates
supplemented with appropriate antibiotic (lOOpg/ml ampicillin or 50pg/ml
kanamycin). Plates were incubated, inverted, at 37°C overnight.
2.2.4 Preparation of Bacterial Stocks for Long Term Storage
A single bacterial colony was isolated from LB/Agar plates and used to inoculate 5 ml
of Luria-Bertani medium supplemented with appropriate antibiotic (lOOpg/ml
ampicillin or 50pg/ml kanamycin) using good bacteriological technique. Cultures
were shaken overnight at 225 rpm in an orbital shaker at 37°C. The following day
500pl of culture was mixed with 500pl of sterile 50% glycerol in FLO. flic sample
was transferred to a 1.8ml cryovial (Nunc) and incubated on ice for at least 2 hours
before storage at -80°C.
2.2.5 Plasmid DNA Isolation from Bacteria (Small Scale)
Plasmid DNA was isolated from transformed bacteria by alkaline lysis of bacterial
cultures followed by silica-gel adsorbtion of DNA using the QIAprep Spin Miniprep
Kit (Qiagen) according to manufacturer's instructions. A single bacterial colony was
isolated from LB/Agar plates and used to inoculate 5 ml of Luria-Bertani medium
supplemented with appropriate antibiotic (lOOpg/ml ampicillin or 50pg/ml
kanamycin) using good bacteriological technique. Cultures were shaken overnight at
225 rpm in an orbital shaker at 37°C.
The following day, bacteria were collected by centrifugation at 4,000 x g in a bench-
top centrifuge for 5 minutes at room temperature. The bacterial pellet was
resuspended in 250pl of Buffer PI and transferred to a 1.5ml microcentrifuge tube.
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Cells were lysed by the addition of 250|al of Buffer P2 followed by gentle inversion
and allowed to stand for 3 minutes. Lysis was stopped by the addition of 350pl of
Buffer N3 followed by gentle inversion. The sample was then centrifuged at 17,900 x
g for 10 minutes in a bench top microcentrifuge to pellet the precipitate.
The supernatant was carefully removed and applied to a supplied spin column by
pipetting. The sample was centrifuged at 17,900 x g for 1 minute to bind plasmid
DNA to the silica-gel membrane and the flow through was discarded. The sample
was washed by applying 500pl of Buffer PB to the column and centrifuging at 17,900
x g for 1 minute. The flow through was discarded. A second wash was performed by
applying 750pl of Buffer PE to the column and centrifuging at 17,900 x g for 1
minute. The flow through was discarded. The column was centrifuged at 17,900 x g
for 1 minute to completely remove residual wash buffer. The column was placed in a
fresh 1.5 ml microcentrifuge tube. 50pl of Buffer EB (lOmM Tris, pi I 8.5) was
applied to the column and allowed to stand for 1 minute. The plasmid DNA was
eluted by centrifugation at 17,900 x g for 1 minute.
2.2.6 Plasmid DNA Isolation from Bacteria (Large Scale)
For large scale isolation of plasmid DNA the QIAGEN Plasmid Maxi Kit (Qiagen)
was used following manufacturer's instructions. A single freshly streaked colony was
isolated and inoculated into 5ml of Luria-Bertani medium supplemented with
appropriate antibiotic (lOOpg/ml ampicillin or 50pg/ml kanamycin). This culture was
grown at 37°C for 6-8 hours in an orbital shaker at 225 rpm and then used to inoculate
500ml of Luria-Bertani medium supplemented with appropriate antibiotic (100pg/ml
ampicillin or 50pg/ml kanamycin). These cultures were shaken overnight at 225 rpm
in an orbital shaker at 37°C.
Bacteria were harvested by centrifugation at 6,000 x g for 15 minutes at 4°C in a
Beckman J2-21 centrifuge. The bacterial pellet was resuspended in 10ml of supplied
Buffer PI and transferred to a fresh 30ml Oakridge tube. Cells were lysed by the
addition of 10ml of Buffer P2 followed by gentle inversion and allowed to stand for 5
minutes. Lysis was stopped by the addition of 10ml of Buffer N3 followed by gentle
inversion and incubated on ice for 20 minutes. The sample was centrifuged at 20,000
x g for 30 minutes at 4°C in a Beckman J2-21 centrifuge to pellet the precipitate. The
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supernatant was then transferred to a fresh Oakridge tube and centrifuged again at
20,000 x g for 15 minutes at 4°C.
A QIAGEN-tip 500 column was equilibrated with 10ml of Buffer QB'I, allowed to
enter the silica resin by gravity flow. The supernatant sample from the centrifuged
cell lysate was then applied to the column. After the entire sample had entered the
resin, the column was washed with a total of 60ml of Buffer QC allowed to pass
through by gravity flow. Plasmid DNA was eluted with 15ml of Buffer QF and
collected in a clean 30ml glass Corex tube. DNA was precipitated by adding 10.5ml
of isopropanol at room temperature to the eluate and mixing by inversion. The
sample was then centrifuged at 15,000 x g for 30 minutes at 4°C in a Beckman J2-21
centrifuge. Following centrifugation, the supernatant was'discarded and the pelleted
DNA sample was washed gently with 10ml of ice-cold 70% ethanol. The pellet was
allowed to air dry and was then redissolved in 500j.il of Tris buffer (lOmM Tris, pH
8.5).
2.2.7 Bacterial Expression of Tagged Proteins
The ToplOF' strain of E. coli was used for the inducible expression of protein from
pTrcHis 2A derived vectors. Single colonies from agar plates were used to inoculate
LB medium containing lOOpg/mi ampicillin. Liquid cultures were incubated
overnight shaking at 225 rpm in an orbital shaker at 37°C. 60pl of the overnight
culture was used to inoculate 2ml of LB and the culture was incubated at 37°C
shaking at 225 rpm in an orbital shaker until the OD600 had reached 0.6 (about 2 - 2.5
hours). Isopropyl-beta-D-thiogalactopyranoside (IPTG, Sigma) was added to the
culture at a final concentration of ImM to induce expression of protein. The culture
was incubated as before and at the indicated timepoints post-induction, 200j.il samples
were transferred to 1.5ml microcentrifuge tubes. Samples were centrifuged for 1
minute at 17,900 x g in a benchtop microcentrifuge and cell pellets were resuspended
in 20pl of 1 x EDTA Free Protease Inhibitor Coctail (Roche). Samples were stored at
-70°C until analysed by Western blot.
2.2.8 Bacterial Lysis for Protein Isolation
Topi OF' bacteria expressing protein were grown and induced as described in Section
2.2.7. A 1.5ml sample of the culture was transferred to a 1.5ml microcentrifuge tube.
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The sample was centrifuged for 5 minutes at 17,900 x g in a benchtop microcentrifuge
and the cell pellet was resuspended in 400pl of CelLytic B bacterial cell lysis reagent
(Sigma). The sample was thoroughly mixed by vortexing and subjected to two rounds
of freeze/thaw. The sample was centrifuged as above and the supernatant was
transferred to a fresh tube (Fraction 1) containing 40pl 10X EDTA-frec protease
inhibitor cocktail (Roche). The pellet was resuspended in 400pl of CelLytic B
supplemented with 0.2mg/ml Lysozyme (Sigma). The sample was shaken gently and
incubated at room temperature for 20 minutes to fragment cell walls. 1 ml of CelLytic
B (diluted 1:10 in FLO and containing IX EDTA-free protease inhibitor cocktail) was
added and the sample was centrifuged as above. The supernatant (Fraction 2) was
transferred to a fresh 1.5ml microcentrifuge tube and the pellet of inclusion bodies
and cell debris was resuspended in 50pl of IX EDTA-free protease inhibitor cocktail.
2.2.9 Immunoprecipitation of Bacterial Lysates
Bacterial lysates containing proteins of interest (Fraction 2, Section 2.2.8) were used
for immunoprecipitation using anti-FLAG antibodies. 20pl of Streptavidin-agarose
(Sigma) slurry was added to 1ml of supernatant sample. The sample was incubated
with constant rocking at 4°C for 1 hour. The sample was centrifuged for 5 minutes at
17.900 x g in a bench top microcentrifuge. The pellet (Pre-Incubation) and a sample
of the supernatant (Supernatant 3) were saved for analysis. The remainder of the
supernatant was transferred to a fresh microcentrifuge tube and incubated overnight
with 4.4pg/ml Anti-FLAG M2 antibody (Sigma). The following day, 40pl of
Streptavidin-agarose slurry was added and the sample was incubated with constant
rocking at 4°C for 1.5 hours. The sample was centrifuged as above and an aliquot of
the supernatant (Supernatant 4) was saved for analysis. The immunoprecipilate pellet
was resuspended in 500pl of CelLytic B bacterial cell lysis reagent (Sigma, diluted
1:10 in FLO) and centrifuged as above. The pellet was washed in this way two more
times and all samples were analysed by Western Blot.
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2.3 Yeast Techniques
2.3.1 Yeast Culture
The AH 109 strain of Saccharomyces cerevisiae was used for all experiments.
Untransfected yeast cells were grown in YPDA media or on YPDA plates with 2%
agar. Transfected yeast cells were grown in SD media containing the appropriate
dropout supplement or on SD/dropout plates with 2% agar. Media was sterilised and
agar melted by autoclaving on a sugar cycle (121°C for 15 minutes). Yeast were
spread on agar plates with a glass spreader or streaked with a wire loop and plates
were incubated, inverted, at 30°C until colonies had grown to a diameter of l-2mm.
For analysis of MEL1 reporter gene activity during growth, lOOpl ofX-u-Gal solution
(5-Bromo-4-chloro-3-indolyl-a-D-galactopyranoside, Clontech, made up to 4mg/ml
in dimethylformamide) was spread onto the surface of selective agar plates. Liquid
cultures were inoculated with a single colony and vortexed to disperse any remaining
clumps of yeast. Plate pouring and all yeast procedures were carried out on a cleared
bench next to a Bunsen burner.
2.3.2 Transformation of Yeast
Yeast were transformed using the polyethylene glycol/lithium actetate method. Small
scale yeast transformations were used to introduce bait vectors into AH 109 yeast or
introduce isolated prey plasmids into bait vector-containing yeast for confirmation of
interactions. Large scale transformations were used to introduce prey library plasmid
DNA into bait vector-containing yeast (sequential transformation).
Fresh yeast colonies of 1-2 mm in diameter were isolated from either YPDA/Agar or
SD-Trp/Agar and inoculated into 50ml of YPDA or SD-Trp and grown overnight at
30°C in an orbital shaker at 225 rpm. The following day, enough of the overnight
culture to produce an OD600 of 0.2-0.3 was transferred to 300ml of YPDA or SD-Trp.
This culture was incubated at 30°C in an orbital shaker at 225 rpm until the OD600
reached approximately 0.5 (usually 3-5 hours). The culture was divided evenly
between 50ml falcon tubes (BD) and centrifuged at 1,500 x g for 5 minutes at room
temperature in a bench top centrifuge. Supernatants were discarded and cell pellets
were pooled and resupended in 50 ml of sterile TE buffer (lOmM Tris, I111M EDTA,
pH 7.5). The cells were again centrifuged at 1,500 x g for 5 minutes at room
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temperature. The supernatant was discarded and the cell pellet was resuspended in
1.5ml of freshly prepared sterile TE/LiAc (lOOmM Lithium acetate, lOmM Tris, ImM
EDTA, pH 7.5). For small scale transformations, 100pl of resuspended cells was
added to a 1.5ml microcentrifuge tube containing 0.1 pg of plasmid DNA and lOOpg
of sheared salmon sperm carrier DNA. For large scale transformations, 1ml of
resuspended cells was added to a 15ml falcon tube (BD) containing 50pg of library
plasmid DNA and 2mg of sheared salmon sperm carrier DNA. Samples were mixed
by vortexing. 600pl (6ml for large scale transformations) of freshly prepared sterile
PEG/LiAc (40% (w/v) polyethylene glycol 3,350, lOOmM Lithium acetate, lOmM
Tris, ImM EDTA, pH 7.5) was added and samples were mixed by vortexing.
Samples were incubated at 30°C for 30 minutes in an orbital shaker at 225rpm. 70pl
(700pl for large scale transformations) of DMSO was added to the samples and gently
mixed by inversion. Samples were heat-shocked in a 42°C water bath for I 5 minutes
and then chilled on ice for 2 minutes.
Cells from small scale transformation samples were collected by centriLigation at
12,000 x g for 30 seconds in a bench top microcentrifuge. Cells were resuspended in
500pl of sterile TE buffer (lOmM Tris, ImM EDTA, pH 7.5) and a 200pl sample was
spread on an agar plate containing the appropriate medium using a glass spreader.
Cells from large scale transformation samples were collected by centri I ligation at
1,500 x g for 5 minutes in a bench top centrifuge and resuspended in 1,5ml of sterile
TE buffer. lOOpl samples were spread over 15 SD-Ade/-Flis/-Leu/-Trp/Agar plates
using a glass spreader. Plates were incubated, inverted, at 30°C until colonies had
grown to 1-2 mm in diameter.
2.3.3 Isolation of DNA from Yeast
Yeast colonies selected for screening were grown in 1ml of selective medium (SD-
Trp-His-Ade-Leu or SD-Trp-Leu). Cultures were shaken overnight at 225rpm in an
orbital shaker at 30°C. Liquid cultures were transferred to 1.5ml microcentrifuge
tubes and yeast were collected by centrifugation at 17,900 x g in a bench top
microcentrifuge for 5 minutes at room temperature. Pellets were resuspended in 50pl
of TE buffer. Alternatively, selected yeast colonies were grown in ~lcm' patches on
plates containing selective medium with 2% agar. Plates were incubated at 30°C until
abundant yeast growth was seen. Yeast were then scraped from the plate and
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resuspended in 50 pi of TE. lOpI of lyticase solution (5units/pl in TE buffer) was
added and the sample was shaken at 225rpm in an orbital shaker at 30°C for 1 hour.
140pl of TE buffer was added and the sample was frozen on dry ice. The sample was
then thawed and an equal volume (200pl) of phenol:chloroform:isoamyl alcohol
(25:24:1 by volume) was added and mixed by vortexing. The sample was separated
by centrifugation at 17,900 x g in a bench top microcentrifuge for 1 minute and the
upper phase was removed to a fresh tube taking care not to disturb the interface.
Residual phenol was removed by the addition of 1 volume of chloroform:isoamyl
alcohol (49:1 by volume). The sample was vortexed and separated by centrifugation.
The upper phase containing the DNA was carefully removed and transferred to a fresh
microcentrifuge tube. DNA was concentrated by ethanol precipitation (Section 2.1.5)
and resuspended in 20ul of Milli-Q H2O for screening by PCR.
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2.4 Southern Blot
2.4.1 Probe Labelling
DNA probes were purified by gel extraction and labelled using the DIG High Prime
DNA Labelling and Detection Starter Kit II (Roche) according to manufacturer's
instructions. 1 pg of template DNA was made up to a volume of 16pl in a thin-walled
0.2ml microtube. The DNA was denatured by heating to 100°C for 10 minutes and
rapidly chilling on ice. 4pl of supplied DIG-High Prime solution was added and the
sample was incubated overnight at 37°C. The labelling reaction was stopped by
adding 2pi of 0.2M EDTA and heating the reaction to 65°C for 10 minutes. Labelling
efficiency was tested by dot blot as follows. Dilutions of probe in PLO were made
from lng/pl to 0.01 pg/pl. lpl from each of the diluted probe samples and the control
samples was dispensed onto Hybond N+ membrane (Amersham) and lixed by cross
linking with a UV Stratalinker 2400 (Stratagene). The probes were delected and
developed as described in Section 2.4.4. The probe signal was compared with that of
the control DNA.
2.4.2 Capillary Transfer
Digested DNA and DIG-labelled ladders were resolved in an agarose gel. The DNA
was denatured with two 20 minute incubations in denaturation buffer (0.5M NaOH,
1.5M NaCl) on a rotary platform and rinsed in distilled PLO. The gel was then
neutralised with two 20 minute incubations in neutralisation buffer (1M Tris-Cl, 1.5M
NaCl) on a rotary platform and rinsed in distilled PLO. The gel was then placed on
top of three layers of Whatmann 3MM filter paper allowed to soak in a lOxSSC
buffer-filled transfer tank. A gel-sized piece of pre-wetted Hybond N+ membrane
(Amersham) was placed on top of the gel. Two pre-wetted sheets of Whatmann 3MM
filter paper were placed on top of the membrane followed by a 15cm stack of dry
paper towels, a glass plate and a 1kg weight. DNA was allowed to transfer to the
membrane overnight by capillary action. The following day, the membrane was
removed from the gel and DNA was fixed by cross linking with a UV Stratalinker
2400 (Stratagene).
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2.4.3 Probe Hybridization
DNA blots were probed using solutions from the DIG High Prime DNA Labelling
and Detection Starter Kit II (Roche) according to manufacturer's instructions.
0.1 ml/cm2 of pre-warmed supplied DIG Easy Hyb solution was added to the
membrane and incubated with gentle turning in a roller bottle at 50°C for 30 minutes.
DIG-labelled DNA probe (2.5ng/cm2) was denatured by incubating at 100°C for 5
minutes and immediately cooling on ice. Denatured probe was added to an
appropriate volume of pre-warmed DIG Easy Hyb solution. The membrane was
incubated with probe solution overnight at 50°C with gentle turning in a roller bottle.
The membrane was washed twice in 2xSSC, 0.1% SDS at room temperature for 5
minutes each with gentle turning in a roller bottle. The membrane was then washed
twice again in 2xSSC, 0.1% SDS at 68°C for 15 minutes each.
2.4.4 Probe Detection
Prior to immunological detection of DIG labelled probes the membrane was rinsed in
washing buffer (0.1M Maleic acid, 0.15M NaCl, 0.3% Tween 20, pH7.5) followed by
a 30 minute incubation in 1 ml/cm2 blocking solution (supplied blocking solution
diluted in 0.1M Maleic acid, 0.15M NaCl, pH7.5) at room temperature with gentle
turning in a roller bottle. Probes were detected by incubating the membrane with
75mU/ml Anti-Digoxigenin-AP antibody in 0.2ml/cm2 blocking solution for 30
minutes at room temperature with gentle turning in a roller bottle. The membrane
was washed twice in 1 ml/cm2 washing buffer for 15 minutes each at room
temperature with gentle turning in a roller bottle. The washed membrane was placed
on plastic wrap in a development folder. 0.1ml/cm2 of supplied ready to use CSPD
was applied to the membrane which was then covered with another sheet of plastic
wrap and the folder was closed to spread CSPD evenly across the membrane. The
Membrane was exposed to Lumi-Film Chemiluminescent Detection film (Roche) in a
dark room for 5-60 minutes at room temperature. Films were developed using an
Optimax processor (Jet).
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2.5 Western Blots
2.5.1 Protein Electrophoresis
7.3 x 10.2cm and 8.3 x 10.2cm gel plates were assembled with spacers using the
Mini-Protean II apparatus (Bio-Rad). Resolving gels containing between 10% and
15% acrylamide (Section 2.9.2) were poured immediately after the addition of
ammonium persulphate (APS) and N, N, N', N'-Tetrametylethylenediamine
(TEMED). Gels were poured to a level just below the bottom of the comb and
overlayed with sec-butanol. Resolving gels were allowed to polymerise for 30
minutes before the butanol was removed and the top surface of the gel was rinsed
with stacking gel solution (Section 2.9.2). Stacking gels were poured on top of the
resolving gels, combs were added and the gel was allowed to polymerise for 30
minutes. Gels were assembled in the Mini-Protean 11 vertical gel tank and the
reservoirs were filled with SDS running buffer (Section 2.9.2). Combs were removed
and wells were rinsed out to remove any unpolymerised acrylamide before use.
Protein samples were mixed 1:1 with 2x boiling buffer (Section 2.9.2) and heated for
5 minutes at 100°C. Samples were loaded into wells and run at 25mA for 1-1.5
hours or until the blue dye front had reached the bottom of the gel. SeeBlue Plus2
(Invitrogen) and Full-Range Rainbow Molecular Weight Markers (GE Healthcare)
protein standards were used for comparative size estimation.
2.5.2 Transfer of Protein to Nitrocellulose Membranes
Protran BA 85 nitrocellulose membrane (Schleicher and Schuell) was cut to the size
of the resolving polyacrylamide gel (approximately 4.5 x 8 cm) and 6 pieces of 3MM
Chr chromatography paper (Whatman) were cut slightly larger. The membrane and
sheets of blotting paper were soaked in transfer buffer (Section 2.9.2) prior to use.
Three sheets of the blotting paper were placed in the centre of the anode of a Semi-
Dry Electroblotter A (Ancos). The nitrocellulose membrane was placed on top of
these followed by the polyacrylamide gel. The remaining three sheets of blotting
paper were placed on top of the gel and any trapped air bubbles were removed from
the assembly by gently rolling the side of a pipette over the top sheet. The cathode
was placed on top of the assembly and a current of 0.4mA/cm2 (based on blotting
paper area) was applied for 1 hour. Following transfer, the membrane was carefully
removed. The membrane was incubated with Ponceau S solution for 1 minute and
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rinsed with dFBO until well defined bands were seen to confirm even transfer of
protein.
2.5.3 Immunological Detection of Protein Blots
For GFP and c-myc detection, protein blots were blocked overnight in PBS containing
2% (w/v) BSA and 0.1% (v/v) Tween 20. The following day, membranes were
incubated with either Anti-GFP (JL-8, Clontech) or Anti-c-myc (9E10 from mouse
ascites fluid, Sigma) primary antibody diluted 1:2,000 (to 0.5pg/ml) or 1:500 in 2%
BSA/PBS, respectively, for 1.5 hours. Membranes were washed twice in 0.1%
Tween-20/PBS for 15 minutes each. Membranes were then incubated with Anti-
Mouse IgG (Fab Specific) Alkaline Phosphatase Conjugate (Sigma) diluted 1:1,000 in
2% BSA/PBS for 30 minutes. Prior to detection, membranes were washed three times
in 0.1% Tween-20/PBS for 20 minutes each. Bound antibody was detected by
incubating the membrane with 5-bromo-4-chloro-3-indolyl phosphate/nilro blue
tetrazolium solution (Sigma, 1 SIGMAA^ST BC1P/NBT tablet dissolved in 10ml
dH20) until clear bands were visible. All washes and antibody incubations were
carried out at room temperature with constant agitation on an orbital platform.
For 3xFLAG epitope tag detection, the above protocol was used with the following
exceptions: biotinylated Anti-FLAG M2 (Sigma) diluted 1:250 to 4.4pg/ml was used
as the primary antibody, Streptavidin-AP Conjugate (Roche) diluted 1:1,000 to lU/ml
was used in place of a secondary antibody and TBS was used in place of PBS in all
solutions.
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2.6 Tissue Culture and Virus Growth
2.6.1 Growth of Established Cell Lines
BHK-21 cells (hamster kidney fibroblasts) were maintained in Glasgow's medium
supplemented with 2% (v/v) newborn calf serum, 10% (v/v) tryptose phosphate broth,
2mM L-glutamine and 200U/L penicillin/streptomycin. CI27 cells (mouse mammary
gland epithelial tumour cells) were maintained in RPM1-1640 medium supplemented
with 10% (v/v) foetal calf serum, 2mM L-glutamine and 200U/L
penicillin/streptomycin. BT (Bovine turbinate) cells were maintained in Iscove's
Minimal Essential Medium (IMEM, Sigma) supplemented with 10% (v/v) foetal calf
serum, 2mM L-glutamine and 200U/L penicillin/streptomycin. Cell lines were
maintained in 175cm2 and 75cm2 tissue culture flasks (Nunc). Confluent cell
monolayers were removed from the flask surface using trypsin/EDTA. Firstly, the
media was poured off and the monolayer was rinsed with approximately lOOpl
versene solution (0.2g/L EDTA-4Na, Gibco) per cm2 of cells. The versene was
removed and the cells were incubated with approximately 30pl Trypsin/EDTA
solution (Gibco) per cm2 until all cells had detached. The cells were resuspended in
10ml of complete medium and centrifuged for 5 minutes at 500 x g in a bench top
centrifuge. The cell pellet was resuspended in complete medium. A sample of the
cell suspension was diluted in Trypan Blue solution (Sigma) and live cells were
counted in a haemocytometer. Viable cell number was calculated using the following
equation: Cells/ml = Number of cells counted in the middle 25 squares x dilution in
Trypan Blue x 104. 175cm2 flasks were seeded with approximately 5xI()'' cells in
40ml of medium. 75cm2 flasks were seeded with approximately 106 cells in 18ml of
medium. Cells were grown in a 37°C incubator with 5% CCL.
2.6.2 Preparation of Cell Lines for Long Term Storage
BHK-21, C127 or BT cells were grown and counted as described in Section 2.6.1.
Cells were then pelleted by centrifugation at 500 x g for 5 minutes in a bench top
centrifuge and resuspended in 1 ml freezing solution (90% foetal calf serum, 10%
dimethyl sulphoxide) per 2x106 cells. Aliquots of 1ml were transferred to 1.8ml
cryovials (Nunc). Cryovials were stored overnight at -80°C wrapped in cotton wool.
Samples were then transferred to liquid nitrogen for long term storage.
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2.6.3 Growing Cell Lines from Frozen Stocks
Vials of frozen cells were removed from liquid nitrogen and kept on dry ice until
ready to thaw. Cells were thawed rapidly in a 37°C water bath. The thawed sample
was transferred to 10ml of prewarmed complete medium. Cells were pelleted by
centrifugation at 500 x g for 5 minutes, resuspended in 8ml of fresh medium and
transferred to a 25cm2 flask (Nunc). Cells were grown in a 37°C incubator with 5%
co2.
2.6.4 MHV-76 and MHV-ALHE DNA Isolation
5xl07 BHK-21 cells were suspended in 5ml and infected with 5xl06 PFIJ (MOI = 0.1)
of virus. Cells were incubated for 90 minutes at 37°C shaking at 225 rpm in an orbital
shaker. The cells were then plated out in 10 x 175cm2 flasks in 40ml complete
medium per flask and incubated at 37°C.
Flasks were checked daily until complete cytopathic effect (CPE) was seen (usually 4-
6 days). Remaining adherent cells were dislodged by shaking and all media from all
flasks was pooled. Cells were pelleted by centrifugation at 500 x g for 20 minutes.
The cell pellet was resuspended in 4 ml of PBS and disrupted by 30 strokes, on ice, in
a dounce homogeniser. The homogenate was centrifuged at 1,700 x g for 20 minutes
at 4°C in a bench top centrifuge. The supernatant was collected and the pellet was
resuspended in 1ml of PBS and subjected to a further 30 strokes in the dounce
homogeniser. The homogenate was centrifuged at 1,700 x g for 20 minutes at 4°C.
The supernatant from this sample was pooled with that of the first round of
homogenisation.
The pooled supernatants were carefully layered onto the top of 30ml of 20% (w/v) D-
sorbitol in PBS in an SW28 tube. The sample was centrifuged at 141,000 x g for 80
minutes in a Beckman L8-70M ultracentrifuge. Pelleted virus was resuspended in
500pl of 50mM Tris, pH 8.0 and added to 5ml of High Molecular Weight DNA
Extraction Buffer (0.625% (w/v) Sodium Dodecyl Sulphate, 125mM El) l'A, 250mM
Tris, pH 8.0). Capsids were digested by adding 550pg PCR grade Proteinase K
(Roche) and the sample was incubated overnight at 53°C.
The sample was carefully transferred to a 15ml polypropylene tube (Falcon). An
equal volume (5.5ml) of phenolxhloroforrmisoamyl alcohol (25:24:1 by volume) was
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added and mixed by gentle rocking on a tilting platform for 30 minutes. The sample
was centrifuged at 500 x g for 5 minutes in a bench top centrifuge to aid separation.
The upper phase was collected taking care not to disturb the interface and transferred
to a fresh 15ml tube. Phenol extraction was repeated 4 times. Residual phenol was
removed by adding 1 volume of chloroforrmisoamyl alcohol (49:1 by volume) and
mixed by gentle rocking on a tilting platform for 30 minutes. The sample was
centrifuged at 500 x g for 5 minutes to aid separation. The upper phase was collected
taking care not to disturb the interface and transferred to a fresh 15ml tube.
Viral DNA was precipitated by adding 1.7ml of 7.5M ammonium acetate and 12ml of
100% ethanol. The precipitate that formed immediately following the addition of the
ethanol was removed using a sealed end Pasteur pipette and transferred to a clean
Corex tube containing 20ml of 70% ethanol. The sample was centrifuged at 8,000 x g
at 4°C for 30 minutes in a Beckman J2-21 centrifuge. Following centrifugation, the
supernatant was discarded and the pelleted DNA sample was washed gently with
10ml of ice-cold 70% ethanol. The pellet was allowed to air dry and then redissolved
in 500pl of Tris buffer (lOmM Tris, pH 8.5).
2.6.5 Transfection of Cell Lines with Viral DNA by Electroporation
BHK-21 cells were grown in 175cm2 flasks until almost confluent. The cells were
trypsinised and counted as described in Section 2.6.1. 5xl06 cells were resuspended
in 800pl of OptiMEM Reduced Serum Medium (Gibco) and transferred to an
electroporator cuvette containing 2pg of highly purified viral DNA, 9pg of insert
vector and 20gg of salmon sperm carrier DNA. Cells were transfected in an Easyject
Plus electroporator (Equibio) using a two pulse protocol (Fl= 600V 75pF 99ohms,
F2= 250V 1050pF 99ohms, 0.1 seconds delay). Immediately following
electroporation, cells were added to 20ml of complete media. Electroporated cells
were combined with lxlO7 untransfected cells to a final volume of 100ml and plated
out in five 96-well plates (approximately 3x104 cells/well) and incubated at 37°C with
5% CO2 until viral plaques formed.
2.6.6 Transfection of Cell Lines with Plasmid DNA by Electroporation
BHK.-21 cells were grown in 175cm2 flasks until almost confluent. The cells were
trypsinised and counted as described in Section 2.6.1. 2.5x106 cells were resuspended
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in 200|oJ of Optimem medium (Gibco) and transferred to a 0.2cm electroporator
cuvette containing lOpg of plasmid DNA. Cells were transfected in a Gene Pulser
Xcell electroporator (BioRad) using the pre-set BHK-21 square wave protocol.
Immediately following electroporation, cells were added to 3ml of complete media in
a 6 well plate and incubated at 37°C with 5% CCL.
2.6.7 Transfection of Cell Lines with Plasmid DNA using Effectene
The day before transfection, a well in a 6 well plate was seeded with I (f BHK-21
cells and incubated overnight at 37°C with 5% CO2. DNA and the Effectene reagent
were complexed by first mixing 0.4pg of plasmid DNA, 3.2pl of supplied Enhancer
solution and supplied Buffer EC to a final volume of lOOpl. The solution was briefly
mixed by vortexing and incubated at room temperature for 5 minutes. 1 Opl of the
Effectene reagent was added and the solution was again mixed by vortexing.
Complexes were allowed to form by incubating the solution at room temperature for
10 minutes. During this incubation, media was aspirated from the BHK-21 cells. The
well was rinsed with 2ml of sterile PBS and 1.6ml of fresh complete Glasgow's
medium was added to the cells. The DNA:Effectene solution was diluted in 600pl of
complete Glasgows medium and added, drop-wise, to the cells. Plates were incubated
at 37°C with 5% C02.
2.6.8 Viral Plaque Harvesting
The entire contents of 96-well plate wells containing BHK-21 cells with a single viral
plaque were removed by scraping with a Gilson P200 pipette tip and mixed by
pipetting. Half of the media volume (lOOgl) was transferred to a 1.7ml cryovial
(Nunc) and stored at -80°C until PCR screening had been performed on the remainder
of the sample (Sections 2.1.1 and 2.6.11).
2.6.9 Limiting Dilution Purification of Virus
Ipl of freeze/thawed viral plaque sample was diluted 11 times by doubling dilution in
complete Glasgow's media in a 96-well plate. 5xl04 BHK-21 cells were added to
each well and plates were incubated at 37°C with 5% C02 until viral plaques formed.
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2.6.10 Agarose Overlay Purification ofVirus
Freeze/thawed viral plaque sample was diluted 1/200, 1/2,000 and 1/20,000 in 2ml of
complete Glasgow's medium. 5xl05 BHK-21 cells were added to each dilution and
shaken at 225 rpm in an orbital shaker for 1 hour at 37°C in. Each dilution was plated
out in a single well of a 6 well plate and incubated overnight at 37°C with 5% CO?.
The following day, complete Glasgow's medium was mixed (1:1 v/v) with 2%
Microseive Low Melt Agarose (Flowgen) in sterile PBS which had been allowed to
cool to approximately 45°C. 4ml of the media/agarose mixture was added to each
well and allowed to set before plates were returned to the incubator. Plates were
incubated at 37°C with 5% CO2 until viral plaques formed. An area containing a
single plaque were marked and removed through the agarose using a sterile Pasteur
pipette. The plaque sample was mixed by pipetting with compete Glasgow's medium
and frozen at -80°C. The sample was rapidly thawed and incubated with 5x 104 BHK-
21 cells in a 96-well plate well for 48 hours and harvested as described in Section
2.6.8.
2.6.11 Plaque DNA Isolation
The entire contents of 96-well plate wells containing a single viral plaque were
removed by scraping with a Gilson P200 pipette tip and mixed by pipetting. Half of
the media volume (lOOpl) was transferred to a 0.5ml microcentrifuge tube. The
sample was centrifuged at 1,500 x g for 5 minutes in a bench top microcentrifuge.
The cell pellet was washed with 500pl of TE buffer (20mM Tris, ImM EDTA, pH
8.0) and centrifuged again. The cell pellet was resuspended in 50pl of TE buffer and
frozen on dry ice for 5 minutes and rapidly defrosted to disrupt cell membranes. 19pg
of PCR grade Proteinase K (Roche) was added and the sample was incubated
overnight at 53°C. The Proteinase K was then heat-inactivated by a 15 minute
incubation at 90°C and lOpl of sample was used as template DNA for screening
PCRs.
2.6.12 Growth of Viral Stocks
2.4xl07 BHK-21 cells were suspended in 5ml and infected with 2.4xl04 PFU (MOI =
0.001) of virus. Cells were incubated for 90 minutes at 37°C with shaking at 225 rpm
in an orbital shaker. The cells were then plated out in 8 x 175cm2 flasks in 40ml
complete medium per flask and incubated at 37°C with 5% CO?. Flasks wore checked
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daily until complete cytopathic effect (CPE) was seen, approximately 6 days post¬
infection. Remaining adherent cells were dislodged by scraping. Media and cells
from all flasks were pooled. Cells were pelleted by centrifugation at 1,700 x g for 20
minutes in a bench top centrifuge. The cell pellet was resuspended in 4 ml of PBS
and disrupted by 30 strokes, on ice, in a dounce homogeniser. The homogenate was
transferred to a glass universal and sonicated in an ice bath for 15 minutes. The lysate
was transferred to a plastic universal and centrifuged at 1,700 x g for 20 minutes at
4°C in a bench top centrifuge. The supernatant, containing the majority of the
infectious virus, was saved on ice. The pellet was resuspended in I ml of PBS,
returned to the homogeniser and homogenised for approximately 30 strokes as before.
The homogenate was centrifuged at 1,700 x g for 20 minutes at 4°C. The supernatant
was pooled with the previous supernatant. Aliquots of this stock were transferred to
1.7ml cryovials and stored at -80°C.
2.6.13 Viral Titration on BHK-21 Cells
Viral samples of 400pl were diluted through a series of 10-fold dilutions in 4ml of
complete Glasgow's medium. 2x106 BHK-21 cells were added to each dilution and
incubated for 1 hour at 37°C with shaking at 225 rpm in an orbital shaker. Each
dilution was made up to 10 ml and plated on two replicate 60mm Petri dishes. Plates
were incubated for 4 days at 37°C with 5% C02. The media from each plate was then
discarded, the cells were rinsed with PBS and fixed with 10% neutral buffered
formalin for 30 minutes. The fixative was discarded and the cells were stained with
0.1% toluidine blue solution for 10 minutes. The plates were rinsed in gently running
HiO and allowed to air dry. The number of plaques on each plate was counted using
a dissecting microscope. The titre of the original stock or tissue was calculated using
the average of the replicate plates of the lowest countable dilution and the following
equation: Titre = (Number of plaques x Dilution)/2ml.
2.6.14 One-Step Growth Curve
5xl06 BHK-21 cells were suspended in 2.5ml complete medium and infected with
2.5xl07 PFU (MOI = 5) of virus. Two samples of2xlCf cells were taken and kept at -
80°C as the -1 hour time point. Remaining cells were incubated for 1 hour at 37°C
with shaking at 225 rpm in an orbital shaker. Two samples of 2x105 cells were taken
and kept at -80°C as the 0 hour time point. Remaining cells were plated out in
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duplicate at 10s cells/well in 1ml of complete medium in 24 well plates (one plate per
time point) and incubated at 37°C with 5% CCC. At the appropriate lime post
infection (1, 4, 8, 12, 18, 24, 30, 36, 48, 60 or 72 hours) a plate was removed, sealed
with parafilm and stored at -80°C. When all samples were collected, all the plates and
the -1 and 0 hour time points were freeze/thawed three times and the samples titrated
as described in Section 2.6.13.
2.6.15 Multi-Step Growth Curve
2.5xl06 BHK-21 cells were suspended in 2.5ml complete medium and infected with
2.5x104 PFU (MOI = 0.01) of virus. Two samples of 105 cells were taken and kept at
-80°C as the -1 hour time point. Remaining cells were incubated for 1 hour at 37°C
with shaking at 225 rpm in an orbital shaker. Two samples of 105 cells were taken
and kept at -80°C as the 0 hour time point. Remaining cells were plated out in
duplicate at 105 cells/well in 1ml of complete medium in 24 well plates (one plate per
time point) and incubated at 37°C with 5% COi. At the appropriate time post
infection (12, 24, 36, 48, 60, 72, 96 or 120 hours) a plate was removed, scaled with
parafilm and stored at -80°C. When all samples were collected, all the plates and the
-1 and 0 hour time points were freeze/thawed three times and the samples titrated as
described in Section 2.6.13.
2.6.16 Viral Infection for Analysis of Temporal Expression of Genes
3x106 CI27 were suspended in 2ml complete medium and infected with 1.5x107 PFU
(MOI = 5) of virus. Cells were incubated for 1 hour at 37°C with shaking at 225 rpm
in an orbital shaker. Samples were transferred to 75cm2 flasks in 18ml of complete
medium and incubated at 37°C with 5% CO2. Cells were collected by trypsinisation
after 24 hours. Where indicated, phosphonoacetic acid (PAA, l()0pg/ml) or
cycloheximide (CHX, lOOpg/ml) was added to the medium. PAA was added at the
time of viral infection and CHX was added to cells 30 minutes prior to infection.
CHX-treated samples were collected 8 hours post infection.
2.6.17 Preparation of Media Containing Secreted Viral Proteins
2.5x106 BHK-21 cells in a 6 well plate well were infected with 1.25x107 PFU of
MHV-ALHE or MHV-76 (MOI = 6) in 3ml of complete DMEM (l)ulbecco's
Modified Eagle's medium (DMEM, Gibco) supplemented with 10% (v v) foetal calf
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serum, 2mM L-glutamine, 200U/L penicillin/streptomycin and 0.5nM |3-
mercaptoethanol). 24 hours after infection, supernatants were removed and passed
through Minisart 0.22 micron filters (Sartorius) to remove cell debris.
2.6.18 Isolation ofPeripheral Blood Mononuclear Cells
Fresh peripheral ovine blood was supplied by Prof. John Hopkins (Department of
Veterinary Biomedical Sciences, University of Edinburgh). Fresh peripheral bovine
blood was supplied by Dr. Alastair Macrae (Easter Bush Veterinary Centre,
University of Edinburgh). Whole heparinised blood was mixed with two volumes of
PBS and gently mixed by inversion. The diluted blood was then carefully layered
over 1 starting volume of room temperature Histopaque-1077 (Sigma) in cither 15 or
50ml conical centrifuge tubes. Blood fractions were separated by centrifugation at
500 x g for 30 minutes at room temperature with no brake in a bench top centrifuge.
Following centrifugation, the opaque interface containing the mononuclear cells was
transferred to a fresh tube using a Pasteur pipette. The cells were then washed twice
using at least 4 starting volumes of sterile PBS and centrifuging at 500 x g for 5
minutes each wash. Cells were resuspended in PBS and counted using trypan blue
exclusion (as described in Section 2.6.1).
2.6.19 Culture ofPeripheral Blood Mononuclear Cells
Bovine and ovine PBMC, isolated as described in Section 2.6.18, were cultured in 96
well plates (4xl05 cells per well) in 300pl of complete DMEM or with lOOpl of
complete DMEM and 200pl of fdtered medium from virally infected BIIK-21 cell
cultures (Section 2.6.17). Concanavalin A (ConA, Sigma) was added to cultures to
the final concentrations indicated.
2.6.20 Propidium Iodide Staining of Suspension Cells
At the indicated time points during culture, bovine and ovine PBMC samples were
transferred from 96 well plates to 0.5ml microcentrifuge tubes. Samples were
centrifuged at 1,000 x g for 5 minutes at room temperature in a bench top
microcentrifuge. Supernatants were transferred to fresh tubes and stored at -80°C.
Cell pellets were resuspended in 50pl of PBS and fixed by adding 50pi of 4%
paraformaldehyde. Samples were incubated at room temperature for 20 minutes and
centrifuged as before. Supernatants were discarded and cell pellets were resuspended
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in lOOpl of PBS containing 0.5% (w/v) bovine serum albumin (BSA), 0.25% (v/v)
Triton X-100, lpg/ml propidium iodide (Fluka), lU/ml RNase A and 40U/ml RNase
T1 (RNase Cocktail, Ambion). Samples were incubated in the dark for 20 minutes
and centrifuged as before. Supernatants were discarded and cell pellets were
resuspended in 200pl of PBS containing 2% paraformaldehyde and 0.5% BSA.
Samples were stored at 4°C wrapped in foil until all samples for an experiment had
been collected for FACS analysis.
2.6.21 Staining of Transfected Cells
Transfected BHK-21 cells (see Sections 2.6.6 and 2.6.7) were removed from 6 well
plate wells using trypsin/EDTA and counted as described in Section 2.6.1. An area of
approximately 4cm2 was marked out on a sterile glass microscope slide (Snowcoat X-
tra Micro Slides, Surgipath) using an ImmEdge pen (Vector Laboratories, Inc.).
Approximately 4xl04 cells in 200-300pl of medium were applied to the slide surface.
Slides were incubated, inside Petri dishes, at 37°C with 5% CCL for 4-8 hours to
allow cells to adhere to the slide surface.
Media was poured off the slide and the cells were gently rinsed with PBS. Cells were
fixed for 20 minutes in 10% (v/v) neutral buffered formalin (Surgipath), for C23
staining, or 4% (w/v) paraformaldehyde in PBS, for c-myc staining. Slides were
washed twice for 5 minutes each in PBS. Cells were permeablised by incubation with
PBS containing 0.25% (v/v) Triton X-100 (t-Octylphenoxypolyethoxyethanol, Sigma)
for 20 minutes followed by two 5 minute washes in PBS.
Slides were blocked with normal goat serum (Sigma) diluted 1:500 in 3% BSA/PBS
(w/v) for 30 minutes. Blocking solution was poured off and cells were stained with
either C23 (MS-3, Santa Cruz Biotechnology) diluted 1:5 to 40pg/ml in 3% BSA/PBS
(w/v) for 3 hours at room temperature or Anti-c-myc antibody (9E10 from mouse
ascites fluid, Sigma) diluted 1:300 in 3% BSA/PBS (w/v) for 1 hour. Slides were
washed twice for 5 minutes each in PBS. Bound antibody was detected using Alexa
Fluor 594 goat anti-mouse IgG (H+L) (Molecular Probes) diluted 1:500 to 4pg/ml in
3% BSA/PBS (w/v) for 30 minutes at room temperature in the dark. RNase A
(Roche, diluted 1:10,000 to lOpg/ml) and either propidium iodide (Fluka, diluted
1:1,000 to lpg/ml) or TO-PRO-3 iodide (Molecular Probes, diluted 1:1,000 to lpM)
were added to the secondary antibody solution to counterstain for DNA. The
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secondary antibody solution was poured off and slides were washed three times in
PBS for 5 minutes each. Coverslips were mounted using either DakoCytomation
Fluorescent Mounting Medium (Dako) or Mowoil (Calbiochem) and slides were
stored, wrapped in foil, at 4°C until viewed.
For cells transfected with GFP constructs that did not require antibody staining, slides
were prepared, fixed, permeablised and counterstained as described above.
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2.7 In Vivo Experiments
2.7.1 Mouse Infection
All animal work was carried out in accordance with Home Office guidelines under
project licence numbers 60/2429 and 60/3283 and personal licence number 60/9208.
Female, 5-6 week old, Balb/c mice were purchased from Harlan. Mice were
anaesthetised with halothane prior to viral infection. Mice were infected either
intranasally with 4x10s plaque forming units (PFU) of virus in 50pl of sterile PBS
applied to the nose and inhaled or by injection of 106 PFU of virus in 500pl of sterile
PBS injected intraperitoneally. Mice were euthanised by CCL asphyxiation for tissue
collection.
2.7.2 Histology
Lungs for histology were inflated via the trachea with 50% Tissue-Tek O.C.T.
compound (Sakura) in water and frozen by immersion in isopentane and dry ice.
Spleens were collected in 10% neutral buffered formalin. Tissues were sent to the
Veterinary Pathology Department Histology facility for processing, sectioning and
staining. Hematoxilin and eosin stained sections were examined under a light
microscope and assessed by Mr. Babunilayam Gangadharan (Division of Veterinary
Biomedical Sciences, University of Edinburgh).
2.7.3 Preparation of Tissues for Viral Titration
Lungs for infectious virus titration were bisected and each half was placed in a 1.7ml
cryovial (Nunc) and frozen on dry ice. Spleens for infectious virus titration were
placed in a 1.7ml cryovial and frozen on dry ice. Tissues (half lungs or whole
spleens) were homogenised using a glass homogeniser in 1ml of complete Glasgow's
medium. The homogenate was transferred to a fresh 1.7 ml cryovial and frozen on
dry ice for 30 minutes to disrupt cell membranes. The homogenate was thawed and
centrifuged at 1,700 x g for 20 minutes at 4°C. Supematants were titrated on BHK-21
cells as described in Section 2.6.13. Remaining homogenate was stored at -80°C.
Peritoneal exudate cells (PEC) for titration were removed by injection of 5ml of
complete RPM1-1640 medium (RPMI-1640 supplemented with 10% (v/v) Ibetal calf
serum, 2mM L-glutamine, 100 U penicillin/streptomycin, 50pM 2-mercaploethanol
and 20mM HEPES) into the peritoneal cavity and collected by draining through a
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peritoneal incision. Cells were collected by centrifugation for 5 minutes at 500 x g in
a bench top centrifuge. The supernatant was poured off and discarded and the cell
pellet was resuspended in the remaining media. Erythrocytes were lysed by the
addition of 1ml sterile distilled water. Samples were immediately equilibrated by
adding 9ml of sterile PBS. A sample of the cell suspension was diluted in Trypan
Blue solution (Sigma) and live cells were counted in a haemocytomcter. Viable
splenocyte number was calculated using the following equation: Cells/ml = Number
of cells counted in the middle 25 squares x dilution in Trypan Blue x 104. The cells
were transferred to a fresh 1.7 ml cryovial and frozen on dry ice for 30 minutes to
disrupt cell membranes. The sample was thawed and volumes equivalent to 105 and
106 cells were added in duplicate to BHK-21 cells for titration.
2.7.4 Infectious Centre Assay
Spleens for analysis of reactivatable virus were removed and kept on ice in complete
RPM1-1640 medium. Spleens were teased into single cell suspensions using a clean
scalpel blade and a 60mm Petri dish and suspended in 10ml of complete RPMI-1640.
Cells were collected by centrifugation for 5 minutes at 500 x g in a bench top
centrifuge. The supernatant was poured off and discarded and the cell pellet was
resuspended in the remaining media. Erythrocytes were lysed by the addition of 1ml
sterile distilled water. Samples were immediately equilibrated by adding 9ml of
sterile PBS. Debris was allowed to settle and the cell suspension was transferred to a
fresh universal. The splenocyte suspension was washed once and resuspended in 5ml
of complete RPMI-1640. A sample of the cell suspension was diluted in Trypan Blue
solution (Sigma) and live cells were counted in a haemocytometer as described in
Section 2.6.1. 107, 106 or 105 cells were added to 60mm Petri dishes containing 106
BHK-21 cells in 5ml of complete RPMI-1640 and incubated for 5 days at 37°C with
5% CO2. The media from each plate was discarded. The cells were rinsed with PBS
and fixed with 10% neutral buffered formalin for 30 minutes. The fixative was
discarded and the cells were stained 0.1% toluidine blue solution for 10 minutes. The
plates were rinsed in gently running H2O and allowed to air dry. The number of
plaques on each plate was counted using a dissecting microscope. The number of
infectious centres per spleen was calculated using the average plaque number of the 2
plates with the highest splenocyte number added that was countable and the following
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equation: Infectious centres/spleen = (Number of plaques x Total splenocyle number)
/ Splenocyte number added per plate.
Peritoneal exudates cells (PEC) for infectious centre assays were collected as
described in Section 2.7.3. Cells were collected by centrifugation for 5 minutes at
500 x g. The supernatant was poured off and discarded and the cell pellet was
resuspended in the remaining media. Erythrocytes were lysed by the addition of 1ml
sterile distilled water. Samples were immediately equilibrated by adding 9ml of
sterile PBS. A sample of the cell suspension was diluted in Trypan Blue solution
(Sigma) and live cells were counted in a haemocytometer as described in Section
2.6.1. 106 or 105 cells were added to 60mm Petri dishes containing 106 BHK-21 cells
in 5ml of complete RPMI-1640 and analysed after 5 days as described above.
SO
Chapter 2 Materials and Methods
2.8 Other Methods
2.8.1 Luciferase Activity Assays
Luciferase reporter activity assays were performed using the Dual-Luciferase
Reporter Assay System (Promega) according to manufacturer's instructions. BHK.-21
cells were transfected, in triplicate, with 2pl each of test plasmid, reporter plasmid
and Renilla luciferase control plasmid using the protocol described in Section 2.6.6.
48 hours post transfection, supernatants were removed from cultures and adherent
cells were briefly rinsed with PBS. 500pl of supplied passive lysis buffer (PLB) was
added to each sample and plates were incubated on an orbital shaker for I 5 minutes at
room temperature.
An appropriate number of lOOpi aliquots of supplied Luciferase Assay Reagent
(LAR) II were dispensed into opaque 96 well microtitre plates. A l.uminskan
luminometer (Labsystems Research Systems) was programmed for a 10 second read
and blanked on the LAR II containing wells. 20pl of cell lysate was added to the
LAR II and mixed by pipetting. The sample was then read for 10 seconds in the
luminometer and the firefly luciferase activity measurement was recorded. The plate
was removed and lOOpl of supplied Stop & Glo Reagent was added to the sample and
mixed by pipetting. The sample was read again for 10 seconds in the luminometer
and the Renilla luciferase activity measurement was recorded. The procedure was
then repeated for all samples.
2.8.2 Confocal Microscopy
Slides of transfected cells were viewed using a Leica confocal laser scanning
microscope at the University of Edinburgh Confocal Microscopy Suite with the
assistance of Ms. Linda Wilson. Image analysis was performed using Leica Confocal
Software (LCS) Lite vs. 2.051347a.
2.8.3 FACS Analysis
Forward scatter (cell size), side scatter (cell granularity) and FL2 lluorescence
(propidium iodide, DNA content) of stained PBMCs was measured on a LACScan
flow cytometer (BD Biosciences). Data was analysed using both Cell Quest (BD
Biosciences) and W1NMDI (http://facs.scripps.edu/software.html) software.
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2.8.4 Statistical Analysis
Statistical analysis was performed using the Graphpad Prism 3.02 software.
Differences in viral titres, spleen weights, splenocyte numbers, infectious centre
numbers and luciferase activity were analysed using the unpaired t test or the Mann-
Whitney test for each time point or group.
01
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2.9 Recipes











4% (w/v) Acrylamide/bis-Acrylamide (37.5:1)
125mM Tris
0.1% (w/v) Sodium Dodecyl Sulphate
0.1% (w/v) Ammonium Persulphate (APS)
0.1% (v/v) N, N, N', N'-Tetrametylethylenediamine (TEMED)
pH 6.8
Resolving Gel
10-15% (w/v) Acrylamide/bis-Acrylamide (37.5:1)
375mM Tris
0.1% (w/v) Sodium Dodecyl Sulphate
0.1% (w/v) Ammonium Persulphate (APS)
0.1% (v/v) N, N, N', N'-Tetrametylethylenediamine (TEMED)
pH 8.8
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Boiling Buffer (2x)
125mM Tris (pH 6.7)
5% (w/v) Sodium Dodecyl Sulphate
25% (v/v) Glycerol
12.5% (v/v) p-mercaptoethanol












0.5% (w/v) Ponceau S
1% (v/v) Acetic Acid
2.9.3 Nucleic Acid Electrophoresis
Tris-Acetate EDTA (TAE)
40mM Tris20mM Acetic Acid
ImM EDTA
pH 8.0
DNA Loading Buffer (6X)
15% (w/v) Ficoll
0.25% (w/v) Bromophenol Blue
0.25%(w/v) Xylene Cyanol
0.25% (w/v) Orange G
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2.9.4 Bacterial and Yeast Media
Luria-Bertani (LB) Broth
1% (w/v) Tryptone
0.5% (w/v) Yeast Extract









6.7g/L Yeast Nitrogen base without amino acids
20g/L Glucose
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3.1 Recombinant Virus Production
3.1.1 Aims
One of the primary objectives in the characterisation of the four unique left hand end
ORFs of A1HV-1 is to assess their contribution to pathogenesis in vivo. Ideally, this
would be studied by creating A1HV-1 mutant viruses with one or more of these genes
knocked out and using these mutant viruses to infect either naturally susceptible hosts,
such as cattle, or laboratory model hosts in which MCF is closely mimicked, such as
rabbits. There were, however, several limitations that precluded such studies. Firstly,
the tissue culture requirements for A1HV-1 growth mean that genetic manipulation
would be difficult. Secondly, the genetic instability of A1HV-1 in vitro would mean
that even if creation of mutant viruses was successful, the exact genotype of such
viruses would be questionable as would any data acquired by their use. Thirdly, the
use of cattle or rabbits as hosts would be costly and impractical and would therefore
severely limit experimental group sizes.
To overcome these restrictions, a mutant virus was created by inserting the genes into
a closely related foreign herpesvirus, murine gammaherpesvirus-76 (MHV-76).
MF1V-76 is a deletion mutant of MHV-68, a well studied rodent herpesvirus that is
often used as a model for gammaherpesvirus infection. The genome sequence of
MHV-76 has been shown to be almost identical to that ofMHV-68 with the exception
of a 9,538 bp deletion at the left hand end of the L-DNA (Macrae et al., 2001). This
area encodes four unique ORFs (M1-M4) and eight viral tRNA-like molecules.
Despite showing similar growth properties in vitro, MHV-76 is attenuated in vivo
(Macrae et al., 2001). This property of MHV-76 makes it a useful tool for the study
of genes thought to be involved in pathogenesis. Mutant MHV-76 viruses created by
either replacing the missing MHV genes (Cliffe, 2006; Macrae et al., 2003; Townsley
et al., 2004) or by the insertion of foreign genes (Brass, 2004; Hindley, 2005; Sacco,
2003) have previously been used to study the specific contribution of these genes to
the various stages of infection in vivo, such as immune evasion, transformation and
reactivation.
Although it is a very artificial system, the use of the MHV model for the study of
A1HV-1 genes offers several advantages over the use of A1HV-1 itself. Firstly, the
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creation of MHV mutant viruses is well established and relatively straightforward.
Secondly, MHV is genetically stable during tissue culture passage. Thirdly, the use of
a small animal model allows for in vivo experiments to be performed on larger groups
of genetically identical hosts, giving more statistically robust results.
The following sections describe the creation of the recombinant virus with an
approximately 6.2 kb region of A1HV-1 inserted into the left hand end of MHV-76
and the analysis of the resultant virus's genomic structure using PCR, restriction
digestion and Southern blot analysis.
3.1.2 A1HV-1 Left Hand End Amplification
The LHE region of the L-DNA from the A1HV-1 genome was amplified for cloning
by PCR. The JEMBOSS EPRIMER3 software was used to identify highly specific
primer sites of sufficient distance downstream of the predicted start codon for ORF
A1 (nucleotide 918) to include promoter sequences and upstream of the predicted
polyadenylation signal for ORF A4 (nucleotide 6,123). The sites chosen were
nucleotide 21 to 40 for the forward priming site and nucleotide 6,197 to 6,216 for the
reverse priming site. Primers were designed using these sequences with .SV//I and Xba\
restriction endonuclease sites added to the forward and reverse primers, respectively,
to facilitate later cloning. PCRs were performed using the high fidelity Expand Long
Template PCR system as described in Sections 2.1.1 and A 1.3.1 and the resulting
product of approximately 6.2 kb is shown in Figure 3.1 A, lane 1.
3.1.3 A1HV-1 Left Hand End Cloning and Sequencing
The LHE PCR product was ligated into the T:A cloning vector pGEM-T Easy as
described in Section 2.1.2. The resulting plasmid preparation was shown by
restriction digest analysis to contain a product of the correct size with the appropriate
restriction sites. The insert was partially sequenced using the T7for and BGHrev
primer sites in pGEM-T Easy as described in Section 2.1.12. The sequence from the
T7for reaction contained the inserted Sal\ restriction site followed by A1HV-1
nucleotides 21-635 and the sequence from the BGHrev reaction contained the inserted
XbaI restriction site followed by A1HV-1 nucleotides 6,216-6,058. The insert size
and end sequences are consistent with the cloning of an appropriate PCR product.
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Figure 3.1. A) PCR for A1HV-1 left hand end (lane 1) and negative control (lane 2). B)
Map of the Lla5 plasmid indicating restriction sites used for cloning and analysis. C)
Restriction digest of LL26-2 plasmid with Sal I (lane 1) and BamH\ (lane 2). D) Map of
the LL26-2 insert vector indicating restriction sites used for cloning and analysis.
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To facilitate insertion of the cloned AIHV-1 fragment into MHV-76, it was cloned
into the insertion vector Lla5 (kindly provided by Dr. Bernadette Dutia). A vector
map of Lla5 adapted from information provided by Dr. Dutia is shown in figure 3.1
B. Lla5 is a pUC-18 based vector with one complete terminal repeat (MHV-68
nucleotides 118,700-119,450/118,237-118,699) inserted at the Pstl restriction site and
an M4/ORF4 sequence (MHV-68 nucleotides 9,538-10,914) inserted between the
BamHI and £coRI restriction sites of the multiple cloning site. The All 1V-1 insert
was intended to be directionally cloned using both the Sal I and Xba\ restriction sites.
However, the M4/ORF4 insert was found to contain an Xba\ site meaning that this
strategy was not possible. Instead, the AIHV-1 insert was removed from pGEM-T
Easy using Sail alone as the fragment was cloned in an appropriate orientation to use
the Sail restriction site in the pGEM-T Easy multiple cloning site. The insert was
isolated by gel purification, ligated into Sal 1 digested Lla5 by T4 DNA ligase and
cloned. A resulting plasmid (LL26-2) was shown to contain the 6.2 kb insert by Sal I
digestion and orientation of the insert was shown by digestion with BamWI, which
cuts the insert once at position 5082 and once between the Lla5 multiple eloning site
and the M4/ORF4 insert, to be consistent with the original design (Figure 3.1 C). A
diagram of the LL26-2 insertion vector is shown in Figure 3.1 D. Attempts to remove
the inserted 30 pGEM-T Easy nucleotides either by re-cloning the A111V-1 LHE
directly flanked by two Sail sites or by exonuclease removal of the nucleotides from
LL26-6 were unsuccessful.
3.1.4 Recombinant Virus Production
The production of recombinant MHV-76 viruses by co-transfection of B1IK-21 cells
with linearised insert vector and highly purified MHV-76 DNA has been well
established. Previous protocols using Lla5 have linearised the vector using EcoRl.
As the inserted pGEM-T Easy sequence in LL26-2 contained an EcoRl restriction
site, the Aatll restriction site in the pUC18 sequence was used instead (Figure 3.1 C).
Linearised vector was purified by phenol:chloroform extraction and concentrated by
ethanol precipitation as described in Section 2.1.4.
BHK-21 cells (2.5xl06) were transfected with linearised insert vector and highly
purified MHV-76 DNA, mixed with untransfected BHK-21 cells and plated in 96-
well plates as described in Section 2.6.5. Five days post-transfection, viral plaques
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were seen in four wells. Cells from these wells were collected and split for further
purification and PCR screening as described in Sections 2.6.8 and 2.6.11.
Crude lysates from plaque positive wells were screened by PCR for the inserted
A1HV-1 ORFs using the programs described in Sections Al.3.2, Al.3.7, Al.3.22 and
A1.3.28. Three of the four samples were found to be positive for A2, A3 and A4 but
only one of these was also positive for Al. This sample was further purified by
limiting dilution of the freeze/thawed sample on fresh BHK-21 cells in 96-well plates
as described in Section 2.6.9. After five days, cells were taken from wells with
plaques at the highest dilution of virus. These samples were processed as before,
screened by PCR and further purified if positive for all inserted ORFs. From the third
round of purification onwards samples were also screened for contaminating wild-
type MHV-76 using the Trepeat/M-4B PCR. This PCR, detailed in Section A 1.3.35,
uses a forward primer in the MHV terminal repeat (119,482-119,504) and a reverse
primer in the portion of ORF M4 remaining in MHV-76 (9,786-9,760). In the
presence of wild-type MHV-76 a product of 293 bp should be amplified but in
recombinant virus, with a large insert between the primers, no product should be
detected.
After five rounds of limiting dilution purification there was still MHV-76 in the
recombinant virus samples. This viral sample was subjected to agarose overlay
purification as described in Section 2.6.10. Two plaque samples that were selected
following this procedure were both free of contaminating MHV-76. One of these
samples, re-named MHV-ALHE, was grown and titrated in BHK-21 cells for use in
subsequent experiments.
3.1.5 PCR Screening of Viral Stock DNA
Highly purified viral DNA from MHV-ALHE was isolated, as described in Section
2.6.4, for confirmation of the expected A1HV-1 left hand end insertion. PCRs for Al,
A2, A3, A4 and the terminal repeat/M4B junction of MHV-76 were performed on 1-
2ng of purified DNA using the programs described in Sections Al.3.3, Al.3.8,
Al.3.21, Al.3.29 and Al.3.36. Al, A2, A3 and A4 products were seen in MHV-
ALHE but not MHV-76 viral stock reactions (Figure 3.2 A, B, C and D). A
Trepeat/M4B product of the appropriate size was seen in MHV-76 but not MHV-
ALHE viral stock reactions (Figure 3.2 E).
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Figure 3.2. PCR screening of recombinant virus. PCRs ofA) ORF Al, B) ORF
A2, C) ORF A3, D) ORF A4, E) Trepeat/M4B and F) A4for/M4B.
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In addition, a PCR was set up to confirm the junction between the insert and the
MHV-76 L-DNA using A4 forward and M4 reverse primers. A product of the
expected size (780 bp) was seen in the recombinant virus sample (Figure 3.2 F).
PCRs with a variety of different parameters were attempted to confirm the junctional
region between the MHV terminal repeats and the inserted A1HV-1 sequence but none
were successful.
3.1.6 Restriction Digest Analysis of Viral Stock DNA
Highly purified viral DNA was analysed by restriction digest to further confirm
appropriate insertion of A1HV-1 sequences. DNA from MHV-ALHE and MHV-76
was digested with either Sac\ or Xho\ and separated by agarose gel electrophoresis.
These enzymes were selected as they cut within the inserted A1HV-1 sequence but not
in the MHV terminal repeats. The MHV-ALHE digest reactions should therefore
yield the extra fragments indicated in Figure 3.3 A of approximately 6.1 kb with Sac\
and 8.9 kb with Xho\. The digest patterns were compared with each other and with
the published digest patterns for MHV-76. The MHV-76 DNA from the stock used in
these experiments showed the same restriction pattern as previously published
(Macrae et al., 2001). The predicted additional MHV-ALHE fragments can be seen
in Figure 3.3 B, lanes 2 and 4.
3.1.7 Southern Blot Analysis of Viral Stock DNA
To further confirm appropriate insertion ofA1HV-1 sequences and clonality ofMHV-
ALHE, Southern blots were performed on viral stock DNA as described in Section
2.4. A probe consisting ofMHV M4/ORF4 sequences (9,538-10,914) was created by
removing this region from the Lla5 plasmid by EcoRI and BamHI restriction digest
and gel extraction of the appropriate fragment. A probe for insert DNA was made by
amplifying the full length ORF A3 coding region by PCR using the protocol
described in Section Al.3.25 and cloning the resulting product into the T:A cloning
vector, pGEM-T Easy. The A3 insert was removed from the vector by /u-oRI and
BglW restriction digest and gel extracted. Both probes were DIG labelled and
labelling efficiency was analysed by dot blot analysis as described in Section 2.4.1.
Highly purified viral DNA was digested using either Pst\ or a combination of Not\
and HindWl, separated by agarose gel electrophoresis and blotted onto nitrocellulose














b m m m
Xhol (18154)
Figure 3.3. A) Restriction digest map showing MHV terminal repeats (black line),
MHV-76 L-DNA (blue line), inserted A1HV-1 DNA (red line) and predicted
additional digest fragments (green line). B) SacI and Xhol restriction digests of
MHV-ALHE and MHV-76 genomic DNA. Additional bands in MHV-ALHE
digests are indicated with arrows.
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membranes by capillary transfer. These restriction enzymes were chosen for various
reasons. Pstl was used because the terminal repeat of Lla5 is a Pstl fragment
consisting of nucleotides 118,700-119,450 followed by nucleotides 118,237-1 18,699
rather than the wild type repeat of nucleotides 118,237-119,450. As such,
recombinant viruses created using the Lla5 plasmid should contain a partial repeat
(nucleotides 118,237-118,699) followed by a Pstl site immediately adjacent to the
inserted sequence. In contrast, the internal Pstl site in the terminal repeat of wild type
MHV-76 is 750 bp downstream of the unique region and therefore a clear difference
in restriction fragment lengths should be seen using this enzyme (Figures 3.4 A and
3.5 A). Notl was used because it cuts within the MHV terminal repeat and the
remaining multiple cloning site of pGEM-T Easy carried into the recombinant virus
with the insert. Hindlll was used to futher digest the Notl fragments and allow them
to be more easily distinguished.
Following transfer, the membranes were probed with either the M4/ORF4 or the A3
probes and resulting bands were compared after visualisation. As shown in Figure 3.4
B, products of 1640 and 260 bp are detected by the M4/ORF4 probe in Pstl digests of
both virus samples but a product of 472 bp is only detected in the MHV-ALHE digest.
The predicted fragment of 1227 bp is detected in the Pstl digest ofMHV-76 and there
is some signal around that size in the MHV-ALHE sample but this is also seen in the
Notl and Hindlll digested samples and is most likely background rather than
contamination of the recombinant virus stock. The absence of contamination is also
supported by the Notl and Hindlll digests in which there is a fragment of 1571 bp
detected the MHV-ALHE sample and not the fragment of 1909 bp as seen in the
MHV-76 sample. The A3 probe detected fragments of 3624 and 2591 bp in the Pstl
digested and fragments of 1828 and 1231 bp in the Notl and Hindlll digested
recombinant virus samples (Figure 3.5 B). No binding of this probe to the MHV-76
samples was seen.
3.1.8 Summary
An MHV-76 recombinant virus clone carrying approximately 6.2 kb from the left
hand end of A1HV-1 (MHV-ALHE) has successfully been created and purified until
free of contaminating wild-type virus. The content, position and orientation of the
insert in this clone have been shown by PCR, restriction digest and Southern blot to
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Figure 3.4. A) Restriction digest map of left hand ends of the MHV-ALHE and
MHV-76 genomes showing MHV terminal repeats (black line), MHV-76 L-DNA
(blue line) and inserted A1HV-1 DNA (red line). B) Southern blot of Pstl and
Notl/Hindlll restriction digests of MHV-ALHE and MHV-76 genomic DNA.
probed with the M4 probe.
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Figure 3.5. A) Restriction digest map of left hand ends of the MHV-ALHE genome
showing MHV terminal repeats (black line), MHV-76 L-DNA (blue line) and
inserted A1HV-1 DNA (red line). B) Southern blot of Pstl and Notl/Hindlll
restriction digests ofMHV-ALHE and MHV-76 genomic DNA. probed with the A3
probe.
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be consistent with the intended genomic structure. This viral clone was used in all
further experiments.
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3.2 Recombinant Virus Characterisation In Vitro
3.2.1 Aims
The biological properties of the recombinant virus were studied in vitro to aid in the
interpretation of any findings from in vivo infection experiments. As the four ORFs
inserted in the recombinant virus are under the control of their natural promoters,
RNA transcripts were analysed to determine if the ORFs were expressed in a murine
host. The growth properties of the virus were studied to determine whether there was
any effect on growth rate which would interfere with the interpretation of in vivo
pathogenesis experiments.
3.2.2 Analysis of A1HV-1 Gene Expression
C127 cells were infected with MHV-ALHE to assess the function of the promoters for
the A1HV-1 genes in a murine host. Cells were infected at on MOI of 5 and harvested
at 24 hours post infection. Total cellular RNA was extracted and gene expression
analysed by reverse transcriptase (RT)-PCR as described in Sections 2.1.15, 2.1.17
and 2.1.18. RNA samples from MHV-76 infected cells and RT-negative assays were
used as controls. Successful infection and viral RNA integrity were checked using the
PCR described in Section Al.3.38 for MHV ORF 50, an immediate early gene
product known to be produced during productive MFIV infection, and all samples
were found to be positive (Figure 3.6 A). PCRs for the inserted AiHV-l ORFs,
described in Sections Al.3.4, Al.3.9, Al.3.23 and Al.3.30, show that transcripts for
all four genes are present in infected murine cells (Figure 3.6 B, C, D and H, lane 1).
No products were seen in the negative control samples. In addition, the presence of a
second band in the A2 PCR that is about 80bp shorter than the DNA product indicates
that A2 message has been spliced as previously reported (Ensser et ai, 1997).
In order to determine the temporal class of the inserted genes, infections were
performed in the presence of protein synthesis inhibitor cycloheximide (CI IX) or the
viral DNA replication inhibitor phosphonoacetic acid (PAA) as described in Section
2.6.16.
Al expression is completely inhibited by CHX and is barely detectable in PAA
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approximately 150bp is detectable in MHV-ALHE infected cells regardless of
treatment (data not shown). This product was cloned and sequenced to determine
whether it was a splice variant of Al. Sequence data showed that this product is
murine mitochondrial 12S ribosomal RNA with no sequence homology to Al. It is
unknown why this product was amplified in MHV-ALHE but not MHV-76 infected
samples.
A2, A3 and A4 products were detected as readily in PAA treated cells as untreated
(Figure 3.6 C. D and E). An A2 product, the correct size for spliced message, and an
A3 product are both present during CHX treatment indicating that although they are
predominantly early transcripts there is some immediate early expression. No
expression of A4 could be detected in CHX treated cells indicating that it is an early
transcript.
BT cells were infected with A1HV-1 and treated with CHX or PAA in the same way
as MHV-ALHE infected C127 cells to analyse temporal expression of the left hand
end ORFs in a more natural cell type. A1HV-1 is strongly cell associated and in vitro
infections are carried out by co-culture of uninfected with infected cells rather than
incubation with purified virus as is used for MHV infections. Due to this
requirement, it was not possible to dissociate newly formed transcripts from those
present in the input virus by RT-PCR. Even following freeze/thaw of the inoculum,
transcripts for all four left hand end ORFs were seen at the time of infection as well as
at later time points (data not shown).
3.2.3 MHV-ALHE Growth In Vitro
The growth rate of recombinant virus was compared to that of wild-type MHV-76
using one-step growth curve analysis (Figure 3.7 A) as described in Section 2.6.14.
Both viruses adsorbed to the cells similarly as shown by the 0 hour time point. The
amount of infectious virus dropped at the 4 and 8 hour time points as expected. The
MHV-ALHE titre at 8 hours post infection were lower than wild-type but this
difference was not statistically significant. Titres of both viruses grew steadily from
12 to 48 hours post infection and reached a plateau of around 107 PFU/ml between 48
and 60 hours. Although the differences in titres at 18, 30 and 36 hours post infection
of the two viruses are statistically significant (p=0.0009, p=0.0424 and p=0.0036
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Figure 3.7. A) One-step (MOI = 5) and B) multi-step (MOI = 0.01) growth curve
analysis ofMHV-ALHE (•) and MHV-76 (o) infected BHK-21 cells.
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respectively, using the unpaired t test) due to the small standard deviations, the
magnitude of these differences is not biologically significant.
3.2.4 MHV-ALHE Spread In Vitro
The growth rate and cell-to-cell spread of virus was compared to that of wild-type
MHV-76 using a multi-step growth curve (Figure 3.7 B) as described in Section
2.6.15. As previously seen with the one-step growth curve, both viruses adsorbed to
the cells similarly as shown by the 0 hour time point and there was a drop in titre at
the 12 hour time point. At 24 hours the production of infectious MIIV-ALHE
appeared to be delayed but this difference was not statistically significant (p=0.1991
using the unpaired t test). By 36 hours, the MHV-ALHE titre was the same as that of
MHV-76. The titres for both viruses rose at similar rates from 36 to 96 hours and
reached a plateau between 96 and 120 hours of around 107 PFU/ml.
3.2.5 Summary
All four of the inserted A1HV-1 left hand end ORFs are expressed from their cognate
promoters in murine cells during infection with the recombinant virus MHV-ALHE.
Late expression of ORF Al, early expression of ORF A4 and immediate-early/early
expression of ORFs A2 and A3 is detectable by RT-PCR. No biologically significant
differences were seen in the growth rate and cell-to-cell spread of MIIV-ALHE
compared to MHV-76 in vitro. Taken together, these results indicate that the use of
MHV-ALHE is a suitable model to study the effects of the inserted A1HV-I left hand
end ORFs on MHV-76 pathogenesis in a murine host.
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3.3 Intranasal Infection of Balb/c Mice
3.3.1 Aims
The ability of the inserted A1HV-1 ORFs to alter the pathogenicity of MHV-76
following intranasal infection was assessed in Balb/c mice. Intranasal infection with
MHV-76, which is thought to be the most likely route of natural transmission, causes
a phase of acute replication in the lungs followed by latent infection of B cells with
transient splenomegaly (Sunil-Chandra et al., 1992a). Mice were infected inlranasally
with 4xl05 PFU of virus and tested at various time points post infection. In the initial
experiment, the lungs of four mice per time point per virus were studied at days 3, 5
and 7 post infection to assess any changes in productive viral replication. Also in this
experiment, the spleens of four mice per time point per virus were studied at days 7,
10 and 14 post infection to assess any changes in viral induced splenomegaly and
latent viral load. Histological studies were also carried out on lungs from infected
mice to assess any changes in host response to the infection. These studies were
initially performed on two mice per time point per virus at days 3, 5 and 7 post
infection but were expanded based on primary results as described in Section 3.3.3.
3.3.2 Productive Infection
Titres of pre-formed infectious virus were studied in the lungs of intranasally infected
mice at early time points post infection. The time points selected were before (day 3),
around (day 5) and after (day 7) peak titre based on previously published data on
intranasal infection of MHV-76 (Macrae et al., 2001). Lungs were collected as
described in Section 2.7.3 and titrated on BHK-21 cells as described in Section 2.6.13.
Mean lung titres on days 3 and 5 post infection are slightly higher (approximately 3
fold) in MHV-ALHE infected mice compared to those infected with Ml IV-76 (Figure
3.8), but these differences are not statistically significant (p=0.2 using the Mann-
Whitney test). By day 7 post infection, mean titres of both groups are the same.
3.3.3 Lung Histology
MHV-76 has previously been shown to induce a more severe inflammatory response
in the lungs of intranasally infected mice than MHV-68 indicating an
immunomodulatory role for the deleted ORFs and/or tRNAs (Macrae et a/.. 2001).
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4 5 6
Days Post Infection
Figure 3.8. Viral lung titres from Balb/c mice infected intranasally with 4 x I05 PFU
MHV-ALHE (•) and MHV-76 (o).
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To determine whether the A1HV-1 ORFs could compensate for the deleted MHV-68
ORFs, hematoxylin and eosin stained sections of inflated lungs of intranasally
infected mice were examined under the light microscope as described in Section
2.7.2. Blinded sample were read by experienced pathologist Mr. Babunilayam
Gangadharan (Division of Veterinary Biomedical Sciences, University of Edinburgh)
and the following results are based on his observations.
In the first experiment, XI (Table 3.1), two mice per time point per group were
studied at 3, 5 and 7 days post infection. Lungs collected from both MHV-ALHE (A5
and A6) and MF1V-76 (F5 and F6) infected mice on day 3 post infection showed no
indications of inflammation or alveolar thickening. Lung collected from MHV-
ALHE infected mice at day 5 post infection (B5 and B6) were beginning to show
signs of focal inflammation. However, the lungs from MHV-76 infected mice at this
time point (G5 and G6) were clear of inflammation. By day 7 post infection, the
inflammation seen in the lungs of MHV-ALHE infected mice (C5 and C6) had
become more widespread and was accompanied by alveolar thickening. I lowever, the
lungs of MHV-76 infected mice at this time point (H5 and H6) were still clear of
inflammation.
As there was a difference seen between the responses to the two viruses and the
response to MHV-76 was far weaker than previously reported (Macrae et al., 2001),
two further experiments were performed. In the first of these experiments, X3 (Table
3.2), two mice per time point per virus were studied at 7 days post infection to
confirm the previous day 7 findings and at 10 days post infection to determine
whether the inflammatory response would increase or resolve. In contrast to the
previous experiment, lungs from both MHV-ALHE infected mice were relatively
clear of inflammation on day 7 post infection (Al and A2). The lungs from one of the
MHV-76 infected mice (B2) was also clear of inflammation but the other sample
taken at this time (Bl) showed some areas of alveolar thickening, again in contrast to
the previous experiment. Lungs collected from both MHV-ALHE (CI) and MHV-76
(D1 and D2) infected mice at day 10 post infection showed areas of alveolar
thickening, some of which were quite severe but still milder than expected for MHV-
76 infection. The lungs of the second MHV-ALHE infected mouse (C2) were poorly
inflated and the degree of inflammation could not be determined.
I 15
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D3 MHV-ALHE A5- more or less clear 0
A6- more or less clear 0
MHV-76 F5- more or less clear 0
F6- more or less clear 0
D5 MHV-ALHE B5- focal inflammation 2
B6- focal inflammation 2
MHV-76 G5- more or less clear 0
G6- more or less clear 0
D7 MHV-ALHE C5- greater inflammation and alveolar thickening J
C6- greater inflammation and alveolar thickening J
MHV-76 H5- more or less clear 0
H6- more or less clear 0
Table 3.1. Lung histology observations and score from experiment XL
D7 MHV-ALHE A1 - more or less clear 0
A2- more or less clear 0
MHV-76 B1 - some areas of thickening
■">
J
B2- more or less clear 0




MHV-76 Dl- areas of thickening (some very severe) 3
D2- areas of thickening (some very severe) 3
Table 3.2. Lung histology observations and scores from experiment X3.
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In the third experiment, X5 (Table 3.3), two mice per time point per group were
studied at 5, 7 and 9 days post infection and one mouse per group was studied at 15
days post infection to determine whether resolution of inflammation could be seen at
this time. Lungs from both MHV-ALHE (A1 and A2) and MHV-76 (B1 and B2)
infected mice showed very mild alveolar thickening on day 5 post infection. By day 7
post infection, lungs from both MHV-ALHE (D1 and D2) and MHV-76 (El and E2)
infected mice showed mild foci of interstitial pneumonia. Occasional foci of
interstitial pneumonia were seen in lungs from MHV-ALHE infected mice (G1 and
G2) at day 9 post infection. At this time point, more extensive focal inflammation
was seen in the lungs of MHV-76 infected mice (HI and H2). By day 15 post
infection, inflammation in the lungs from the MHV-AHLE infected mouse (Jl) was
resolving with only a small number of very mild inflammatory foci remaining.
Similarly, the lungs of the MHV-76 infected mouse at day 15 post infection (K1)
were almost entirely clear of inflammation. As the previous two experiments had
given unexpected results for MHV-76, a third group was infected using MHV-76
from a stock known to induce the expected inflammatory response in Balc/c mice
(MHV-76con, supplied by Miss Anna Cliffe). In this experiment, however, even this
virus induced unexpected pathology. On day 5 post infection, lungs from one of the
two mice (C2) showed multiple foci of interstitial pneumonia as expected but the
lungs of the other mouse (CI) were clear of inflammation. By day 7 post infection,
the lungs of the mouse studied (Fl) were clear but those of the mouse studied at day 9
(II) showed multiple foci of interstitial pneumonia.
To simplify the overall analysis of the inflammatory response induced by the different
viruses over the three experiments, each sample was assigned a score of 0 to 3 based
on the following scale: 0) predominantly clear, 1) a few small foci of mild
inflammation, 2) moderate focal inflammation and 3) severe inflammation. The
scores for each individual sample are shown in the right hand columns of Tables 3.1,
3.2 and 3.3. The pooled scores from the three experiments are represented, with mean
severity, in Figure 3.9. Examples of lungs showing the different grades of
inflammation severity are shown in Figure 3.10. Although the group numbers are
small and there was a large amount of variability, these experiments show that the
time-course of the inflammatory response was similar to previous studies, although
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D5 MHV-ALHE Al- vv mild thickening 1
A2- vv mild thickening 1
MHV-76 B1 - vv mild thickening 1
B2- vv mild thickening 1
MHV-76con CI - clear 0
C2- multiple foci of interstitial pneumonia 3
D7 MHV-ALHE Dl- mild foci of interstitial pneumonia 1
D2- mild foci of interstitial pneumonia 1
MHV-76 El- mild foci of interstitial pneumonia 1
E2- mild foci of interstitial pneumonia 1
MHV-76con Fl- clear 0
D9 MHV-ALHE Gl - few foci of interstitial pneumonia 2
G2- occasional foci of interstitial pneumonia 2
MHV-76 HI - bit more extensive focal interstitial pneumonia 3
H2- bit more extensive focal interstitial pneumonia 3
MHV-76con 11- multiple foci 3
D15 MHV-ALHE J1 - v few foci of interstitial pneumonia 1
MHV-76 K.1- almost clear 0
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Figure 3.10. Example lung sections showing A) no (X5K1, grade 0), B) mild
(X5E1, grade 1), C) moderate (X5G1, grade 2) and D) severe (X5H2, grade 3)
inflammation.
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with reduced severity, and both MHV-ALHE and MHV-76 elicited a similar
response.
As there was an apparent difference in mean inflammation severity in the lungs
collected from different groups at day 5 post infection, these samples were sent for
independent blinded analysis by a second experienced pathologist. Dr. Susan Rhind
(Division of Veterinary Biomedical Sciences, University of Edinburgh). The results
of this analysis are shown in Table 3.4. Inflammation severity scores from this
analysis are shown in the right hand column, with the previous score shown in
parentheses for comparison, and plotted in Figure 3.11. The two MHV-ALHE
infected samples previously graded as having moderate inflammation were scored as
normal (X1B5) and mild (X1B6), although the faded staining hindered analysis. The
MHV-76 infected samples from this experiment (X1G5 and XIG6) were graded as
having mild inflammation rather than the previous scoring of more or less clear. Both
MHV-ALHE infected samples (X5A1 and X5A2) and one of the MHV-76 infected
samples (X5B1) from the second experiment were scored as showing severe
inflammation and the remaining MHV-76 infected sample (X5B2) was scored as
moderate. Contrary to initial findings, the overall result from the second analysis is
that both groups showed the same mean inflammation severity (Figure 3.11).
3.3.4 Latent Infection
MHV-76 is known to establish a latent infection in the spleens of intranasally infected
mice albeit at a greatly reduced level compared to that of MHV-68. To assess
whether the inserted ORFs had an effect on the establishment of latency, splenocytes
from infected mice were used in ex vivo reactivation (infectious centre) assays as
described in Section 2.7.4. The mean infectious centre number from MHV-ALHE
infected mice at days 7 and 21 post infection was found to be extremely low (Figure
3.12 A) and the levels at these time points were the same as those found in MHV-76
infected mice. One of the four MHV-ALHE mice tested at day 14 post infection had
an infectious centre number approximately five fold higher than the other three
members of this group. An occasional outlier of this type is not uncommon during
MHV-76 infection (Dr. Bernadette Dutia, Personal Communication) and the
difference in mean infectious centre numbers between this group and the MHV-76
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MHV-ALHE
XIB5 Faded 0(2)
X1B6 Mild PB and PV inflammation 1 (2)
X5A1 PB and PV inflammation extending to interstitium 3(1)
X5A2 PB and PV inflammation extending to interstitium 3(1)
MHV-76
X1G5 Mild predominantly PB inflammation 1 (0)
X1G6 Mild focal PB and PV inflammation 1 (0)
X5B1 PB and PV inflammation extending to interstitium 3(1)
X5B2 PB and PV inflammation 2(1)
Table 3.4. Independent analysis of peribronchiolar (PB) and perivascular (PV)
inflammation in lungs samples taken at day 5 post infection. Severity scores are
given in the right hand column with previous scores shown in parentheses.


















Figure 3.11. Inflammation severity in the lungs taken at day 5 post infection of
mice infected with MHV-ALHE (•) or MHV-76 (o) based on second analysis.
Bars indicate mean severity.




































Figure 3.12. A) Spleen infective centres, B) spleen weights and C) spleenocyte
numbers from Baib/c mice infected intranasally with 4 x 105 PFU MHV-ALHE (•)
and MHV-76 (o).
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infected group at this time point was not statistically significant (p=0.6857 using the
Mann-Whitney test).
3.3.5 Splenomegaly
To determine whether the insertion of A1HV-1 ORFs altered the amount of
splenomegaly induced following intranasal infection, spleens from MHV-ALHE and
MHV-76 infected mice were removed at various time points after infection and
weighed (Figure 3.12 B). Splenocyte numbers were counted following mechanical
disruption of the spleen and lysis of erythrocytes (Figure 3.12 C). Again, the time
points selected were predicted to be before (day 7), around (day 14) and after (day 21)
the peak of splenomegaly based on previously published data for MHV-76 (Macrae et
al., 2001). There was no significant difference in the spleen weights or splenocyte
numbers between the MHV-ALHE and MHV-76 infected groups at any of the three
time points.
3.3.6 Analysis of A1HV-1 Gene Expression
To determine whether the inserted ORFs were expressed during infection, total RNA
was extracted from infected lung tissue and screened by RT-PCR. Two separate
samples were taken from the lung of an MHV-ALHE infected mouse at day 5 post
infection (peak viral titre). One sample of lung tissue from an MFIV-76 infected
mouse at the same time point was used as a control. All RT+ lung samples were
positive for P-actin after one 40-cycle round of PCR and all RT- samples were
negative (data not shown) indicating that the RNA was intact and free of cellular
DNA contamination.
No expression of the inserted ALHV-1 ORFs or MHV-ORF 50 could be detected
after a single 40-cycle round of PCR therefore 1 jul of this primary reaction was used
as template for a secondary 40-cycle reaction. Using the two round PCR described in
Section Al.3.39, MHV-ORF 50 expression was seen in all RT+ samples but not in the
RT- samples (Figure 3.13 A) indicating that there was productive infection in the lung
areas sampled and the RNA was free from viral DNA contamination. No AI product
was detected in either of the MHV-ALHE infected samples (Figure 3.13 B). Using
full-length A2 primers, no products were seen in the MHV-ALHE infected lung
samples (data not shown). Internal A2 primers were designed, one of which
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Figure 3.13. In vivo RT-PCR. A) MHV-ORF 50, B) ORF Al, C) ORF A2, D)
ORF A3 and E) ORF A4 PCRs performed on cDNA from infected lungs at 5 days
post infection.
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recognised sequences either side the intron so only cDNA made from mature spliced
mRNA should be detected. In reactions using these primers, described in Section
Al.3.10, expression was detected in both MHV-ALHE infected samples (Figure 3.13
C). No full-length A3 product could be detected in either of the MHV-ALHE
infected samples. Again, internal primers were designed to amplify a smaller product.
In reactions using these primers, described in Section A 1.3.24, expression of A3 could
be detected in one of the MHV-ALHE infected samples (Figure 3.13 D). A4
expression, using full-length primers, was detectable in both MHV-ALHE infected
samples (Figure 3.13 E). No expression of A1HV-1 ORFs was seen in the MHV-76
infected sample or the RT- reactions.
3.3.7 Summary
Although expression of three of the four inserted ORFs could be detected in the lungs
of intranasally infected mice, MHV-ALHE does not show any phenotypic differences
from MHV-76 during productive infection at early time points post infection. Studies
on changes to the inflammatory response against viral challenge in the lung were
difficult to interpret due to the large amount of variation between experiments and in
the control groups but there did not appear to be any difference induced by the
inserted ORFs. There was also no difference seen between the pathogenesis of the
two viruses at later time points in the spleen as measured by reactivatable latent virus,
spleen weight and splenocyte number, although expression of the inserted ORFs in
infected spleens could not be determined.
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3.4 Intraperitoneal Infection of Balb/c Mice
3.4.1 Aims
As there were no significant differences between MHV-ALHE and MHV-76
pathogenesis following intranasal infection, Balb/c mice were infected
intraperitoneally to assess any changes in pathogenesis occurring when productive
infection occurs in a different location. Intraperitoneal infection is a commonly used
route of infection for MHV-68 and related recombinant viruses, including
MHVA9473 which carries a deletion homologous to MHV-76 (Clambey el al., 2002).
Following infection through this route, there is productive replication in the peritoneal
cells and spleen rather than the lung epithelia. As the primary productive infection
occurs in different cell types and the time course of infection is different,
intraperitoneal infection could highlight differences that were not detected following
intranasal infection. In the initial experiment, groups of four mice per lime point per
virus were infected intraperitoneally with 106 PFU of virus. Titres of productive virus
were measured in the spleens and peritoneal exudate cells (PECs) on days 4 and 9
post infection and reactivatable latent virus was measured in these locations at day 17
post infection. Splenomegaly, as measured by spleen weight was assessed at all time
points. A second experiment in which eight mice per virus were infected for study at
day 4 post infection was performed based on results of the primary experiment.
3.4.2 Productive Infection
To determine if there is an effect of the inserted A1HV-1 ORFs on the magnitude of
productive infection in the intraperitoneal infection model, the titres of pre-formed
infectious virus were measured in spleens (Figure 3.14 A) and PECs (Figure 3.14 B)
on days 4 and 9 post infection (Figures 3.11 A and B). The titres measured on day 4
post infection were pooled from two independent experiments. There is no
statistically significant difference between the titres of MHV-ALHE and MHV-76 at
this time point in either spleens or PECs. By day 9 post infection, the productive
infection appears to have been completely cleared as all samples for both viruses were
below the limit of detection for the assay. This finding is consistent with the
published findings for MHVA9473 (Clambey et al., 2002).












































































Figure 3.14. Viral titres in the A) spleens and B) peritoneal exudate cells of Balb/c
mice infected intraperitoneally with 106 PFU MHV-ALHE (•) and MHV-76 (o).
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3.4.3 Latent Infection
To assess whether the inserted ORFs had an effect on the establishment of latency in
the intraperitoneal infection model, infectious centre assays were performed using
splenocytes (Figure 3.15 A) and PECs (Figure 3.15 B) from infected mice at day 17
post infection. The total number of infectious centres in the spleens of both groups at
this time point was low and there was no statistically significant difference between
MHV-ALHE and MHV-76 infected mice. One of the MF1V-ALHE infected mice had
an infectious centre number in the PECs much greater than the other three members of
the group and the MHV-76 infected mice. It is unclear whether this difference would
be significant as sufficient PECs for the assay were obtained from only two of the
four MHV-76 infected mice.
3.4.4 Splenomegaly
Spleen weights were measured at days 4, 9 and 17 post infection to determine whether
there is an effect of the inserted A1HV-1 ORFs. In both MHV-ALHE and MHV-76
infected mice, there is an increase in spleen weight at day 4 post infection. In the first
experiment, this increase was significantly (p=0.0286 using the Mann-Whitney test)
greater in the MHV-ALHE infected mice. To confirm this finding, a further eight
mice per group were infected. The results of the second group of mice alone (data not
shown) and the pooled results (Figure 3.15 C) from the two experiments do not show
a significant difference (p=0.5737 and p=0.0999, respectively, using the Mann-
Whitney test) between MHV-ALHE and MHV-76 infected mice. By day 9 post
infection it appears that the spleen weights of MHV-76 infected mice have dropped
back to normal levels and those of MHV-ALHE infected mice remain elevated but
this difference is not statistically significant (p=0.1143 using the Mann-Whitney test).
On day 17 post infection there is no difference between the spleen weights of the two
groups and both have returned to a normal level (~150 mg).
3.4.5 Spleen Histology
Although the increased splenomegaly was not found to be reproducible, hematoxylin
and eosin stained sections of spleens from infected mice at 4 days post infection were
examined microscopically to determine if there was any change in splenic
architecture. No obvious differences were seen between spleens of MHV-ALHE and
MHV-76 infected mice.
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Figure 3.15. Infectious centres in the A) spleens and B) peritoneal exudate cells of
Balb/c mice infected intraperitoneally with 106 PFU MHV-ALHE (•) and MFIV-76
(o). C) Spleen weights of Balb/c mice infected intraperitonealiy with 106 PFU
MHV-ALHE (•) and MHV-76 (o).
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3.4.6 Analysis ofAIHV-1 Gene Expression
To determine whether the inserted ORFs were expressed during intraperitoneal
infection, total RNA was extracted from infected spleens at 4 days post infection and
screened by RT-PCR. One sample from each of the two virus infected groups was
taken. Both RT+ assays were positive for |3-actin after one 40-cycle round of PCR,
described in Section Al.3.40, and both RT- assays were negative indicating that the
RNA was intact and free of cellular DNA contamination. No expression of MHV-
ORF 50 could be detected even after 2 x 40 cycles. It is possible that there was either
no infection in the area of spleen tested or that the level of viral gene expression was
below the limit of detection.
3.4.7 Summary
As with intranasal infection, no differences in the pathogenesis of MHV-ALHE and
MHV-76 were seen following intraperitoneal infection. The levels of productive
infection, reactivatable latent virus and splenomegaly were the same in mice infected
with either virus as was splenic architecture. One possible explanation for the lack of
differences is that the inserted ORFs are not expressed. However, as transcripts have
previously been detected in MHV-ALHE infected murine CI27 cells and lungs, it is
more likely that the level of expression was low rather than absent.
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3.5 Discussion of Recombinant Virus Results
The infection of mice with a recombinant MHV-76 based virus was chosen as the
model with which to study the influence on pathogenesis of the four unique left hand
end ORFs of AIHV-1. It was decided to create the recombinant by inserting a large
AIHV-1 left hand end region of approximately 6.2 kb, containing all four ORFs and
their cognate promoter and polyadenylation sequences, rather than creating separate
viruses with the individual ORFs under the control of a foreign promoter, a strategy
that has also been used for the insertion of foreign herpesvirus genes into MHV-76
(Brass, 2004; Hindley, 2005; Sacco, 2003). There were some drawbacks to creating a
single virus but this strategy offered several advantages. Firstly, it was simpler to
make one virus versus four and the pathogenesis studies would require fewer animals.
Secondly, no artefactual results would arise from either over-expression of the
inserted gene due the use of a strong promoter or from the presence of any traceable
marker, such as GFP. Approximately 6.2 kb of AIHV-1 DNA was cloned and
inserted into the left hand end of MHV-76 as planned with the exception that an
additional 30 bp sequence from the cloning vector pGEM-T Easy was inserted along
with the AIHV-1 sequence. Although the presence of this short sequence is not ideal,
it is very small and does not interrupt any of the inserted coding or promoter
sequences and should therefore have no influence on the phenotype of the
recombinant virus. Attempts to create a virus without this insert were unsuccessful.
One major disadvantage with the single virus strategy is that the function of the
AIHV-1 promoter sequences used had not previously been determined in a murine
host and, therefore, it was possible that no expression of the inserted ORFs would be
seen. To address this possibility, expression of the genes in murine cells was assessed
prior to any in vivo experiments. All four inserted ORFs were indeed found to be
expressed in CI27 cells infected in vitro with the recombinant virus. It is interesting
that any expression of ORF A1 was seen as other studies have implied that this ORF
does not represent an entire gene and may only be an exon as Northern blot analysis
detected transcripts larger than 230 bp (Dr. David Haig, Personal Communication). If
this is the case, expression of this ORF from the recombinant virus implies that it can
be expressed by itself, the other exons are present in the inserted AIHV-1 sequence or
MHV-76 sequences can substitute for the other exons. Although the genes were
expressed to the RNA level, this does not completely ensure their translation into
I J J
Chapter 3 Recombinant Virus Results
protein and, as the ORFs are inserted without any additional epitope tag sequence, the
expression of protein cannot be determined at this time due to the lack of specific
antibodies.
RT-PCR analysis of cells infected in the presence of cycloheximide or
phosphonoacetic acid showed that, in the context of recombinant virus infection, ORF
A1 is a late transcript, ORF A4 is an early transcript and ORFs A2 and A3 are
immediate early/early transcripts. Detection of immediate early transcription of ORF
A2 supports the hypothesis that it encodes a transcription factor. Attempts were made
to determine whether this same temporal transcription profile of the left hand end
ORFs was seen following A1HV-1 infection of bovine turbinate cells, however, the
results were inconclusive due to contamination with transcripts present in the viral
inoculum.
Mice were infected with recombinant MHV-ALHE or MF1V-76 via either the
intranasal or intraperitoneal routes. The intranasal route of infection was chosen for
the primary study as this is the most likely route of natural transmission and is well
characterised in Balb/c mice. The parameters investigated were based upon previous
studies which have shown an acute phase of productive viral infection in the lung
followed by splenomegaly and the establishment of a latent infection, predominantly
in splenic B cells (Sunil-Chandra et al., 1992b; Sunil-Chandra et al., 1992a). In
addition, a cohort of mice was infected intraperitoneally. This artificial route of
infection was chosen as a means of studying productive infection in cell types that are
more similar to those thought to be involved in MCF pathogenesis, lymphocytes and
macrophages, and are therefore more likely to be responsive to the inserted A1HV-1
ORFs. Although lymphocytes and macrophages also become infected following
intranasal infection, the attenuation ofMHV-76 could mean that too few of these cell
types become infected for an effect of the inserted ORFs to be detectable.
Productive recombinant viral titres were the same as those of MHV-76 at early time
points in both intranasally and intraperitoneally infected mice. In the lungs of
intranasally infected mice, the titres of both MHV-ALHE and MHV-76 rose between
day 3 and day 5 post infection and there was some evidence of viral clearance by day
7. As the in vitro growth curve analyses of these viruses showed that their growth
rates are the same, it can be implied from these results that their clearance rates are
134
Chapter 3 Recombinant Virus Results
also identical. Similarly, in the spleens and PEC of intraperitoneal^ infected mice,
the titres of both viruses were high at day 4 post infection and completely cleared by
day 9.
To determine whether the similarities in viral titres between the two viruses were due
to a lack of expression of the inserted ORFs, RT-PCR analysis was preformed on
infected tissues. In the lung of an intranasally infected mouse at day 5 post infection,
transcripts for ORFs A2, A3 and A4 were detected. The ORF A4 primers used in this
experiment are designed to amplify a full-length transcript, however, the ORF A2 and
ORF A3 transcripts were detected using internal primers and it is therefore possible
that full-length transcripts were not present. Assuming that the transcripts are full-
length and expressed to protein level, these results suggest that these three A1HV-1
ORFs do not make the virus more immunogenic or contribute to its ability to evade
immune responses in this system. It is also interesting to note that the relative
intensities of the PCR products of the inserted ORFs taken from different areas of
infected lung appear to correlate inversely with those of MHV ORF 50. This could
indicate that the ORF 50 gene product can directly or indirectly down-regulate
expression of the inserted ORFs or vice versa, although the PRC used is not
quantitative and the sample number used is far too small to draw any conclusions. No
transcripts for the inserted ORFs were seen in spleen samples following
intraperitoneal infection; however this may simply indicate that the level of infection
in that particular area was too low as MHV ORF 50 transcripts were also
undetectable.
There was no consistent histological difference seen between the lungs of mice
infected intranasally with MHV-ALHE compared to those infected with MHV-76.
Data pooled from three experiments (XI, X3 and X5) showed increasingly severe
focal inflammation, detectable at day 5 post infection and peaking around day 9 or 10
post infection, following infection with either virus and almost complete resolution of
inflammation by day 15 post infection. Based on the results of the first analysis, it
was thought that a difference in inflammation severity was detectable on day 5 post
infection, however, this difference was not reproducible in a second experiment. In
addition, grading of all day 5 post infection samples by a second pathologist showed
no difference between the groups, underlining the importance of independent analysis
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of experiments where the results are somewhat subjective. The lack of' any marked
difference in inflammatory response supports the hypothesis that the three expressed
AIHV-1 ORFs do not make the virus more immunogenic or contribute to its ability to
evade immune responses in this system. Histologically, the spleens of mice infected
with either MHV-ALHE or MHV-76 looked normal when studied on day 4 post
infection. As with the data on viral titre at this time, the lack of difference may be due
to lack of expression.
Latent viral loads were assessed in the spleens of infected mice using the infectious
centre assay which measures viral reactivation. Although no significant differences
were seen in the number of reactivations of either virus from the spleens of
intranasally infected mice at days 7, 10 and 14 post infection or the spleens and PECs
of intraperitoneally infected mice at day 17 post infection, there may be a difference
in the absolute latent viral load. To address this point, and to determine any
difference in reactivation frequency, it would be necessary to determine the viral
DNA copy number of the tissue by either limiting-dilution or real-time PGR. Even if
differences in DNA load or reactivation frequency were found it would not be
possible to definitively attribute these differences to the AIHV-1 genes as transcripts
of the inserted ORFs could not be detected.
In summary, a recombinant virus containing four AIHV-1 ORFs was successfully
created but showed no biological differences to the parental MHV-76. It is therefore
not possible to determine any function of these ORFs from these studies. There are
several possible explanations for the lack of phenotypic change conferred by the
inserted sequences. Transcripts for all four inserted ORFs were found in vitro and at
least three are found in vivo but, as mentioned above, this does not guarantee that
protein is expressed. Even if protein is produced, it is possible that the protein or
nucleic acid with which these proteins interact are not sufficiently conserved between
the mouse and ruminant species (or between AIHV-1 and MHV-76) for interaction, or
are completely absent from this model system, and therefore no effect would be seen.
It is also possible that the proteins are having an effect on an aspect of infection that
has simply not been assessed in these studies. If this is the case, the recombinant
virus model may still be a useful in the future to support further any studies that
determine a possible function for any of the four inserted ORFs.
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4.1 Mammalian Expression of LHE ORFs
4.1.1 Aims
In addition to the in vivo characterisation studies using the recombinant virus, a
number of experiments were designed to characterise the LHE ORFs in vitro. In the
first group of experiments, the individual ORFs were expressed as tagged fusion
proteins in mammalian cells. These experiments were carried out in baby hamster
kidney (BHK)-21 cells as this cell type is easy to handle in tissue culture, can
transfect at higher efficiencies than the available bovine cell lines and is biologically
relevant as previous studies have shown that this cell type is permissive for A1HV-1
infection (Frame, 2006). The primary objective of these studies was to determine the
localisation of the proteins within cells or whether they were secreted as this would
give some indication of function. In the case of ORF A2, further experiments were
carried out using one of the tagged proteins to investigate whether this construct could
affect transcription from a number of reporter plasmids containing representative
A1HV-1 promoter sequences.
4.1.2 Expression of c-myc/6xHIS Tagged LHE ORFs
Initial localisation experiments were performed using sequences ofORFs Al, A2 and
A4 cloned into pcDNA3.1/myc-His(-)A. This vector is used for the production of
inserted genes with a small C-terminal c-myc/6xHIS tag of 21 amino acids (aa) under
the control of the cytomegalovirus (CMV) immediate early promoter for high level
constitutive expression. The 10 aa c-myc epitope (EQKLISEEDL) can be used for
immunological detection of fusion protein and the 6 histidine epitope can be used for
both metal-affinity purification and for metal-affinity or immunological detection.
The predicted coding regions of ORFs Al (912-1208), A2 (2490-1799) and A4
(5732-6094) were amplified by PCR using the reactions described in Sections A 1.3.6,
Al.3.11 and Al.3.32. Products were cloned into the T:A cloning vector pGEM-T
Easy and sequenced before being inserted in frame into pcDNA3.1/myc-l Iis(-)A.
Diagrams of the resultant vectors are shown in Figure 4.1 A, B and C. Expression
vectors were transfected into BHK-21 cells either by electroporation as described in
Section 2.6.6 or by creating DNAdipid complexes with Effectene as described in
Section 2.6.7. Transfected cells were transferred to microscope slides 48 hours post
transfection for c-myc staining as described in Section 2.6.21. Supernatants from
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pEGFP-Cl pEGFP-Nl
Figure 4.1. Diagrammatic representations of constructs used for the expression of
tagged AIHV-1 ORF gene products in BHK-21 cells. Not to scale. Red arrows
indicate relative position and orientation of CMV IE promoters. Yellow blocks
indicate inserted AIHV-1 sequences and the relative positions of GFP and c-
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transfected cultures were collected 48 hours post transfection and analysed by
Western blot as described in Sections 2.5.1 -2.5.3.
In cell cultures transfected with the ORF A1 and ORF A4 constructs, no cells were
found to be positive for staining with the anti-c-myc antibody (data not shown).
Western blot analysis of concentrated supernatants from these cultures also showed
no obvious staining above background (data not shown). Based on the low
transfection efficiencies seen in cultures transfected in parallel with positive control
and ORF A2 constructs, it is likely that any secreted protein would be too dilute
within the supernatant to be detected.
In cells transfected with the ORF A2 construct, c-myc staining was found to localise
within the nucteus (Figure 4.2). In the majority of cells, staining co-localised with
DNA and was not seen in distinct areas within the nucleus where DNA was also
absent (Figure 4.2 A, C and E). It was hypothesised that these areas were nucleoli.
This hypothesis was tested in the experiments detailed in the following section. It
was also observed that a disproportionately large percentage of transfected cells had
an unhealthy nuclear morphology (as represented by the cell on the left in Figure 4.2
B, D and F as compared to the non-transfected cells on the right) and were most likely
undergoing apoptosis. The presence of the intron (2312-2231) within ORF A2 did not
affect the localisation of the gene product as the same pattern of staining was seen
following transfection with a construct containing ORF A2 cloned from cDNA of
infected cells rather than viral genomic DNA (diagram shown in Figure 4.1 D, data
not shown).
4.1.3 Localisation of ORF A2 GFP Fusion Proteins within Nuclei
In order to determine the nature of the areas from which ORF A2 protein was
excluded, transfected cultures were stained using the C23 antibody specific for
nucleolin. As both the C23 antibody and the anti-c-myc antibody are murine IgG,
simultaneous staining of cells was not straightforward. Instead, ORF A2 (2477-1798,
Section A 1.3.12) was cloned into the pEGFP-Nl and pEGFP-Cl vectors to allow its
production a fusion protein with Enhanced Green Fluorescent Protein (GFP). The
use of the GFP tag has the advantage that no staining procedure is required for the
visualisation of recombinant protein. However, the use of such a large tag could
interfere with the normal behaviour of the ORF A2 protein and constructs were
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Figure 4.2. A and B) Localisation of c-myc/6xHis tagged ORF A2 protein (red)
expressed in BHK-21 cells 48 hours post transfection. C and D) Nuclei
counterstained with TO-PRO-3 (blue). E and F) Overlay images.
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therefore made with either N- or C-terminal GFP. Digrams of the N- and C-
terminally GFP tagged ORF A2 vectors (pE-GFP-A2 and pE-A2-GFP, respectively)
are shown in Figure 4.1 E and F.
BHK.-21 cell cultures were transfected with the GFP tagged ORF A2 and stained
using the C23 antibody 48 hours post transfection as described in Section 2.6.21. The
GFP signal in cells transfected with the C-terminally tagged ORF A2 vector (Figure
4.3) showed a similar pattern of distribution as c-myc staining of cells transfected
with A2-mycHis, with signal present in the nucleus but preferentially excluded from
distinct areas. As hypothesised, these areas were positive for C23 staining indicating
that they are indeed nucleoli. In contrast, the GFP signal in cells transfected with the
N-terminally tagged ORF A2 vector was still nuclear but more intense in distinct
areas (Figure 4.4). Although these areas of more intense GFP signal co-localise with
C23 staining, they do not appear to be nucleoli as there is also co-localisation with
TO-PRO-3 and are most likely nuclear aggregates. Two possible explanations for the
finding that C- and N-terminally tagged ORF A2 proteins are either preferentially
excluded from nucleoli or included in nuclear aggregates are that 1) the recombinant
ORF A2 protein is being cleaved and the different termini are localising
independently or 2) the large GFP tag is interfering with the normal localisation of the
protein. Experiments to address these hypotheses are described in the following
section.
4.1.4 Localisation of N- and C-Termini of ORF A2
In order to differentiate between the cleavage and altered localisation hypotheses
mentioned above, a construct was produced encoding both N- and C-terminal epitope
tags. The expression plasmid was produced by cloning a GFP-A2 PCR product into
pcDNA3.1myc/His(-)A. The GFP-A2 PCR was performed using the pTH-GFPA2c
vector (Section Al.3.17) as a template and the product was first cloned into the
pGEM-T Easy cloning vector before being inserted into pcDNA3.1myc/His(-)A. A
diagram of the final construct is shown in Figure 4.1 G.
The vector for the dual-tagged construct was tranfected into BHK.-21 cells and
transferred to microscope slides 48 hours post transfection for c-myc staining as
previously described. Cells representative of the majority of strongly GFP positive
cells are shown in Figure 4.5. In such cells, the c-myc (C-terminal) localisation
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Figure 4.3. Co-localisation ofA) C-terminal GFP tagged ORF A2 (green) expressed
in BHK-21 cells 48 hours post transfection with B) C23 staining of nucleoli (red).
C) Nuclei are counterstained with TO-PRO-3 (blue). D) Overlay image.
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Figure 4.4. Co-localisation ofA) N-terminal GFP tagged ORF A2 (green) expressed
in BHK-21 cells 48 hours post transfection with B) C23 staining of nucleoli (red).
C) Nuclei are counterstained with TO-PRO-3 (blue). D) Overlay image.
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Figure 4.5. Localisation of A) GFP fused to the N-terminus (green) and the B) c-
myc tag fused to the C-terminus (red) of ORF A2 protein expressed in BHK-21
cells 48 hours post transfection. C) Nuclei are counterstained with TO-PRO-3
(blue). D) Overlay image.
145
Chapter 4 In C/7/Y)Cliaiai.lcrisalion
pattern was similar to that previously shown for C-terminal myc/His and C-terminal
GFP tagged ORF A2 products, showing co-localisation with DNA but absence
from distinct areas within the nucleus. In contrast, the GFP (N-terminal) signal is
present in some but not all of the areas where c-myc staining is absent. Based on the
previous findings using the GFP-A2 construct, the area to which the GFP signal
localises is probably a nuclear aggregate as there is co-localisation with the TO-PRO-
3 stain. Images were further analysed using the Leica Lite software to belter represent
the distribution pattern. Signal intensities along an arbitrary line drawn across a
representative cell (Figure 4.7 A) were plotted in the histograms shown in Figures 4.7
C (GFP) and E (c-myc staining). These plots conclusively demonstrate that the
signals are in different areas. This analysis also shows that there is an increase in c-
myc signal immediately adjacent to GFP, although the significance of this finding is
unclear. These results support the hypothesis that the ORF A2 protein is cleaved and
the two termini localise independently.
Another population of cells with a markedly different pattern of c-myc and GFP
localisation was also seen in the transfected culture. Examples of these types of cells
are shown in Figure 4.6. In these cells, the signal intensities for both c-myc staining
and GFP are lower and both localise to the same nuclear compartment. I lowever, the
signals do not completely overlap as there would be yellow signal throughout this
compartment rather than distinct red and green in the overlaid image (Figure 4.6 D).
Similar to the findings previously seen with C-terminal myc/His and C-lerminal GFP
tagged ORF A2 products, the signals are absent from distinct areas in the nucleus.
Again, images were analysed using the Leica Lite software. Signal intensity
histograms along the line of the representative cell in Figure 4.6 B are shown in
Figures 4.7 D (GFP) and F (c-myc staining). Both histograms have a similar overall
pattern but, as expected, do not completely overlap, again indicating that the protein is
cleaved. As at least two major patterns of distribution are seen with the same
construct, some factor must be affecting the localisation of the protein (or its cleavage
products) other than either the ORF A2 sequence or the addition of the traceable
markers.
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Figure 4.6. Localisation of A) GFP fused to the N-terminus (green) and the B) c-
myc tag fused to the C-terminus (red) of ORF A2 protein expressed in BHK-21
cells 48 hours post transfection. C) Nuclei are counterstained with TO-PRO-3
(blue). D) Overlay image.
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Figure 4.7. A and B) Representative BHK-21 cells expressing GFP fused to the N-
terminus (green) and the c-myc tag fused to the C-terminus (red) ofORF A2 protein
48 hours post transfection. C-F) Histograms representing the signal intensity of
GFP (C and D) and c-myc staining (E and F) across the lines shown in the example
cells in A (C and E) and B (D and F).
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4.1.5 Transcriptional Activity of ORF A2 Protein
The nuclear localisation of the ORF A2 gene product in transfected cells is consistent
with its predicted role as a transcription factor (Ensser et al., 1997). To further
investigate this prediction, studies were undertaken using a promoter-reporter assay to
look for transcriptional activity of this protein. BHK.-21 cells were co-transfected
with the ORF A2myc/His construct (see Section 4.1.2) or empty pcDNA3.1/myc-
His(-)A along with one of a number of previously constructed promoter-reporter
constructs. The promoter-reporter constructs were based on pGL3-Basic (Promega).
This plasmid contains a multiple cloning site, into which a promoter region of interest
can be inserted, upstream of the firefly luciferase reporter gene. Plasmids were
previously constructed by Dr. Thonur Leenadevi and Dr. Fiona Frame containing
A1HV-1 promoter sites. Constructs containing promoter regions of ORF 6 (major
single stranded DNA binding protein) as a representative late gene, ORF 21
(thymidine kinase) as an early-late gene and ORF A9 (Bcl-2 homologue) as an early
gene were used. Constructs with ORF 50 (Rta homologue) and ORF 57 (Mta
homologue) were used as representative immediate early genes and because of their
importance in the control of viral gene transcription. Firefly luciferase expression
driven by the cytomegalovirus immediate-early promoter was used as a positive
control for Firefly activity. A plasmid containing Renilla luciferase driven by the
herpes simplex virus thymidine kinase promoter for low to moderate constitutive
expression was used to control for transfection efficiency.
Transfections were performed in triplicate and 48 hours post transfection, luciferase
activity was measured as described in Section 2.8.1. Raw luciferase readings are
shown in Appendix 2 and the mean results of the triplicate assays are shown in Figure
4.8, represented as the ratio of Firefly to Renilla luciferase measurements. The
presence of the ORF A2 vector (grey bars) in transfected cultures neither increased
nor decreased the levels of transcription from any of the promoter constructs tested,
compared to cultures co-transfected with empty pcDNA3.1/myc-His(-)A (black bars).
Although these results show no transcriptional activity of the ORF A2, the promoters
tested represent only a small fraction of the potential targets for a transcription factor.
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Figure 4.8. Ratios of firefly to Renilla luciferase activity in BHK-21 cells
transfected with promoter construct and either A2 expressing plasmid (grey bars) or
control vector (black bars). Error bars indicate standard deviation of triplicate
readings.
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4.1.6 Expression of ORF A3 and A4 GFP Fusion Proteins
The products of ORFs A3 and A4 contain sequences consistent with known signal
peptides and are therefore predicted to be secreted (Ensser et al., 1997). Previous
experiments using c-myc/6\HIS tagged ORF A4 failed to show any evidence that this
gene product was secreted, however, this may have been due to the low transfection
efficiency or the insensitivity of the detection system used. To facilitate detection,
ORF A3 (3491-5451) and ORF A4 (5732-6094) were amplified by PCR using the
reactions described in Sections A 1.3.26 and A 1.3.33 for cloning into pEGFP-Nl and
pEGFP-Cl. These vectors are used for the production of the inserted genes as C- or
N-terminal GFP fusion proteins, respectively. Vectors for N-terminally tagged ORF
A3 (GFP-A3) and for N- and C-terminally tagged ORF A4 (GFP-A4 and A4-GFP)
were successfully created and diagrams of these constructs are shown in Figure 4.1 H,
I and J. Several attempts to clone a C-terminally tagged ORF A3 were unsuccessful.
Vectors were transfected into BHK-21 cells as previously described. Eight hours
post-transfection, culture media was replaced with Optimem (Invitrogen) low-serum
media to reduce background protein staining in Western blots. Cell and supernatant
samples were collected 48 hours post-transfection for Western blot analysis and cell
samples were transferred to slides for nuclear counterstaining and microscopic
analysis. In cells transfected with vectors for GFP-A3 or GFP-A4, green lluorescent
signal was seen throughout the cell in a pattern indistinguishable from empty pEGFP-
C1 (Figure 4.9). An anti-GFP Western blot of cell and concentrated supernatant
samples is shown in Figure 4.10. No obvious products are seen in either cells or
supernatants from GFP-A4 or A4-GFP. The product seen in the cells and supernatant
of GFP-A3 transfected cultures is the same size as that of GFP alone indicating that
the fusion protein is incompletely produced or cleaved. That product is seen in the
supernatant of pEGFP-Cl transfected cultures as well as the cells, despite there being
no reason for secretion ofGFP, suggests that there is contamination of the supernatant
samples, most likely from dead or dying cells. This is also the likely cause of product
presence in GFP-A3 supernatants.
4.1.7 Summary
All four LHE ORFs of A1HV-1 were cloned for their expression as fusion proteins in
mammalian cells. The results ofORF Al, ORF A3 and ORF A4 were inconclusive.
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Figure 4.9. Localisation ofGFP (A), GFP-A3 (B), GFP-A4 (C) and A4-GFP (D) in






































Figure4.10.Anti-GFPWesternblotof(A)c llandBsupernatantamplesfrBHK-21c lultur s transfectedwithhindicacons ruct.Posit onsfmolec larw ightrkers(kD)h wntlef Diagramsofpredictedfusionrotei srh wn(C)indica ngalativep si onfGFPt g.
Chapter 4 In FfVroCharaeterisation
No c-mys/6xHIS tagged ORF A1 was found in transfected cells or in the supernatants
of transfected cultures. No evidence to support the predicted secretion of either ORF
A3 or ORF A4 could be found. Green signal was seen in cells transfected with N-
terminally GFP tagged ORF A3 and ORF A4 although this is most likely due to
interference of GFP or incomplete expression of fusion protein. Neither C-terminally
c-myc/6xFIIS nor C-terminally GFP tagged ORF A4 fusion proteins were detected in
culture supernatants or in transfected cells. It is possible that these fusion proteins
were present in supernatants but the sensitivity of detection assays was simply too
low.
As predicted, the gene product of ORF A2 was found to localise to the nucleus. The
precise localisation appeared to vary based upon the location of the tag within the
fusion protein. Based on data obtained using a dual-tagged fusion protein, the
variation in localisation of protein was most likely due to cleavage, although this
cannot be confirmed without Western blot analysis. The transcriptional activity of
ORF A2 fusion proteins was tested by co-transfection of BF1K-21 cells with
A2myc/His vector along with various luciferase promoter-reporter constructs. The
presence of ORF A2 gene product neither increased nor decreased the basal
transcription levels from any of the constructs tested.
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4.2 Bacterial Expression of LHE ORFs
4.2.1 Aims
To follow on from previous data supporting the role of ORF A2 product as a
transcription factor, it was hoped that sufficient quantities of protein could be
produced for purification and biochemical analysis. However, levels of protein
produced by transfection of mammalian cells were insufficient even for detection by
Western blot and certainly not enough for purification. Instead, constructs were
designed for the production of protein in bacteria using the pTrcHis2 A vector system
(Invitrogen). This system is designed for high level inducible expression of
recombinant protein with C-terminal c-myc/6xHIS epitope tags.
4.2.2 Expression of Single-Tagged ORF A2 Constructs
ORF A2 was cloned for expression using the pTrcHis2 A vector system. No gene
splicing occurs in bacteria and it was therefore necessary to clone the coding region of
ORF A2 without the intron (2312-2231). This was accomplished by PGR
amplification of the selected ORF A2 sequence (2474-1799, Section A 1.3.15) using
cDNA produced from BHK-21 cells infected with the recombinant MHV-ALHE virus
rather than A1HV-1 viral DNA as the template. The resulting PCR product was
cloned first into pGEM-T Easy and then into the pTrcHis2 A vector using methods
previously described. A diagram of this construct is shown in Figure 4.11 A.
Cultures of TOPI OF' cells containing the pTrcHis2 A/ORF A2 cDNA construct
(pTH-A2c) or empty pTrcHis2 A vector as a control were grown to the appropriate
optical density and recombinant protein production was induced by the addition of
IPTG as described in Section 2.2.7. Bacterial samples were collected prior to the
addition of IPTG and at 1, 2, 3, 4 and 5 hours post induction. Samples were analysed
by Western blot using antibodies specific for the c-myc epitope (9EI0) or the 6xHIS
epitope as described in Section 2.5. Neither blot showed any specific staining at the
predicted molecular weight of around 27 kD in any of the induced samples (data not
shown).
The lack of product may due to the low sensitivity of the detection system or a
problem with protein synthesis. To determine whether the lack of product seen was
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Figure 4.11. Diagrammatic representations of constructs used for the expression of
tagged ORF A2 gene products in E. coli. Not to scale. Red arrows indicate relative
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due to a problem with the detection of the c-myc/6xHIS epitope tag rather than a
problem with protein synthesis, ORF A2 constructs were made containing either
3xFLAG (DYKDHDGDYKDHDIDYKDDDDK) or GFP tags.
The 3xFLAG epitope was added to an existing pTHA2c construct (containing an ORF
A2 cDNA construct cloned using the PGR protocol described in Section A 1.3.14) by
the insertion of synthesised oligonucleotides that were annealed and ligated into the
vector as described in Section 2.1.21. A diagram of the resultant vector (pTFI-FLAG-
A2c) is shown in Figure 4.11 B. Cultures of TOPIOF' E. coli transformed with this
construct or empty pTrcHis2 A vector as a control were grown and protein production
was induced as before. Bacterial samples were collected prior to the addition of IPTG
and at 30 minutes and 3 hours post induction. Figure 4.12 A shows the Western blot
of these samples stained with the Anti-FLAG M2 antibody. A product of the
predicted size of full-length protein (approximately 30 kD, indicated by the blue
arrow) is present in the sample taken after 30 minutes of induction. The staining
intensity of this product is reduced in the 3 hour sample indicating that degradation of
the protein is occurring. Supporting this hypothesis, two smaller products of
approximately 18 and 21 kD (indicated by red arrows) were also seen in the 30
minute sample and were far more intense after 3 hours. Any cleavage seen is likely to
have occurred during culture as a protease inhibitor cocktail was added to the samples
at the time of collection.
The A2 cDNA was also cloned into the bacterial expression vector with both N- and
C-terminal GFP tags. A2 sequences (2477-1794 and 2477-1798 for N- and C-
terminal fusions, respectively) were amplified using cDNA from MHV-ALHE
infected BHK-21 cells as template using the protocol described in Sections Al.3.13
and Al.3.14 and cloned into pGEM-T Easy before ligation into pEGFP-Cl or -Nl.
A2c-GFP and GFP-A2c products were amplified from these vectors by PCR using the
protocols described in Sections A 1.3.16 and A 1.3.17 incorporating appropriate
restriction endonuclease sites for cloning into pTrcHis2 A and cloned as previously
described. As controls, GFP alone was inserted into pTrcHis2 A either by cloning
directly from pEGFP-Nl (pTH-GFP-N) or by PCR amplification (Section Al.3.41)
using pEGFP-Cl as a template and subsequent pGEM-T Easy cloning (pTH-GFP-C).
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vectors are shown in Figure 4.11 C, D, E and F. Bacterial cultures transformed with
these constructs were grown and protein production was induced as before.
A Western blot of cultures transformed with either pTH-GFP-A2c or p'Fi 1-GFP-C and
stained using the anti-GFP (JL-8) antibody is shown in Figure 4.12 B. No obvious
product of the predicted molecular weight for full-length GFP-A2c protein
(approximately 50 kD) can be seen in any of the three samples taken at 30 minutes, 1
hour and 3 hours following the induction of protein production with IPTG. A number
of smaller products (at least four, indicated with red arrows) can be seen in these
samples. The smallest of these products is not much larger than GFP alone
suggesting that very little ORF A2 gene product remains in the construct. Similar
results were seen using the C-terminally tagged ORF A2 construct, f igure 4.12 C
shows an anti-GFP stained Western blot of pTH-A2c-GFP and pTH-GFP-N
transformed cultures. Again, no obvious product of the predicted molecular weight
for full-length A2c-GFP protein was seen in induced samples although several smaller
products (indicated with red arrows) were. These results support the hypothesis that
the ORF A2 protein produced in this system is rapidly degraded.
4.2.3 Expression of Dual-Tagged ORF A2 Constructs
To better assess the nature of the degradation of the A2 protein, another vector was
constructed to produce A2 protein with both N- and C-terminal epitope tags. This
would allow for the simultaneous analysis of both termini from the same transformed
culture to determine whether complimentary fragments representing full-length
protein could be seen. The new vector (pTH-FA2G) was designed to have both N-
terminal 3xFLAG and C-terminal GFP tags and was created by the insertion of A2c-
GFP sequence from pTH-A2c-GFP into pTH-FLAG. A diagram of this vector is
shown in Figure 4.11 G. Bacterial cultures transformed with this construct were
grown and protein production was induced as before.
Figure 4.13 A shows the anti-FLAG Western blot stained of bacterial cultures
transformed with pTH-FA2G, pTH-FLAG-A2c or empty pTrcFlis2 A vector induced
with IPTG for one hour. Full-length products of the predicted sizes for both dual- and
FLAG-tagged A2 protein (approximately 56 and 31 kD respectively, indicated with
red arrows) are seen in the appropriate samples. In addition, smaller products of equal
sizes (blue and purple arrows) are seen in both samples indicating that A2 portion of
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the fusion proteins is being cleaved at the same place. Figure 4.13 B shows the anti-
GFP Western blot of a bacterial culture transformed with pTFl-A2c-GFP induced with
IPTG for one hour along with the same pTH-FA2G and pTrcHis2 A transformed
samples analysed in Figure 4.13 A. No obvious products of the predicted molecular
weight for full-length dual- and GFP-tagged proteins (approximately 56 and 50 kD
respectively, indicated with red arrows) are visible despite the presence of full-length
dual-tagged protein in the anti-FLAG blot, implying that the anti-FLAG staining
protocol is more sensitive. Smaller products of equal sizes are seen in both the pTFI-
FA2G and pTFl-A2c-GFP transformed samples (blue and purple arrows), again
indicating that A2 portion of the fusion proteins is being cleaved at the same place.
A diagrammatic representation of a cleavage model fitting this data is shown in
Figure 4.13 C. Cleavage of full-length dual- and FLAG-tagged A2 fusions at the
position indicated by the blue arrow would result in a product of approximately 18 kD
with an N-terminal 3xFLAG tag (as seen in Figure 4.13 A, blue arrows). A
corresponding product of approximately 38 kD with a C-terminal GFP tag would also
be produced from cleavage of the dual- or GFP-tagged fusion proteins at this site
(Figure 4.13 B, blue arrows). Similarly, cleavage of full-length dual- and FLAG-
tagged A2 fusions at the position indicated by the purple arrow would result in a
product of approximately 21 kD with an N-terminal 3xFLAG tag (as seen in Figure
4.13 A, purple arrows). A corresponding product of approximately 38 kD with a C-
terminal GFP tag would also be produced from cleavage of the dual- or GFP-tagged
fusion proteins at this site (Figure 4.13 B, purple arrows). In order to support these
findings the ORF A2 protein sequence was analysed using the ExPASy PeptideCutter
software (http://us.expasy.org/cgi-bin/peptidecutter) to detect all putative protease
cleavage sites. The full results of this analysis are shown in Appendix 3 but no
obvious single candidate protease is consistent with the proposed model above.
4.2.4 Immunoprecipitation of ORF A2 Constructs
Attempts were made to purify bacterially expressed ORF A2 protein and its cleavage
products for further biochemical analysis. In order to perform the purification by
immunoprecipitation, it was first necessary to lyse bacteria and obtain a suspension of
protein. The ORF A2 fusion containing the N-terminal 3xFLAG tag was chosen for
precipitation for several reasons. Firstly, the 3xFLAG tag is much smaller than GFP
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and therefore less likely to interfere with downstream analysis of protein function.
Secondly, the anti-FLAG detection system appears to be more sensitive than the anti-
GFP and full-length FLAG-A2 fusion protein has been detected. Lastly, the cleavage
model supported by the experiments detailed above suggests that cleavage is
occurring towards the C-terminus of the ORF A2 product and therefore a larger
portion of the protein would remain in the cleavage products precipitated with an N-
terminal tag.
Bacteria transformed with pTH-FLAG-A2 plasmid were grown as previously
described and harvested at one hour after induction of protein expression with IPTG
as this is the time at which the largest proportion of full-length product was detected
in previous experiments. Bacterial lysis into two separate fractions was performed
using the CelLytic B (Sigma) reagent using the protocol described in Section 2.2.8
based on manufacturer's recommendations. Fraction 1 contains soluble proteins
extracted by freeze/thaw of bacterial pellets and lysis with the CelLytic B reagent.
The insoluble materiaffrom the first lysis step was treated with CelLytic B containing
0.2 mg/ml of lysozyme to digest bacterial cell wall components. Proteins solubilised
during this step are represented in the Fraction 2 sample with all remaining insoluble
material in the pellet.
An anti-FLAG stained Western blot of whole bacteria and lysate fractions is shown in
Figure 4.14. Products consistent in size with full-length FLAG-A2 fusion protein
(blue arrow) as well as two cleavage products (red arrows) were found in the pTrcFIis-
FLAG-A2 (Whole Cell +) but not pTrcHis2 A whole cell sample (Whole Cell -)
confirming previous findings. The majority of the smaller (approximately 18 kD) and
some of the larger (approximately 21 kD) cleavage products but no full-length protein
were seen following disruption of the cells by freeze/thaw and lysis with CelLytic B
alone (Fraction 1). Following lysozyme treatment, full-length fusion protein and
more of both cleavage products were found in solution (Fraction 2) however, some of
the full-length protein remained insoluble (Pellet). Based on these findings, Fraction
2 was chosen for use in immunoprecipitation.
Bacterial cultures transformed with pTrcHis-FLAG-A2 or pTrcHis2 A were grown as
above. The pTrcHis-FLAG-A2 sample was lysed as before and Fraction 2 was used
for immunoprecipitation as described in Section 2.2.9. An anti-FLAG stained
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Figure 4.14. Anti-FLAG Western blot of bacterial samples transformed with either
pTrcHis2 A (Whole Cell -) or pTrcHis-FLAG-A2 (Whole Cell +) and lysate
fractions of pTrcHis-FLAG-A2 transformed cells. All samples were taken from
cultures harvested one hour after induction of protein production with IPTG. Blue
arrow indicates approximate predicted molecular weight for full length recombinant
protein. Red arrows indicate probable cleavage products.
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Western blot of whole bacteria, lysate fractions and immunoprecipitate samples is
shown in Figure 4.15. The presence of full-length ORF-A2 fusion protein (blue
arrow) and the two cleavage products (red arrows) is clearly seen in the whole cell
samples of pTrcHis-FLAG-A2 transformed (Whole Cell +) but not pTrcHis2 A
transformed (Whole Cell -) bacteria. The lysate samples show a similar distribution
of protein as the previous experiment with the majority of the smaller cleavage
product in Fraction 1 and presence of full-length fusion protein and the larger
cleavage product in Fraction 2. In this experiment, however, a larger portion of the
full-length protein remained insoluble in the final Pellet sample. In addition, an
unknown product of approximately 14 kD was also seen in Fraction 2 that was not
present in the whole cell sample.
Prior to immunoprecipiation, Fraction 2 was pre-incubated with the streptavidin-
agarose slurry to remove any proteins that would non-specifically bind. The pre¬
incubation slurry and supernatant samples shown in Figure 4.15 show that none of the
full-length fusion protein or large cleavage product was removed during this step.
Following immunoprecipiation, two products of approximately 50 and 25 kD (the
heavy and light chains, respectively, of the immunoglobulin used in precipitation) and
the larger fusion protein cleavage product are present. No full-length product could
be detected in the precipitate although it was still present in the supernatant indicating
that it had not been degraded. The supernatant from the immunoprecipitate also
contains products consistent with the immunoglobulin heavy and light chains
indicating that insufficient streptavidin-agarose was used for the amount of antibody.
Even if complete precipitation could be achieved, immunoprecipitated preparations
using this protocol would be no more suitable than crude whole cell lysates for further
studies as the purity of recombinant protein was not complete as demonstrated by the
presence of other products in the sample including the major background protein of
approximately 22 kD present in all anti-FLAG stained samples as well as products of
approximately 6 and 14 kD.
4.2.5 Summary
In an attempt to produce sufficient quantities of recombinant ORF A2 fusion protein
for purification and biochemical analysis, a bacterial expression system was used.
Fusion proteins with either GFP or the 3xFLAG tag were produced in sufficient
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Figure 4.15. Anti-FLAG Western blot of whole cell, lysate and immunoprecipitate
samples form pTrcHis-FLAG-A2 transformed cells. Positions of molecular weight
markers (in kD) shown to the left of each blot. Blue arrow indicates approximate
predicted molecular weight for full length recombinant protein. Red arrows indicate
probable cleavage products. Details in text Section 4.2.4.
165
Chapter 4 In Vilroi'haracterisation
quantities for detection although the majority of product appeared to be cleaved. To
further characterise this finding, experiments were performed using a dual-tagged
construct. Results from these experiments were consistent with the hypothesis that
cleavage is occurring within the ORF A2 protein, although no clear candidate
protease could be determined. Attempts to immunoprecipitate full-length fusion
protein or the cleavage products were unsuccessful.
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4.3 Effects of Secreted Proteins on Ruminant Lymphocytes
4.3.1 Aims
The marked expansion of lymphocytes in an infected host is one of the hallmarks of
MCF. A soluble factor secreted from infected cells is thought to be involved in this
process as the majority of studies have found that most of the proliferating
lymphocytes are uninfected (Bridgen et al., 1992; Edington et ai, 1979; Patel &
Edington, 1980). Two of the ORFs studied in this work are predicted to encode
secreted proteins and therefore may contribute to lymphoproliferation. This is
especially true ofORF A3 as it is predicted to encode for a member of the semaphorin
family (Ensser & Fleckenstein, 1995) which includes several members involved in
immune regulation. The following sections describe studies addressing the effects of
these proteins on cultured lymphocytes.
In order to overcome the problems of low transfection efficiency and the possible
prevention of secretion by epitope tags seen using the mammalian expression methods
described in Sections 4.1.2 and 4.1.6 for the production of ORF A3 and ORF A4
proteins, lymphocytes were grown in media taken from BHK-21 cells infected with
the recombinant MFIV-ALHE virus. This strategy should ensure that the genes of
interest are delivered to almost every cell and therefore lead to the highest possible
level of protein production. The presence of ORF A3 and ORF A4 products in this
media could not be confirmed as the proteins are untagged and no specific reagents
are available. Flowever, the results in Section 3.2.2 suggest that protein is produced
as mRNAs for both ORF A3 and ORF A4 are seen in MHV-ALF1E infected cultures.
In addition to the proteins of interest, several other factors are expected to be present
in the media from infected cells. These factors could either be produced from MHV-
76 sequences or of cellular origin, induced or released in response to infection. To
account for the effects these additional secreted factors, lymphocytes grown in media
from MHV-76 infected BF1K-21 cells were used as a control.
Lymphocytes of ovine and bovine origin were used in these studies as both were
available and it is thought that they may react differently as these hosts respond
differently to infection with members of the MCF virus family.
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4.3.2 Establishment of Assays and Controls
Peripheral blood mononuclear cells (PBMC) were isolated from ovine blood as
described in Section 2.6.18. Cells were cultured in triplicate in complete DMEM
(negative control) or DMEM containing various concentrations of Concanavilin A
(ConA) as described in Section 2.6.17. to establish assays for measurement of
activation and an approximate time course for study using virally infected media. The
number of viable cells in each culture sample was measured by trypan blue exclusion.
The results of viable cell counts taken at the time of isolation (time 0) and after 24,
48, 72 or 144 hours in culture are shown in Figure 4.16 A. The number of viable cells
per well dropped from time 0 to 72 hours in culture in all samples but most
substantially in those samples containing high concentrations of ConA (10, 20 and
40pg/ml). From 72 to 144 hours, proliferation was seen in samples cultured with 1, 5
and 10 pg/ml ConA whereas the cell numbers in samples cultured with 20 and 40
pg/ml continued to decline as did those of negative controls.
In addition to viable cell counts, activation was measured by size and DNA content of
cells using FACS analysis. Following trypan blue counts, cells from negative controls
and samples containing 1 or 5 pg/ml ofConA were collected, fixed, permeablised and
stained with propidium iodide as described in Section 2.6.20. Cells from samples
containing 10, 20 and 40 pg/ml of ConA were not studied as viable cell counts
indicated that these concentrations may be toxic. Samples were acquired using a
FACScan flow cytometer with the forward scatter, side scatter and FL2 fluorescence
all set on linear scales. The mean forward scatter (size) and propidium iodide
fluorescence of all cells within an arbitrary viable lymphocyte gate were measured for
each sample. The mean size of viable cells from cultures containing 1 and 5 pg/ml of
ConA showed a steady increase over the course of the experiment whereas the size of
the negative control cells showed a slight reduction (Figure 4.16 B). A representative
histogram showing the mean forward scatter readings of samples from negative
control (red fill) and 1 pg/ml ConA (black line) cultures taken at 72 hours is shown in
Figure 4.16 D. The mean DNA content of cells from cultures containing 1 and 5
pg/ml ConA showed a sharp increase between 48 and 72 hours, just before
proliferation is seen by trypan blue exclusion, and remains high at 144 hours (Figure
4.16 C). There is also a transient increase in the mean DNA content of negative
control samples at 72 hours although no proliferation of these samples was seen by
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Figure 4.16. A-C) Ex vivo activation of ovine peripheral blood mononuclear cells
in media containing 0 (■), 1 (□), 5 (A), 10 (A), 20 (•) or 40 (o) pg/ml of
Concanavalin A (ConA) represented by viable cell number (A), cell size (B) and
DNA content (C). D and E) Representative FACS plots showing the cell size (D)
and DNA content (E) of samples cultured with 0 (Negative, red fill) or I (Positive,
black line) pg/ml ofConA collected at 72 hours.
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viable cell counts. A representative histogram showing the propidium iodide
fluorescence readings of samples from negative control (red fill) and 1 pg/ml ConA
(black line) cultures taken at 72 hours is shown in figure 4.16 E. Although a clear
difference between the samples can be seen, no clear peak of tetraploid cells is visible.
These results demonstrate that activation of PBMCs can be detected using these
assays and occurs over the course of about 6 days.
4.3.3 Ovine Lymphocyte Cultures
Ovine PBMC were isolated as before and cultured in duplicate in complete DMEM
(Negative), media containing 1 pg/ml ConA (Positive), media from M11V-ALHE
infected BHK-21 cells or media from MHV-76 infected BHK-21 cells. Viable cell
numbers, mean cell size and mean cellular DNA content in all samples were measured
using previously described methods at the time of isolation and after 72 or 120 hours
of incubation.
Viable cell counts (Figure 4.17 A), mean cell size (Figure 4.17 C) and mean cellular
DNA content (Figure 4.17 E) in positive (filled circles) and negative (filled squares)
controls are consistent with the findings of previous experiments. The samples
incubated in MFIV-ALHE infected BHK-21 cell media (open circles) and MHV-76
infected BHK-21 cell medium (open squares) behaved the same as negative controls
for all parameters measured. This indicates that no factors, or insufficient
concentrations of factors, are present in the supernatants ofMHV-ALHE or MHV-76
infected BHK-21 cell cultures that are able to activate ovine lymphocytes.
4.3.4 Bovine Lymphocyte Cultures
Bovine PBMC were isolated, cultured and analysed as described above for ovine
PBMC. Positive control samples (filled circles) showed a similar increase in viable
cell numbers (Figure 4.17 B), mean cell size (Figure 4.17 C) and mean cellular DNA
content (Figure 4.17 E) as ovine PBMC although the increases in mean cell size and
mean cellular DNA content were more transient and had returned close to baseline
levels by 120 hours. No increases in any of the parameters measured were seen in
either the samples incubated in MHV-ALHE infected BHK-21 cell media (open
circles) or those incubated with MHV-76 infected BHK-21 cell medium (open
squares) which both behaved the same as the negative controls (tilled squares)
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Figure 4.17. Ex vivo activation of ovine (A, C and E) and bovine (II, D and F)
peripheral blood mononuclear cells cultured in complete DMEM (a, negative
control), complete DMEM containing 1 gg/ml ConA (•, positive control), media
from MHV-ALHE infected BHK-21 cells (o) or media from MHV-76 infected
BHK-21 cells (□). Activation represented by viable cell number (A and B), cell
size (C and D) and DNA content (E and F).
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throughout the experiment. Like the ovine PBMC experiment, this indicates that no
factors, or insufficient concentrations of factors, are present in the supernatants of
MHV-ALHE or MHV-76 infected BHK-21 cell cultures that are able to activate
bovine lymphocytes.
4.3.5 Summary
To determine whether the left hand end region of A1HV-1 encodes any proteins
involved in the activation of lymphocytes, ovine and bovine PBMC were cultured in
media from MHV-ALHE infected BHK-21 cell cultures. No activation as measured
by proliferation, cell growth and increase in DNA content was seen in either ovine or
bovine samples incubated with this media. These results suggest that proteins
encoded by the in the left hand end of A1HV-1 do not activate lymphocytes, however
without specific reagents, it is not possible to confirm whether these proteins are even
present in the culture media.
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4.4 Yeast Two-Hybrid Screening
4.4.1 Aims
One of the main objectives of this study was the functional characterisation of the
protein products of the four left hand end ORFs of All IV-1. It was hoped that further
experiments could be performed on purified recombinant proteins expressed either in
mammalian or bacterial cells. However, as detailed above, problems with low
expression and/or degradation of these proteins precluded such studies. Instead,
attempts were made to identify proteins interacting with the ORF products using the
yeast two-hybrid system. This system allows for the screening of a large number of
target proteins without the need for purification and its high sensitivity means
interactions should be detected even if the ORFs are poorly expressed.
Experiments were performed using the Matchmaker 3 Two-Flybrid system
(Clontech). This system employs four separate reporter genes (H1S3 and ADE2 for
nutritional selection and MEL1 and lacZ for blue/white galactosidase selection) under
the control of three distinct GAL4 upstream activating sequences (UASs) and TATA
boxes (GAL1 UAS/GAL1 TATA for HIS3, GAL2 UAS/GAL2 TATA for ADE2 and
MEL1 UAS/MEL1 TATA for MEL1 and lacZ). Expressed sequences from A1HV-1
ORFs A2, A3 and A4 were cloned into the pGBK-T7 (GAL-4 binding domain, bait)
vector and used to screen a novel bovine cDNA library cloned, as described below in
Section 4.4.2, into the pGAD-T7 (activation domain, prey) vector.
4.4.2 Library Construction and Testing
A cDNA library was constructed using RNA extracted from freshly isolated bovine
PBMC and cultured bovine turbinate (BT) epithelial cells. These cell types were
selected as they are representative of the different cell types most likely to be involved
in MCF pathogenesis and are readily available. To account for the possibility that the
gene products would interact with other A1HV-1 proteins, half of the BT cells used
were infected with the pathogenic C500 strain of A1HV-1 48 hours prior to
harvesting. RNA was extracted separately from 108 freshly isolated PBMC and from
3.5x107 mixed infected and uninfected BT cells with RNAwiz (Ambion) as described
in Section 2.1.16. 40 pg of total RNA was isolated from the PBMC and 490 pg was
isolated from the mixed BT cells. The RNA samples were pooled and mRNA was
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purified from a 500 pg sample using the Poly(A) Purist Kit (Ambion) as described in
Section 2.1.19. 5.52 gg of mRNA was collected from this procedure and the entire
sample was used for cDNA synthesis and ligated into the pGAD-T7 vector following
the protocol described in Section 2.1.20.
XL-10 Gold Ultra competent cells (Stratagene) were transformed with the library
ligation mixture using the protocol described in Section 2.2.3 and plated onto fifteen
26.7 cm2 LB/Agar plates supplemented with 100 jig/ml of ampicillin. following
overnight incubation at 37°C colonies had grown to a density of approximately 100
per cm2 and, therefore, approximately 13,500 total colonies.
Twelve individual colonies were selected for screening to determine the quality of the
library. The colonies were grown in LB broth overnight and plasmid DNA was
extracted using the protocol described in Section 2.2.5. To determine the presence
and size of inserted sequences, plasmid DNA was used as template for the pGAD-T7
insert PCR reaction described in Section A 1.3.42 and also analysed by restriction
digestion using EcoK\ and Xhol restriction endonucleases. The results of colony
screening are summarised in Table 4.1. Plasmids from only 6 of the 12 colonies
selected were positive by PCR. By restriction digest analysis, the plasmid from one
of these colonies (colony 7) contained a fragment of the appropriate size for pGAD-
T7 (approximately 800 bp) but no insert. Another of the PCR positive plasmids
(colony 1) contained a fragment of approximately the same size as the PCR product
but the other fragment was not the correct size for pGAD-T7. Overall, 4 of the 12
colonies (colonies 2, 5, 10 and 11) contained appropriate library vectors. The insert
sizes of these colonies ranged from approximately 700 to 4000 bp. By extrapolation,
the library represented approximately 4,500 (one third of 13,500) good sequences.
Assuming all of these sequences have inserted in the correct orientation, it is likely
that only one in three will be inserted in frame to make with the GA1.-4 activation
domain sequence and many of these will be duplicates. Taken together, this leaves
the final complexity of the library at below 1,500 different fusion proteins. All
remaining colonies were pooled and library plasmid DNA was extracted using the
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4.4.3 Bait Construct Production and Testing
Coding sequences from ORFs A2, A3 and A4 were cloned into the pGBK-T7 vector
for expression as GAL4 binding domain fusion proteins to use for screening the
bovine cDNA library. The full length coding sequence of ORF A2 (2477-1799) was
amplified by PCR from A1HV-1 genomic DNA and cloned into pGEM-T Easy, but all
attempts to clone the sequence into pGBK-T7 were unsuccessful. To determine
whether the presence of the intron was responsible for the cloning difficulties, the
PCR was repeated using cDNA from MHV-ALHE infected BHK-21 cells as
template. Again this PCR product cloned into pGEM-T Easy but all attempts to clone
the sequence into pGBK-T7 failed. The next strategy was to clone overlapping
truncations of the ORF rather than the entire sequence. Sequences lacking 201 bp
(2000-1799) coding for 67 C-terminal amino acids (A2AC) or 280 bp (2477-2197)
coding for 66 N-terminal amino acids and the 82 bp intron (A2AN) were amplified
using the programs detailed in Sections A 1.3.19 and A 1.3.20. Again, cDNA from
MHV-ALHE infected BHK-21 cells was used as template as truncation of the
sequence could interfere with proper splicing of the A2AC product. Both sequences
were successfully cloned into pGBK-T7.
To increase the likelihood of ORF A3 and ORF A4 GAL4 binding domain fusion
proteins localising appropriately to the yeast nucleus, the coding sequences were
cloned lacking their predicted signal peptides. To determine the predicted location of
the signal peptides, ORF A3 and ORF A4 amino acid sequences were analysed using
the SignalP 3.0 software (http://www.cbs.dtu.dk/services/SignalP). The results for
ORF A3 and ORF A4 are shown in Figure 4.18. The s-score (green line) represents
the relative probability that the amino acid at that position is part of a signal peptide.
The c-score (red lines) represents the likelihood of cleavage occurring at t hat position.
The y-score (blue line) is derived from the c-score combined with the s-score to give
the best prediction for cleavage.
As shown in Figure 4.18 A, the ORF A3 amino acid sequence based on the originally
predicted start codon (Ensser & Fleckenstein, 1995) does not show a clear signal
peptide location. It has now been shown that translation of the protein begins at what
was thought to be the second methionine (Dr. Armin Ensser, Personal
Communication) and ORF A3 therefore shows greater N-terminal homology to the
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Figure 4.18. Signal peptide prediction results using SignalP 3.0 software for the N-
terminal of A) ORF A3 beginning with the methionine encoded by nucleotides
3492-3494, B) ORF A3 beginning with the methionine encoded by nucleotides
3633-3635 and C) ORF A4.
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other members of the semaphorin family than originally predicted (Knsser &
Fleckenstein, 1995). The sequence was resubmitted beginning instead with this start
codon. As shown in Figure 4.18 B, a high probability signal peptide is predicted
followed by three possible cleavage sites, the most likely occurring between S22 and
R23. To exclude this region, the ORF A3 sequence was amplified for cloning by
PCR using a forward primer with sequences from nucleotides 3717-3736 (A3ASP) as
detailed in Section Al.3.27. The PCR product was successfully cloned into pGBK-
T7.
The protein sequence encoded by ORF A4 beginning with the predicted start codon
(Ensser et al, 1997) (encoded by nucleotides 5732-5734) was also submitted for
signal peptide prediction. As shown in Figure 4.18 C, a high probability signal
peptide followed by a high probability cleavage between A24 and A25 was predicted.
To remove this region from the fusion protein, the ORF A4 sequence was amplified
for cloning by PCR using a forward primer with sequences from nucleotides 5822-
5839 (A4ASP) as detailed in Section A 1.3.32. The PCR product was successfully
cloned into pGBK-T7.
Diagrammatic representations of the coding sequences from ORF A2, ORF A3 and
ORF A4 that were used for the creation ofGAL4 binding domain fusion proteins are
shown in Figure 4.19 A with cross-hatched regions representing coding sequences
that were excluded from the final vectors. The A2AN, A2AC, A3ASP and A4ASP
vectors were transformed into AH 109 yeast using the protocol described in Section
2.3.2 for the first step of sequential library transformation and grown on SD-Trp
selection plates until colonies appeared. To determine whether any of the four binding
domain fusion proteins possessed any intrinsic GAL4 activating activily, colonies
were streaked onto SD-Trp plates supplemented with X-a-Gal. As shown in Figure
4.19 B, growth of all transformed yeast was seen. A blue colour, indicating a-
galactosidase activity, was seen in the A2AN transformed yeast. This shows that the
C-terminal portion of the ORF A2 gene product has the ability to activate
transcription of the MEL1 reporter gene in the absence of an interaction with the
GAL4 activation domain and therefore was unsuitable for further use in the library
screening.
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Figure 4.19. A) Diagrammatic representations of the coding regions of ORF A2,
ORF A3 and ORF A4 with nucleic acid coordinates. Hatched areas represent
regions not included in bait constructs. B) Growth of yeast transfected with
indicated bait constructs on SD-Trp/Agar plates supplemented with X-a-Gal.
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4.4.4 Library Screening
Library pGAD-T7 vectors were introduced to cultures of A2AC, A3ASP and A4ASP
transformant yeast colonies as described in Section 2.3.2. Library transformations
were plated on 15 high stringency (SD-Ade/-His/-Leu/-Trp) agar plates and incubated
at 30°C until clear colonies had formed. Colonies were subsequently grown for DNA
extraction either by replating an approximately 1 cm2 area on a high stringency plate
or by overnight growth in 2 ml of high stringency broth. If sufficient secondary
growth was seen, DNA was isolated from the yeast as described in Section 2.3.3. The
DNA was then used as a template for the pGAD-T7 PCR detailed in Section A 1.3.42
to amplify sequences inserted into the pGAD-T7 vector. PCR products from positive
reactions were sequenced either directly using the forward primer from the pGAD-T7
PCR as described in Section 2.1.13 or by first cloning the product into pGLM-T Easy
and subsequently sequencing from plasmid DNA as described in Section 2.1.12.
Direct sequencing has the advantages that it is less time consuming than first cloning
the PCR product and allows for the orientation of the product relative to the pGAD-
T7 vector but the disadvantage that a large proportion of the reactions returned
sequences that were unreadable. Returned sequences were submitted for analysis
using the NCBI nucleotide-nucleotide BLAST (http://www.ncbi.nlm.nih.gov/BLAST)
and TIGR Cattle Gene Index BLAST software (http://tigrblast.tigr.org/lgi). In most
cases, the interacting protein was assumed to be the product of the bovine gene with
the highest homology to the query sequence. Complete sequences returned from
successful sequencing reactions are presented in Appendix 4 and are summarised
below.
A2
A total of five colonies grew from the A2AC library screen. Of these, only three
showed sufficient secondary growth for DNA extraction. One of the three PCRs gave
no product (A2B3), one gave a single strong product (A2B4) and one gave multiple
weak products implying that it was a mixed colony (A2B5). Direcl sequencing
reactions from the three products of the A2B5 PCR returned unreadable results. The
sequence returned from the A2B4 PCR product sequencing reaction identilied the
gene as bovine amyloid beta precursor protein. However, this protein would not be
produced as a fusion with the GAL4 activation domain as the gene was inserted in the
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antisense orientation. No genes in the sense orientation with high homology to the
query sequence were found and the true amino acid sequence encoded was not
determined.
A3
Three colonies grew from the A3ASP library screen, all of which showed sufficient
secondary growth for DNA extraction. Two of the three PCRs gave strong single
products of unique molecular weights (A3B8 and A3B9) and one gave no product
(A3B7). The positive reactions were sequenced by first cloning into pGEM-T Easy as
the reactions were performed prior to use of the direct sequencing method. The
returned sequences were found to encode bovine type 111 pro-collagen (A3B8) and a
bovine gene similar to tenascin precursor. Collagen and tenascin are related structural
proteins and collagen-like proteins have been found to be a common class of false
positives in yeast two-hybrid screens owing to their ability to bind non-specillcally to
a wide range of proteins (www.biologicalprocedures.com/bpo/arts/1/16/m 16.htm).
Although the orientation of these sequences relative to the GAL4 activation domain
could not be determined due to the non-directional cloning of PCR products into
pGEM-T Easy, it is likely that these are the proteins encoded based on the large
number of similar sequence found in the correct orientation in the A4ASP screening
described below.
A4
Unlike the A2AC and A3ASP screens, a large number (over 160) of colonies grew in
the A4ASP library screen. Of the 160 colonies selected, 139 showed sufficient
secondary growth for DNA extraction and from these 67 PCRs gave at least one
product. From the first 58 colonies screened (A4B1 to A4B60), 15 PCRs gave
positive products. Restriction digest analysis using the frequent cutting Sau3AI
restriction endonuclease was used to eliminate replicate inserts. It was found that the
products amplified from colonies A4B5, A4B8 and A4B9 had identical restriction
patterns as did those of colonies A4B27, A4B30 and A4B32. All unique products and
one product from each replicate group (A4B5 and A4B30) were cloned into pGEM-T
Easy for sequencing. The genes corresponding to the returned sequences are shown
in Table 4.2. From the remaining 81 colonies screened (A4B61 to A4B160), 52 PCRs
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Colony Result
A4B1 Bos taurus COL1A2 mRNA for alpha2(l) collagen
A4B5 Bos taurus similar to tenascin
. A4B7 Bos taurus retina G protein-coupled receptor kinase 7 mRNA
A4B8 Bos taurus similar to tenascin
A4B9 Bos taurus similar to tenascin
A4B16 Bos taurus similar to pro alpha 1(1) collagen
A4B27 Bos taurus similar to tenascin
A4B28 Cloning vector psiLentGene Basic
A4B30 Bos taurus similar to tenascin
A4B32 Bos taurus similar to tenascin
A4B34 Bos taurus low molecular mass ubiquinone-binding protein mRNA
A4B40 Bos taurus similar to 40S ribosomal protein SI 6
A4B41 Bos taurus similar to eIF-3 pi 10 subunit
A4B50 Bos taurus similar to tenascin
A4B52 Bos taurus similar to Ubiquitin-like 1 activating enzyme El A
Table 4.2.
pGAD-T7
A4ASP library screening results obtained by pGEM-T Easy cloning of
Insert PCR products.
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gave positive products. Direct sequencing reactions were performed on all of these
products. Of the returned sequences, 21 were unreadable. The genes corresponding to
the returned sequences of the remaining 31 reactions are shown in Table 4.3.
The results of the A4ASP library screen are summarised in Table 4.4. The vast
majority of the returned sequences corresponded to tenascin (20 of 46) or collagen (10
of 46) related proteins. A number of other proteins belonging to groups that have
previously been shown to give false positive results (www.biologicalprocedures.com/
bpo/arts/l/16/m 16.htm) were also found. These include three members of the
ribosomal protein family (A4B40, A4B101 and A4B138), two proteins involved in
the ubiquitin/proteasome pathway (A4B34 and A4B52) and a matrix protein (matrix
metalloprotease, A4B116). One sequence was a contaminant (pSilenetiA4B) most
likely acquired while attempting to clone the PCR product into pGEM-T Easy.
The nine remaining sequences were considered genes of interest. Pour of these
sequences encoded nucleic acid binding proteins including three sequences from a
poly(rC) binding protein (A4B123, A4B134 and A4B151) and one from another
nucleic acid binding protein (A4B142). The other sequences showed homology to
retina G protein-coupled receptor kinase 7 (A4B7), a bovine gene similar to the eIF-3
pi 10 subunit (A4B41), tumor necrosis factor-receptor (TNFR) 1 (A4B82), GPAA1P
anchor attachment protein (A4B98) and the Ras related protein Rab-8A (A4B126).
Further study was performed on four of these colonies (A4B82, A4B98, A4B126 and
A4B151) as described in the following section. Although the sequence from A4B82
is 5' of the coding region for the TNFR-1 protein and the sequence for coding
GPAA1P in A4B98 is in the wrong orientation relative to GAL4 activation domain, it
was possible that novel amino acid sequences that bind the ORF A4 gene product
could be determined by their use.
4.4.5 Confirmation Experiments
The pGAD-T7 based vectors in colonies A4B82, A4B98, A4B126 and A4B151 were
isolated for use in confirmation experiments. Chemically competent F. coli were
transformed using the crude DNA preparations from these colonies and incubated on
LB/Agar plates supplemented with lOOpg/ml ampicillin. Colonies were selected for
plasmid DNA extraction. The presence of a plasmid consistent with the PCR
screening results was determined by restriction digest analysis using EcoRI irndXhol
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Colony Result Orientation
A4B62 Bos taurus similar to Tenascin precursor +
A4B80 Bos taurus collagen alpha 2(1) chain precursor +
A4B82 Bos taurus tumor necrosis factor-receptor 1 +
A4B83 Bos taurus similar to Tenascin precursor +
A4B86 Bos taurus COL1A2 mRNA for alpha2(I) collagen +
A4B96 Bos taurus similar to pro alpha 1(1) collagen +
A4B98 Bos taurus GPAA1P anchor attachment protein 1 homolog -
A4B101 Bos taurus similar to 60S ribosomal protein L22 -
A4B102 Bos taurus similar to pro alpha 1 (I) collagen +
A4B111 Bos taurus COL1A2 mRNA for alpha2(I) collagen +
A4B114 Bos taurus similar to Tenascin precursor +
A4B116 Bos taurus matrix metalloproteinase 2 +
A4B118 Bos taurus similar to pro alpha 1(1) collagen +
A4B123 Bos taurus similar to nuclear poly(C)-binding protein +
A4B126 Bos taurus Ras-related protein Rab-8A +
A4B129 Bos taurus similar to Tenascin precursor +
A4B131 Bos taurus similar to Tenascin precursor +
A4B132 Bos taurus similar to Tenascin precursor +
A4B134 Bos taurus similar to nuclear poly(rC)-binding protein +
A4B135 Bos taurus similar to Tenascin precursor +
A4B138 Bos taurus similar to 40S ribosomal protein S26 +
A4B142 Bos taurus similar to nucleic acid binding protein +
A4B143 Bos taurus similar to pro alpha 1(1) collagen +
A4B145 Bos taurus COL1A2 mRNA for alpha2(I) collagen +
A4B147 Bos taurus similar to Tenascin precursor +
A4B148 Bos taurus similar to Tenascin precursor +
A4B150 Bos taurus similar to Tenascin precursor +
A4B15I Bos taurus similar to nuclear poly(rC)-binding protein +
A4B154 Bos taurus similar to Tenascin precursor +
A4B157 Bos taurus similar to Tenascin precursor +
A4B158 Bos taurus similar to Tenascin precursor +
Table 4.3. A4ASP library screening results obtained by direct sequencing of
pGAD-T7 Insert PCR products. Orientation of insert relative to the GAL4
activation domain is indicated in the right hand column.
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Tenascin and Related 20
Collagen and Related 10
Nuclear Poly(rC)-Binding Protein 4
Ribosomal 3
Ubiquitin Pathway 2
Retinal G-Protein Coupled Receptor 1
Cloning vector psiLentGene Basic 1
eIF-3 pi 10 Subunit 1
TNF Receptor 1 1
GPAA1P Anchor Attachment Protein 1
Matrix Metalloprotease 1
Ras-related Protein Rab-8A 1
Table 4.4. Summarised results of the A4ASP library screen indicating probable
false positives (blue), a contaminant (red) and genes of interest (black).
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restriction endonucleases and by repeating the pGAD-T7 insert PCR with plasmid
DNA as template. Using this cloning strategy, the pGAD-T7 based plasmid from
A4B98 (pGAD98) was successfully isolated but attempts to directly isolate the other
three vectors were unsuccessful. Instead, the pGAD-T7 based vectors I'rom A4B82,
A4B126 and A4B151 (pGAD82, pGAD126 and pGAD151, respectively) were
recreated by cloning PCR products from the pGAD insert PCR screening of the
colonies into pGAD-T7 using £coRI and Xhol restriction endonucleases. All three
vectors were successfully recreated using this strategy.
Inserts in the pGAD82, pGAD98, pGAD126 and pGAD151 plasmids were sequenced
from the T7 promoter upstream of the multiple cloning site to reconlirm previous
findings and also to determine the reading frame relative to the GAL4 activation
domain and therefore the precise amino acid sequence translated. All four reactions
returned sequences consistent with previous results. Translated sequences of the
inserts determined from the reading frame of the GAL4 activation domain are shown
in Table 4.5 with the amino acids encoded by the vector shown in red and those
encoded by the insert shown in black. Although the inserted sequence of pGAD82
appeared to originate from mRNA for bovine TNFR1, it only encoded a further
fourteen amino acids when read in frame with the GAL4 activation domain and this
amino acid sequence showed no homology to know proteins using Protein-Protein
BLAST (http://www.ncbi.nlm.nih.gov/blast/Blast.cgi) analysis. Similarly, the
inserted sequence of pGAD98 encoded only five amino acids. In contrast, the inserts
in the pGAD126 and pGAD151 vectors encode fairly long polypeptides of 121 and
175 amino acids, respectively. Although a high degree of homology was found
between the nucleic acid sequence inserted in pGAD126 and the Rab 8A gene, very
little alignment between the translated sequence of the insert and any of the predicted
ORFs of Rab 8A was seen using the SIM Alignment software
(http://www.expasy.ch/tools/sim-prot.html) and no other proteins of high homology to
the translated sequence were found using Protein-Protein BLAST. As shown in
Figure 4.20, there is an almost total alignment between the translated insert of
pGAD151 and the bovine poly(rC) binding protein 2 with a four amino acid insertion
in pGADl 51 being the only difference.
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Table 4.5. Translated sequences of four inserts based on sequencing data using the
T7 primer site upstream of the multiple cloning site with vector encoded amino
acids shown in red and those encoded by the insert shown in black.
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Figure 4.20. Protein sequence alignment comparing the translated insert sequence
from the pGAD151 plasmid with the sequence from the bovine gene similar to
nuclear poly(rC)-binding protein.
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To confirm the interactions of the pGAD82, pGAD98, pGAD126 and pGAD151
encoded proteins with the ORF A4 product, AH 109 yeast containing the
pGBKA4ASP plasmid were transfected with the appropriate vector or empty pGAD-
T7 as a negative control. To test the specificity of the interactions, the pGAD vectors
were also transfected into AH 109 yeast containing empty pGBK-T7. Transfected
yeast were initially plated on low stringency (SD-Leu/-Trp) agar plates to allow for
growth of yeast containing both a bait and a prey plasmid regardless of interaction.
Colonies were then transferred to high stringency (SD-Ade/-His/-Leu/-Trp/+X-a-gal)
agar plates to determine whether any interaction between bait and prey proteins could
be detected. As shown in Figure 4.21 A, colonies containing all the bait/prey
combinations tested could be established and grown on low stringency plates.
Growth and a-galactosidase activity of the A4/151 yeast was seen on the high
stringency plates (Figure 4.21 B), but was also seen in the BK./151 yeast and is
therefore a false positive interaction. The other interactions tested were not
reproducible as no growth of the A4/82, A4/98 or A4/126 yeast was seen on the high
stringency plate. The lack of growth was not due to absence of the appropriate pGAD
plasmid as pGAD-T7 Insert PCR products of the appropriate sizes for pGAl)82 (-400
bp), pGAD98 (-850 bp) and pGAD126 (-450 bp) could be amplified from DNA
extracted from the colony used to inoculate the high stringency plate (Figure 4.21 C)
4.4.6 Summary
Bait constructs containing sequences from ORF A2 (A2AC), ORF A3 (A3ASP) and
ORF A4 (A4ASP) were produced and used to screen a novel bovine prey construct
library representing approximately 4,500 genes. Few colonies grew in the A2AC and
A3ASP library screens but a large number grew in the A4ASP screen. Of those
colonies from which the insert in the pGAD-T7 plasmid could be determined, the
majority contained sequences encoding proteins known to produce false positive
results. Four of the interactions from the A4ASP screen were carried forward for
further analysis and confirmation. One of these four was found to be a false positive
interaction and the remaining three interactions were not reproducible.
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Figure 4.21. Growth of yeast colonies transfected with the indicated bait and prey
vectors on A) low stringency (SD-Leu/-Trp) and B) high stringency (SD-Ade/-
His/-Leu/-Trp/+Xgal) agar plates. C) pGAD-T7 Insert PCR screening of DNA
extracted from yeast colonies transfected with the indicated bait and prey vectors.
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4.5 Discussion of In Vitro Experiment Results
A number of different experiments were undertaken to assess various biological
properties of the gene products of the LHE ORFs of A1HV-1. The expression of the
ORF products as fusion proteins in mammalian cells was used in an attempt to
determine the intracellular localisation or secretion of the proteins. The mammalian
cell expression system was also employed to assess the potential transcriptional
regulatory activity of the ORF A2 gene product. A bacterial system was also used for
the expression of ORF A2 as a means of producing large amounts of recombinant
protein and, although unsuccessful in this objective, provided data of possible
relevance to the mammalian expression results. Supernatants from BIIK-21 cell
cultures infected with the recombinant MHV-ALHE virus were used to study the
effects of secreted viral proteins, predicted to include the ORF A3 and ORF A4 gene
products, on bovine and ovine PBMCs. Finally, a yeast two-hybrid system was used
to screen a novel bovine cDNA library for proteins interacting with the I.HE ORF
gene products.
ORF A1 was successfully cloned for expression in mammalian cells as a ('-terminally
c-myc/6xFUS tagged fusion protein. No clear signal could be detected in transfected
cell cultures immunostained using the anti-c-myc antibody. There are several
possible reasons for the lack of detection. It is possible that the protein is not
produced or is secreted, but these are unlikely as the CMV IE promoter should ensure
a high level of constitutive expression and no conserved signal sequences were found
in the gene product. A more likely explanation is that protein is present in some of
the cells but at a low level, possibly due to degradation or poor translation of mRNA
or protein instability, and is therefore below the sensitivity of the detection protocol.
Mammalian expression of ORF A2 was more successful. ORF A2 gene products C-
terminally tagged with either c-myc/6xHIS or GFP showed localisation within the
nucleus of transfected cells but were preferentially excluded from nucleoli. N-
terminally GFP tagged ORF A2 gene products also showed nuclear localisation but
appeared to localise into nuclear aggregates. It was initially thought that the reason
for this apparent discrepancy was the presence of a large tag interfering with
appropriate localisation considering that the molecular weight of GFP is similar to
that predicted for the ORF A2 gene product. As the results obtained from bacterial
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expression of ORF A2 indicated that the gene product was rapidly cleaved, attempts
were made using a dual-tagged fusion protein to assess whether this was also the case
in mammalian cells and whether such cleavage could account for the discrepancy
between the localisation ofN- and C-terminally tagged fusion proteins. The results of
this study also supported a model in which proteolytic cleavage was involved. In
transfected cells expressing relatively low amounts of protein, both N-tcrminal GFP
signal and C-terminai c-myc staining localised within the nucleus but were excluded
from distinct areas, most likely nucleoli based on the findings of C-terminally GFP-
tagged fusion protein. Importantly, signals from the two termini did not completely
overlap, indicating cleavage. The difference in localisation of the GFP signal and c-
myc staining became more pronounced as the signal intensities increased, with the
GFP signal localising preferentially to areas within the nucleus from which the c-myc
staining was excluded. Although no direct evidence for proteolytic cleavage was
obtained due to the insufficient expression for detection by Western blot of any of the
ORF A2 fusion proteins, a cleavage model is the most rational explanation for the
observed results. Assuming that cleavage is involved, there remain several issues to
be addressed. Firstly, there is no indication of where and when the cleavage is
occurring. The issue of how the cleavage products localise separately also raises
several questions. For example, do the different cleavage products contain their own
localisation signals? As two distinct localisation patterns were seen using the same
construct, the possibility of a time or protein level effect on localisation would also
have to be addressed possibly using a construct under the control of an inducible
promoter. It is also possible that no cleavage of the ORF A2 gene product itself is
occurring and only the N-terminal GFP tag is cleaved and sequestered in nuclear
aggregates. However, without antibodies directed against specific epitopes of the
ORF A2 gene product it is not possible to analyse the true localisation of this protein
in the absence of any potentially artefactual results.
As the ORF A2 gene product was found to have nuclear localisation and has a
predicted basic leucine zipper motif (L23-Y76), it is likely to be a l)NA binding
protein and may function as a transcription factor, as originally predicted (Fnsser et
al. 1997). The possibility that this protein affects transcription from viral promoter
sequences was tested using a luciferase reporter system. The ORF A2 c-myc/6xHIS
construct was used for the production of ORF A2 gene product in BHK -21 cells and
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cultures were co-transfected with one of five reporter constructs containing promoter
sequences from selected immediate-early, early and late genes encoded by AIHV-1.
No change in transcription of the reporter gene was seen with any of the constructs in
the presence of ORF A2 gene product. This finding was not unexpected as it is not
confirmed that the protein is indeed a transcription factor and, assuming it is, the
promoter sequences tested represent a very small fraction of the sequences potentially
targeted including the remaining AIHV-1 promoters as well as those of Wildebeest
and species susceptible to MCF. As immediate-early ORF A2 transcripts were seen
in the context of the recombinant virus (Section 3.2.2), the most likely candidate
promoter sequences are those of the AIHV-1 early genes and these could serve as the
basis for future experiments.
It was hoped that the DNA binding ability of the ORF A2 gene product could be
assessed using purified recombinant protein. Unfortunately, insufficient protein could
be produced using the mammalian expression system and most of the protein
expressed in bacteria was cleaved and could not be cleanly immunoprecipilated from
cell lysates. One attempt was made to perform South-Western blot analysis using
DIG-labelled DNA to probe crude bacterial lysates electrophoresed and blotted under
both denaturing and non-denaturing conditions. No obvious binding was seen in
samples from pTH-FLAG-A2c transformed cultures versus those transformed with
empty pTrcHis2 A (data not shown), although the quality of the assay could not be
established as appropriate controls were not readily available. To overcome some of
the problems experienced during these experiments, the production of protein could in
future be carried out in bacterial strains better optimised for recombinant protein
production (such as BL21 or Rosetta) and express a known DNA binding fusion
protein in parallel as a control. With sufficient protein amounts expressed, problems
arising from the low sensitivity of detection and purification should be more easily
resolved.
Mammalian expression experiments failed to demonstrate the predicted secretion of
either ORF A3 or ORF A4. The GFP signals in cells transfected with N-terminal
fusions of both the ORF A3 and ORF A4 gene products were seen throughout the cell
in a pattern indistinguishable from that of GFP expressed alone. Western blot
analysis showed that, in cells transfected with the ORF A3 construct, the expressed
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fusion protein is of a molecular weight identical to GFP alone. Possible explanations
for this finding include the incomplete translation of the fusion protein or cleavage of
the GFP tag from the ORF A3 gene product, possibly occurring during secretion.
Some of this product was also found in concentrated supernatant samples but this is
likely to be indicative of cellular contamination or release from dead or dying cells
rather than true secretion as the same was seen using GFP alone. N-terminally tagged
ORF A4 was not detected by Western blot most likely due to lower transfection
efficiency although it would probably give results analogous to ORF A3 if the fusion
protein were similarly cleaved or incompletely translated as is suggested by the
localisation. One would predict that C-terminal fusion proteins of theses two gene
products would localise more appropriately as the tags would be more distant from
the predicted signal sequences and therefore less likely to interfere with secretion or
be cleaved. Unfortunately, attempts to clone C-terminally tagged ORF A3 fusion
proteins were unsuccessful. C-terminally GFP and c-myc/6xFIIS tagged ORF A4
constructs were successfully cloned but no signal or staining could be detected in
transfected cells or their culture supernatants although this may simply represent a
lack of sensitivity of the detection assays used.
As potentially secreted proteins, it was thought that the ORF A3 and ORF A4 gene
products could exhibit biological effects on lymphocytes, contributing to the
lymphoproliferation and immune disregulation seen in MCF. To test this hypothesis,
PBMCs of ovine and bovine origin were cultured in media predicted to contain these
proteins. As insufficient protein levels could be produced and secretion could not be
demonstrated using plasmid vector based expression of tagged fusion proteins, the
recombinant MHV-ALF1E virus was used for highly efficient gene delivery to BHK-
21 cells for expression. This system had the advantage that the efficiency of gene
delivery should be almost 100% but did have some drawbacks. The major
disadvantage is that there was no way to confirm the presence of the gene products in
the supernatants without specific reagents, although previous experiments had
demonstrated expression to the mRNA level in similar cultures. To address the
possibility that MHV encoded genes or other factors secreted by infected cells could
also have effects on the PBMCs, supernatants from MHV-76 infected B1IK-21 cell
cultures were used as controls. No change in the proliferation of PBMC cultures of
ovine or bovine origin were seen in the presence of supernatants from cell cultures
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infected with either MHV-ALHE or MHV-76, as measured by cell number, cell size
and DNA content. It is possible that the lack of an effect is due to the absence ofORF
A3 and ORF A4 gene products in the supernatants as the translation and secretion of
these proteins could not be conclusively demonstrated. Assuming the proteins are
present, it is entirely possible that they would have an effect on the PBMCs other than
the induction of proliferation or have effects on entirely different cell types.
In an attempt to identify proteins interacting with the ORF A2, ORF A3 and ORF A4
gene products, the yeast two-hybrid system was used for several reasons. Firstly, it
requires no purification of recombinant proteins which had proven difficult for the
gene products to be analysed. Secondly, due to the high sensitivity of this assay,
protein interactions should be detectable even if fusion proteins are poorly expressed
or rapidly degraded as had been suggested by previous findings. Lastly, as little is
known about the ORF gene products in question, it provided a useful tool for
screening a large number of potential interactions without the need for prior
prediction of possible functions. In order to perform these screens, it was first
necessary to produce a prey library and bait constructs. The prey library was
composed of cDNAs from different bovine cell types that may be involved in MCF
pathogenesis i.e. turbinate cells and PBMCs. As it is possible that the gene products
of interest interact with other virally encoded proteins, half of the BT cells used were
infected with A1HV-1. It was hoped that a 1:1 mixture of PBMC and BT RNA would
be used for construction of the library. However, using the RNA isolated this would
have resulted in a maximum starting sample of only 80 ng which, based on pilot
mRNA isolation, would have yielded insufficient mRNA for cDNA synthesis.
Therefore, an approximately 1:11 mixture of PBMC and BT RNA was used.
Approximately 13,500 colonies grew from the library transformation but analysis of
plasmid DNA extracted from randomly selected colonies indicated that a high
percentage contained either empty vector (-17%) or plasmids having a restriction
digest profile inconsistent with that of pGAD-T7 (-50%). Taking together with the
with the fact that about two thirds of these inserts will not be in frame and there is
likely to be a large proportion of duplicate sequences, this implied that only around
750-1,500 genes were appropriately represented by this library. This number is very
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small compared to commercially available libraries and although sufficient for a small
pilot study was unlikely to identify any specific interactions.
Several issues complicated the construction of an ORF A2 bait vector with which to
screen the library. Numerous attempts to clone the full length ORF as a GAL4
binding domain fusion protein, either from viral genomic DNA or cDNA lacking the
intron were unsuccessful. It was initially thought that the cloning difficulty may be
due to incompatibility between insert and plasmid DNA sequences; however, this is
unlikely as two overlapping truncations of this ORF cloned successfully on the first
attempt. Of these two constructs, the one producing a fusion protein lacking 66 N-
terminal amino acids of the ORF A2 gene product (A2AN), but not the one producing
a fusion protein lacking 67 C-terminal amino acids (A2AC), showed auto-activation
of the lacZ reporter gene indicating possible transcriptional activity in the C-terminal
portion of the gene product. It is known that highly acidic proteins can show such
activity, however, analysis of the protein sequence indicated that the C-terminal
portion does not contain a very large percentage of acidic residues or at least no
higher than the N-terminal portion. Taken together, these results suggest that the C-
terminal portion of the ORF A2 gene product contains a domain, or domains, capable
of specifically interacting with DNA or DNA binding proteins, a finding consistent
with the predicted role of this gene product as a transcription factor. The construction
of ORF A3 and ORF A4 bait vectors was comparatively straightforward. Both were
successfully cloned using primers designed to exclude the predicted signal peptides,
so as to minimize the possibility of cleavage from the GAL4 binding domain or
inappropriate localisation.
Library screening transformations were carried out using the A2AC, A3ASP and
A4ASP construct bait vectors. Compared with the library co-transfeclion using the
A4ASP construct, very few colonies grew from those using the A2AC and A3ASP
constructs. It is possible that this difference was simply due to a much higher
transfection efficiency being achieved with the A4ASP containing yeast. It is also
possible that the ORF A4 gene product exhibits more non-specific binding than those
of ORF A2 and ORF A3. The vast majority of interacting inserts sequenced in all
library screens were for collagen and tenascin related structural proteins. This finding
may be indicative of over-representation of these genes in the library, possibly due to
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high levels of expression in source cells, most likely BTs. Of the potentially
interesting proteins interacting with the ORF A4 construct, many were intracellular
proteins which were unlikely to be true positives as the ORF A4 gene product is
predicted to be secreted. Indeed, one of these interacting proteins, a nuclear poly(rC)
binding protein, was shown to be a clear false positive in follow-up experiments.
Three other interactions were found to be irreproducible. One possible explanation
for this finding is that the colonies containing these plasmids that grew in the original
library screen contained other prey vectors responsible for the growth, either through
auto-activation or a true interaction with the ORF A4 gene product, but present at low
levels and, therefore, not detected by insert screening PCR or rescued by bacterial
transformation with extracted yeast DNA. It is also possible that proteins produced
from other prey vectors could have interacted with both the ORF A4 fusion protein
and the cloned prey fusion protein and without this binding intermediate, the
interaction could not be reproduced. For either of these occurrences to have taken
place in three out of the four colonies tested does seem unlikely although no other
rational explanation can be found.
In summary, experiments using tagged ORF A2 gene product consistently found
nuclear localisation in mammalian cells. This finding supports the prediction that this
protein is a transcription factor although attempts to verify this were unsuccessful.
Cleavage of this protein was seen during bacterial expression and is also likely to
occur in mammalian cells. Attempts to demonstrate the secretion of ORF A3 and
ORF A4 gene products were unsuccessful and hindered by the low transfection
efficiency of plasmids, insensitivity of detection assays and inability to clone select
constructs. Assuming that these proteins are secreted in sufficient quantities from
B11K-21 cells infected with the recombinant MF1V-ALHE virus, they have no effect
on the proliferation of ovine and bovine PBMCs. A yeast two-hybrid system was
employed to screen a novel bovine cDNA library for proteins interacting with the
gene products of ORF A2, ORF A3 and ORF A4. Although no specifically
interacting proteins could be identified and confirmed, analysis of the bait constructs
used indicated that there is a domain or domains in the C-terminus of the ORF A2
gene product capable of interacting with DNA or DNA binding proteins.
Chapter 5: Conclusions
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The primary objective of this study was the production of a recombinant virus
containing the LHE ORFs of AIHV-1 in MHV-76 to use as a tool for the study of the
role of these genes in viral pathogenesis in vivo. This virus was successfully created
and upon initial investigation appeared to be appropriate for in vivo study as the ORFs
were expressed from their cognate promoters in the context of murine cells and the
recombinant virus did not show any overt changes in its ability to replicate. 1 lowever,
no differences in viral pathogenesis between the recombinant and wild-type viruses
were seen in mice infected via either the intranasal or intraperitoneal route. Without
specific antibodies to the AIHV-1 gene products, there is no way to conclusively
determine whether lack of protein is responsible for the lack of phenotype although
this is unlikely as transcripts for three of the genes could be found in infected lungs.
Assuming that the gene products are present, it is unknown whether these proteins are
able to interact with the murine or MHV counterparts of their natural targets found in
wildebeest or AIHV-1. A lack of such interaction may also account for the inability
of AIHV-1 to infect mice (Jacoby et al., 1988b).
The lack of phenotype is similar to the findings of other studies using recombinant
MHV-76 viruses into which genes from other herpesviruses had been inserted (Brass,
2004; Hindley, 2005; Sacco, 2003). These studies also found little difference between
viral pathogenesis of the recombinant and wild-type or marker control viruses. Taken
together, the results of this and previous studies suggest that the use of MHV-76
recombinants, while a powerful strategy in theory, may not be the best approach to
studying the pathogenesis genes of foreign herpesviruses.
Although not possible at the outset of this project, the creation of a deletion mutant
lacking the LHE ORFs using the recently created AIHV-1 BAC (Dewals el al., 2006)
would be a much better system to assess the contribution of these genes to
pathogenesis. Being of AIHV-1 background, such a virus could be used in more
biologically relevant animal species that are known to develop MCF, ideally cattle but
also small laboratory animals such as rabbits and hamsters.
One notable finding from this part of the study was the expression of ORF Al in the
context of a recombinant virus. If this gene is indeed part of a larger transcript, as has
been suggested (Dr. David Haig, Personal Communication), then this finding
indicates that either it can be expressed alone or the other sequences to which it is
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associated are present in the recombinant virus or can be substituted for by sequences
present in MHV-76. It may be of interest in the future to further analyse the ORF A1
transcripts produced from the recombinant virus, possibly by Northern blot and
eventually cloning, to determine their precise nature.
The secondary objective of this project was to gain functional information about the
LHE gene products from their expression in a variety of in vitro systems. This proved
to be less straightforward than initially predicted due to complications arising from
low expression, inefficient detection and the apparent instability of certain fusion
proteins. Although no conclusive functional data was generated from these studies, a
number of interesting properties of the ORF A2 gene product were found.
The results from several of the studies using the ORF A2 gene product are consistent
with the possibility that this protein is able to interact with DNA or DNA binding
proteins. It is of interest to note that the C-terminal portion of the protein which had
transcriptional activity in the yeast two-hybrid system is likely to be same portion of
the protein which consistently localised to the area of the nucleus, outside the
nucleolus, containing the DNA where transcription occurs. This finding should assist
with functional mapping of the protein and provide an initial target around which to
design truncated or mutated recombinant proteins for future investigation.
In conclusion, while this study has not provided any conclusive data on the functions
of the A1HV-1 LHE ORFs and their role in viral pathogenesis, it has raised a number
of interesting issues concerning these genes and generated results that may support or
provide a starting point for future experiments. In addition, a number of the reagents
generated throughout this study, including the recombinant virus, the bovine cDNA
library and a number of the expression vectors, could prove useful in other
investigations.
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A1.1 Recipes
A. Expand Long-Template PCR System
1 Ox Buffer 3 5pl
dNTP (lOmM) 1.75pl
Primer 1 (0.1 pg/pl) 1 pi
Primer 2 (0.1 pg/pl) lpl
Template DNA * pi
Enzyme Mix 0.75pl
Milli-Q H2Q to 50pl
B. Taq DNA Polymerase (Roche)
lOx Buffer + MgCE 5pl
dNTP(lOmM) lpl
Primer 1 (0.1 pg/pl) lpl
Primer 2 (0.1 pg/pl) lpl
Template DNA * pi
Taq DNA Polymerase lpl
Milli-Q H2O to 50pl
C. Taq DNA Polymerase (Invitrogen)




pGADfor Primer (0.1 pg/pl) lpl
pGADrev Primer (0.1 pg/pl) Ipl
Template Yeast Colony DNA 5pl
Taq DNA Polymerase 0.5pl
Milli-Q H20 33 pi
Note: Template DNA volumes (*) varied according to template concentrations and
the requirements of specific reactions and are listed below. Milli-Q LEO volumes
were adjusted accordingly.
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A1.2 Reaction Conditions
Pre-Heat 94°C 10 sec
94°C Hold
Initial Denaturing 94°C 2 min
Denaturing 94°C 10 sec
Annealing * °c 30 sec
Extension 68°C * min
Final Extension 68°C 7 min
4°C Hold
Pre-Heat 95°C 10 sec
95°C Hold
Initial Denaturing 95°C 3 min
Denaturing 94°C 10 sec
Annealing 55°C 45 sec
Extension 72°C 45 sec
Final Extension 72°C 7 min
4°C Hold
Note: Annealing temperatures, extension times and cycle numbers (*) varied
according to the requirements of specific reactions and are listed below.
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A1.3 Specific Reaction Details
Al.3.1





Template DNA: lpl A1HV-1 genomic DNA
Reaction Conditions: A
Annealing Temperature: 60°C
Extension Time: 4 min 20 sec
Cycle Number: 30
Al.3.2





Template DNA: lOpl crude plaque lysate
Reaction Conditions: A
Annealing Temperature: 58°C
Extension Time: 1 min
Cycle Number: 35
Al.3.3





Template DNA: lpl genomic viral DNA
Reaction Conditions: A
Annealing Temperature: 58°C
Extension Time: 1 min
Cycle Number: 35
Al.3.4





Template DNA: lpl infected BHK-21 cDNA
Reaction Conditions: A
Annealing Temperature: 58°C
Extension Time: 1 min
Cycle Number: 35
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Al.3.5




Primer 2: A1 rev+Hind
Template DNA: Ipl lung or spleen cDNA (first round), lpl first reaction (second
round)
Reaction Conditions: A (2 Rounds)
Annealing Temperature: 58°C
Extension Time: 1 min
Cycle Number: 40
Al.3.6





Template DNA: lpl AIF1V-1 genomic DNA
Reaction Conditions: A
Annealing Temperature: 58°C
Extension Time: 1 min
Cycle Number: 30
Al.3.7





Template DNA: lOpl crude plaque lysate
Reaction Conditions: A
Annealing Temperature: 50°C
Extension Time: 1 min
Cycle Number: 35
Al.3.8





Template DNA: lpl genomic viral DNA
Reaction Conditions: A
Annealing Temperature: 50°C
Extension Time: 1 min
Cycle Number: 35
Appendix 1 PGR Programs
Al.3.9
ORF A2 (2490-1799, in vitro RT-PCR)
Recipe: B
Product Size: 707 (625 spliced)
Primer 1: A2_for+Nhe
Primer 2: A2_rev+Bam
Template DNA: lpl infected BHK-21 cDNA
Reaction Conditions: A
Annealing Temperature: 50°C
Extension Time: 1 min
Cycle Number: 35
Al.3.10





Template DNA: 2pl lung or spleen cDNA (first round), 1 pi first reaction (second
round)
Reaction Conditions: A (2 Rounds)
Annealing Temperature: 50°C
Extension Time: 1 min
Cycle Number: 40
Al.3.11





Template DNA: lpl AIHV-1 genomic DNA
Reaction Conditions: A
Annealing Temperature: 50°C
Extension Time: 1 min
Cycle Number: 30
Al.3.12





Template DNA: Ipl AIHV-1 genomic DNA
Reaction Conditions: A
Annealing Temperature: 50°C
Extension Time: 1 min
Cycle Number: 30
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Al.3.13
ORF A2 cDNA (2477-1794. pEGFP-Cl Cloning)
Recipe: A
Product Size: 699 (617 spliced)
Primer 1: A2_for+Bgl
Primer 2: A2_rev2+Hind
Template DNA: lpl infected BHK-21 cDNA
Reaction Conditions: A
Annealing Temperature: 48°C
Extension Time: 1 min
Cycle Number: 35
Al.3.14
ORF A2 cDNA (2477-1798, pEGFP-Nl Cloning)
Recipe: A
Product Size: 695 (613 spliced)
Primer 1: A2_for+Bgl
Primer 2: A2_rev2+Bam
Template DNA: lpl infected BHK-21 cDNA
Reaction Conditions: A
Annealing Temperature: 48°C
Extension Time: 1 min
Cycle Number: 35
Al.3.15
ORF A2 cDNA (2474-1799, pTrcHis2 A Cloning)
Recipe: A
Product Size: 691 (609 spliced)
Primer 1: A2_for_TH-Xho
Primer 2: A2_rev_TH-Hind
Template DNA: lpl infected BHK-21 cDNA
Reaction Conditions: A
Annealing Temperature: 50°C
Extension Time: 1 min
Cycle Number: 35
Al.3.16





Template DNA: pEGFP-Nl-A2cDNA plasmid
Reaction Conditions: A
Annealing Temperature: 48°C
Extension Time: 1 min
Cycle Number: 40
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Al.3.17





Template DNA: pTH-GFPA2c plasmid
Reaction Conditions: A
Annealing Temperature: 56°C
Extension Time: 1 min
Cycle Number: 35
Al.3.18





Template DNA: pEGFP-Cl-A2cDNA plasmid
Reaction Conditions: A
Annealing Temperature: 48°C
Extension Time: 1 min
Cycle Number: 40
Al.3.19
ORF A2AC (2477-2000, N-term pGBK-T7 Cloning)
Recipe: A
Product Size: 41 1
Primer 1: A2_for+Nde
Primer 2: A2i_rev+Bam
Template DNA: lpl infected BF1K-21 cDNA
Reaction Conditions: A
Annealing Temperature: 50°C
Extension Time: 1 min
Cycle Number: 35
Al.3.20





Template DNA: lpl infected BHK-21 cDNA
Reaction Conditions: A
Annealing Temperature: 50°C
Extension Time: 1 min
Cycle Number: 35
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Al.3.21





Template DNA: lpl genomic viral DNA
Reaction Conditions: A
Annealing Temperature: 58°C
Extension Time: 1 min
Cycle Number: 35
Al.3.22





Template DNA: lOpI crude plaque lysate
Reaction Conditions: A
Annealing Temperature: 58°C
Extension Time: 1 min
Cycle Number: 35
A 1.3.23





Template DNA: lpl infected BHK.-21 cDNA
Reaction Conditions: A
Annealing Temperature: 58°C
Extension Time: 1 min 30 sec
Cycle Number: 35
Al.3.24





Template DNA: 1 pi lung or spleen cDNA (first round), 1 pi first reaction (second
round)
Reaction Conditions: A (2 Rounds)
Annealing Temperature: 58°C
Extension Time: 1 min
Cycle Number: 40
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Al.3.25





Template DNA: lpl A1HV-1 genomic DNA
Reaction Conditions: A
Annealing Temperature: 56°C
Extension Time: 2 min
Cycle Number: 30
Al.3.26





Template DNA: lpl AIHV-1 genomic DNA
Reaction Conditions: A
Annealing Temperature: 56°C
Extension Time: 2 min
Cycle Number: 30
Al.3.27





Template DNA: lpl A1F1V-1 genomic DNA
Reaction Conditions: A
Annealing Temperature: 56°C
Extension Time: 1 min 30 sec
Cycle Number: 30
Al.3.28




Primer 2: A4 rev+Hind
Template DNA: lOpI crude plaque lysate
Reaction Conditions: A
Annealing Temperature: 62°C
Extension Time: 1 min
Cycle Number: 35
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Al.3.29





Template DNA: Ipl genomic viral DNA
Reaction Conditions: A
Annealing Temperature: 62°C
Extension Time: 1 min
Cycle Number: 35
Al.3.30





Template DNA: lpl infected BHK-21 cDNA
Reaction Conditions: A
Annealing Temperature: 62°C
Extension Time: 1 min
Cycle Number: 35
Al.3.31





Template DNA: 1 pi lung or spleen cDNA (first round), 1 pi first reaction (second
round)
Reaction Conditions: A (2 Rounds)
Annealing Temperature: 62°C
Extension Time: 1 min
Cycle Number: 40
Al.3.32





Template DNA: lpl A1F1V-1 genomic DNA
Reaction Conditions: A
Annealing Temperature: 62°C
Extension Time: 1 min
Cycle Number: 30
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Al.3.33





Template DNA: lpl A1F1V-1 genomic DNA
Reaction Conditions: A
Annealing Temperature: 58°C
Extension Time: 1 min
Cycle Number: 35
Al.3.34





Template DNA: lpl A1HV-1 genomic DNA
Reaction Conditions: A
Annealing Temperature: 56°C
Extension Time: 1 min
Cycle Number: 30
Al.3.35





Template DNA: lOpl crude plaque lysate (first round), lpl first reaction (second
round)
Reaction Conditions: B (2 Rounds)
Cycle Number: 40
Al.3.36





Template DNA: lpl genomic viral DNA (first round), lpl first reaction (second
round)
Reaction Conditions: B (2 Rounds)
Cycle Number: 40
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Al.3.37
ORF A4/M4B (Recombinant Virus Analysis)
Recipe: B
Product Size: 788
Primer 1: A4_for+Nhe 1
Primer 2: M4B
Template DNA: lpl genomic viral DNA
Reaction Conditions: A
Annealing Temperature: 62°C
Extension Time: 1 min 30 sec
Cycle Number: 35
Al.3.38














Template DNA: 1 pi lung or spleen cDNA (first round), 1 pi first reaction (second
round)
Reaction Conditions: B (2 Rounds)
Cycle Number: 40
Al.3.40





Template DNA: 1 pi (lung) or 5p! (spleen) cDNA
Reaction Conditions: B
Cycle Number: 40
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Al.3.41





Template DNA: pEGFP-Cl plasmid
Reaction Conditions: A
Annealing Temperature: 56°C













A1 for+Xba GGT CTA GAC CTT CAT GAG GCT ACA TTT TC
A1 rev+Hind GGA AGC TTT TTT GTG GTG TCT TCA TTT GC
A2 for+Bgl GAA GAT CTA TGT CCC AAA ACT CAA ATT C
A2 for+Nde GGC ATA TGA TGT CCC AAA ACT CAA ATT C
A2 for+Nhe GGG CTA GCC AAA TCC TCA AAA ATG TCC C
A2 for RT CAA CAA GAA AAA GGG CTG
A2 for TH+Xho GGC TCG AGA TCC CAA AAC TCA AAT TCT GA
A2i for+Nde GGC ATA TGC TGC GAT GCC AAG TGG
A2 rev+Bam GGG GAT CCT AAA TTG TAC AAG TTG TTC C
A2 rev2+Bam GGG GAT CCC ATA AAT TGT ACA ACT TGT TC
A2 rev2+Hind GGA AGC TTT TAT AAA TTG TAC AAG TTG T
A2 rev RT GTG TGT AAG GTA GCT GTT GC
A2 rev TH+Hind GGA AGC TTT AAA TTG TAC AAG TTG TTC C
A2i rev+Bam GGG GAT CC TTT AAG TTG TTA GTT GTA TAC
A3 for+Bgl GGA GAT CTA TGG CCT ACT TAA ATG CTA C
A3 forA75 GGC ATA TGA GGC TGA TTG TTA ACC TAA C
A3CTscr for CAC TAT GCT CCA ACT GTG G
A3scr for CTT AGC CCC CTT CTC ACC AT
A3 rev+Eco GGG AAT TCA CAT CAG TGT CAC ATT CAC CTC
A3C rev+Sal GGG TCG ACT GTT ACA TCA GTG TCA CAT TC
A3scr rev CCT GCC CCA CTC TAG GTA CA
A4 for+Bgl GGA GAT CTA TGG TTG CTC AGC TCT ACC
A4 for+Nhe GGG CTA GCC ATG GTT GCT CAG CTC TAC C
A4 forASP GGC ATA TGG ATG ATG AAG AGG ACT TC
A4 rev+Bam GGG GAT CCT TAT GGT ATT GCT GAT GGT AG
A4 rev+Hind GGA AGC TTT GGT ATT GCT GAT GGT AGT AC
AHV LHE for+Sal GGG TCG ACG CAC TTT TCT GGC TCT CTG G
AHV LHE rev+Xba GGT CTA GAT ACT GTG GCC TGT GGT TAG C
B-actin-for CGA GCA CAG CTT CTT TGC AG
B-actin-rev GCC AAT AGT GAT GAC CTG GC
GFP for+Xho GGC TCG AGA ATG GTG AGC AAG GGC GAG G
GFP rev+Hind GGA AGC TTT TAC TTG TAC AGC TCG TCC A
MHV ORF 50 for AGG GCT AAT GGG TGA AAA TGG C
MHV ORF 50 rev AAA AGT TCT GCA TCC CAG ACC C
M4B CGC GGA ATT CGG TTC TAG AAA GTC ATA AAT(TC AAT ACC
pGAD-for TAC GAC GTA CCA GAT TAC GC
pGAD-rev TCA GTA TCT ACG ATT CAT CTG C
Trepeat GCG CAA GGA GGA GCT AGG CCA CG
Sequences in red indicate inserted restriction endonuclease sites.








































1 672 80.74 0.020708
1.979 95.72 0.020675
1.195 98.2 0.012169
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The sequence to investigate:
10 20 30 40 50 60
MSQNSNSESP SPRKKRYVKM CDLTEEQKER RRSINRRASK NFLKRRRIFE EQOKKGKIRI
70 ' 80 90 100 110 120
LREWLNYHKC TTLQNYNTGP PEPRVKVENS LEMQCATAFL NLDQQYTTNN LN1 PET'/SGN
130 140 150 160 170
NTTNGFAAAT ATLHTNCYEK TLANNTNNFE AKLNCEVLPS FTSALDDLLS IDWIINI.YNL


















These enzymes cleave the sequence:
i .\P;i\v Peptide < ill!!" Results
Arg-C proteinase 13 13 16 30 31 32 36 37 45 46 47 59 62 84




7 21 24 25 28 49 50 53 56 62 81 87 91 102 114 138 149 155
165 166 171
BNPS-Skatole 2 64 173
CNBr 3 1 20 93
Chymotrvpsin-high
specificity (C-term to
TFYW1, not before P)






1 17 20 23 42 43 49 61 64 65 67 68 73 76 91 93 99 100 102
106 111 126 133 134 138 142 149 153 161 165 168 169 173
176 177 179
Clostripain 13 13 16 30 31 32 36 37 45 46 47 59 62 84
Glutamyl
endopeptidase
16 8 25 26 29 50 51 54 57 63 82 88 92 115 139 150 156
Hydroxylamine 1 124
Iodosobenzoic acid 2 64 173
LvsC 11 14 15 19 28 40 44 55 69 86 140 152
LvsN 11 13 14 18 27 39 43 54 68 85 139 151
NTCB (2-nitro-5-
thiocyanobenzoic acid)
5 20 69 94 136 154
Pepsin (pH1.3) 52
22 23 41 43 60 63 65 66 67 72 73 75 76 90 01 08 99 99 100
101 102 105 106 110 111 125 126 132 133 137 138 141 148
149 152 153 158 161 164 165 167 168 168 160 172 173 175
176 176 177 178 179
Pepsin (pH>2) 39
22 23 41 43 60 65 72 73 90 91 98 99 99 100 101 102 110 111
125 126 132 133 141 148 149 152 153 158 161 164 165 167
168 168 169 175 176 178 179
Proteinase K 69
17 18 23 24 34 3842 43 48 49 58 6061 64 65 67 71 72 73 76
78 85 87 91 96 97 98 99 100 102 106 107 108 111 113 116 117
122 123 126 127 128 129 130 131 132 133 135 138 141 142
143 146 149 151 153 157 158 161 162 164 165 168 169 171
173 176 177 179
Staphylococcal
peptidase I
14 8 25 29 50 54 57 63 82 88 92 115 139 150 156
Thermolysin 39
17 19 33 37 41 42 47 48 59 60 64 72 84 86 00 05 97 98 99 101
110 116 125 126 127 128 130 132 141 142 148 152 160 163
164 168 170 175 178
Trypsin 22


















AspGluN Ch hi Ch lo ProtK
ProtK Therm




Ch lo LysN Pnl.3 Pn2 ProtK


















Ch lo Pnl.3 Pn2 ProtK
Pnl.3 Pn2
AspN AspGluN
CNBr Ch lo NTCB
LysC Therm Tryps
LysN ProtK




ArgC Clost LysN Tryps
Glu Staph
AspGluN|
CNBr Ch lo ||
I I I
MSQNSNSESPSPRKKRYVKMCDLTEEQKERRRSINRRASKNFLKRRRIFEEOfEKCI-i





Ch lo Pnl.3 Pn2 ProtK
Pnl.3 Pn2 Therm
ProtK
Ch hi Ch lo Pnl.3 ProtK
AspN AspGluN Ch lo Pnl.3 Pn2 ProtK
Pnl.3 Pn2 Therm
Ch lo Pnl.3 Pn2 ProtK
Ch hi Ch lo Pnl.3 Pn2 ProtK Therm











ArqC Clost Therm Tryps
Glu Staph
AspGluN
Ch hi Ch lo Pnl.3 ProtK
Ch lo Pnl.3 Pn2 ProtK
Pnl.3 Pn2 ProtK Therm
LysC NTCB Tryps
Ch lo LysN
Ch hi Ch lo Pnl.3 ProtK
Pnl.3
Ch lo Pnl.3 Pn2 ProtK
BNPS Ch hi Ch lo Iodo ProtK Therm I
Glu Pnl.3 Staph 1 I
ArqC AspGluN Clost TrypsI I I
Ch lo ProtK|I||
I I I I I I
LREWLNYHKCTTLQNYNTGPPEPRVKVENSLEMQCATAFLNLDQQYTTNNLNI
Appendix 3 LxPasy Peptide ( niler Results
Pnl.3 Pn> Th«-
Ch hi Ch lo Pnl.3 l-roi
Ch lo Pnl.3 Pn2 mi Y
Pnl.3 Pn2 T
BNPS Ch hi Ch lo Iodo Pnl.3 Pro Y | |
Pnl. 1 1 1
AspN AspGluN ProtK 1 1 1
Therm| 1 1 1
Ch lo Pnl.3 Pn2 ProtKI I 1 1 1
Ch lo Pnl.3 Pn2 ProtK Therm I | I 1 1 1
Pnl.3 Pn2Mil 1 1 1
AspN AspGluNI | I I | 1 1 1
AspN AspGluN Ch lo Pnl.3 Pn2 ProtKI 1 1 1 II 1 1 1
Pnl.3 Pn2 ProtK Therm| 1 1 1 II I 1 1 1
ThermI||||||| 1 1 1
ProtK | M M M 1 1 1 1 1
Ch hi Ch lo Pnl.3 Pn2 ProtKI||||||||| 1 1 1
ThermlII11IIII11 1 1 1
Pnl.3 Pn2 ProtK II M M M M 11 1 1 1
ProtKI 111111111111 1 1 1
Glu Staph|| 111II1111111 1 1 1
AspGluN| || I I I 1 1 1 1 1 1 I 1 1 1 1 1
NTCBI III 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Ch lo Pnl.3 Pn2 ProtK||||| 111111111111 1 1 1
LysC Pnl.3 Pn2 Therm TrypsI 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1
LysN ProtKI I 1 I I 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1
Glu Staph I 1 I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
AscGiuN Ch hi Ch lo Pnl.3 Pn2 ProtKI 1 I I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Pnl.3 Pn2 Therml 1 1 II 1 1 1 1 1 1 II II 1 1 1 1II I 1 1 1
ProtK 1 I 1 I I 1 1 1 1 I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
ProtK I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Ch lo ProtK Therml I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Pnl.3 Pn2 ProtK ThermlI I 11111111111 111111111111 1 1 1
LysC TrypsIII I 1 1 1 1 1 I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Glu LysN Staph|III I 11111111111 111111111II1 1 1 1
AspGluN C r. hi Ch lo Pnl. 3 ProtK I I | | | | 1 I I 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Pnl.3111111 I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
NTCB1 1 1 I 1 I 1 I II II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
ProtK| 1 I I I I I I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Ch lol 1 1 1 I I 1 I I I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Ch 1 o Pnl.3 Pn2 ProtK1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1
Pnl.3 Pn2 ProtK Therml11111II111 1 111111111II 111111111111 1 1 1
ProtK| 1 1 1 1 1 1 1 I 1 1 1 I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1
ProtK Therm| 1 I 1 I 11 1 I 1 11 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
ProtKI 1 1 1 1 1 1 1 1 1 11 11 1 1 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
ProtK Therml 1 1 1 I 1 1 1 1 || 1 I 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1
ProtK Therml 11 1 1 1 1 1 11 1 1 11 11 I 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 II 1 1 1
Pnl.3 Pn2 ?rotK Therml1111111111111111 1 11111111111 111111111111 1 1 1
Pnl.3 ?r.2 Therml 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Hydro 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
ProtK| 1 1 1 1 1 1 1 1 1 1 1 I I I 1 1 I I I I I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
ProtK| 1 1 1 1 1 1 1 1 1 1 1 1 I 1 1 I I I I I I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 i 1 1
NTTNGFAAATATLHTNCYEKTLANNTNNFEAKLNCEVLPSFTSALDDLLSIL'WNNI.
Appendix 4: Yeast Two-Hybrid Sequences
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CAGCAGGGTCCGGTCATACTGGATGAGGATGTCTTTGATCTCC I I C 1 I GGA
AGCCTCATCCACATATTTCTGGTAATAGGCCACCAAGGCTTTGGAGATGG
227
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